#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Changes in Gray Matter Density, Regional Homogeneity, and Functional Connectivity in Methamphetamine-Associated Psychosis: A Resting-State Functional Magnetic Resonance Imaging (fMRI) Study
#Text=Background
#Text=Using regional homogeneity (ReHo) blood oxygen level-dependent functional MR (BOLD-fMRI), we investigated the structural and functional alterations of brain regions among patients with methamphetamine-associated psychosis (MAP).
1-1	0-7	Changes	_	
1-2	8-10	in	_	
1-3	11-15	Gray	_	
1-4	16-22	Matter	_	
1-5	23-30	Density	_	
1-6	30-31	,	_	
1-7	32-40	Regional	_	
1-8	41-52	Homogeneity	_	
1-9	52-53	,	_	
1-10	54-57	and	_	
1-11	58-68	Functional	_	
1-12	69-81	Connectivity	_	
1-13	82-84	in	_	
1-14	85-111	Methamphetamine-Associated	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[1]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[2]	
1-15	112-121	Psychosis	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[1]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[2]	
1-16	121-122	:	_	
1-17	123-124	A	_	
1-18	125-138	Resting-State	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[3]	
1-19	139-149	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[3]	
1-20	150-158	Magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[3]	
1-21	159-168	Resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[3]	
1-22	169-176	Imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[3]	
1-23	177-178	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[3]	
1-24	178-182	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[3]	
1-25	182-183	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[3]	
1-26	184-189	Study	_	
1-27	190-200	Background	_	
1-28	201-206	Using	_	
1-29	207-215	regional	_	
1-30	216-227	homogeneity	_	
1-31	228-229	(	_	
1-32	229-233	ReHo	_	
1-33	233-234	)	_	
1-34	235-240	blood	_	
1-35	241-247	oxygen	_	
1-36	248-263	level-dependent	_	
1-37	264-274	functional	_	
1-38	275-277	MR	_	
1-39	278-279	(	_	
1-40	279-288	BOLD-fMRI	_	
1-41	288-289	)	_	
1-42	289-290	,	_	
1-43	291-293	we	_	
1-44	294-306	investigated	_	
1-45	307-310	the	_	
1-46	311-321	structural	_	
1-47	322-325	and	_	
1-48	326-336	functional	_	
1-49	337-348	alterations	_	
1-50	349-351	of	_	
1-51	352-357	brain	_	
1-52	358-365	regions	_	
1-53	366-371	among	_	
1-54	372-380	patients	_	
1-55	381-385	with	_	
1-56	386-412	methamphetamine-associated	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[4]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[5]	
1-57	413-422	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[4]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[5]	
1-58	423-424	(	_	
1-59	424-427	MAP	_	
1-60	427-428	)	_	
1-61	428-429	.	_	

#Text=Material/Methods
#Text=This retrospective study included 17 MAP patients, 16 schizophrenia (SCZ) patients, and 18 healthy controls.
2-1	430-438	Material	http://www.case.edu/ProvCaRe/provcare#StudyMethod[6]	
2-2	438-439	/	http://www.case.edu/ProvCaRe/provcare#StudyMethod[6]	
2-3	439-446	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[6]	
2-4	447-451	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
2-5	452-465	retrospective	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
2-6	466-471	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
2-7	472-480	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
2-8	481-483	17	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
2-9	484-487	MAP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[8]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[9]	
2-10	488-496	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[8]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[9]	
2-11	496-497	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
2-12	498-500	16	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
2-13	501-514	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[10]	
2-14	515-516	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[10]	
2-15	516-519	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[10]	
2-16	519-520	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[10]	
2-17	521-529	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[10]	
2-18	529-530	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
2-19	531-534	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
2-20	535-537	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
2-21	538-545	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[11]	
2-22	546-554	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[11]	
2-23	554-555	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[11]	

#Text=Informed consent was obtained from all patients before the clinical assessment, the severity of clinical symptoms was evaluated prior to the fMRI scanning, and then images were acquired and preprocessed after each participant received 6-min fRMI scanning.
3-1	556-564	Informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
3-2	565-572	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
3-3	573-576	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
3-4	577-585	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
3-5	586-590	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
3-6	591-594	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
3-7	595-603	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
3-8	604-610	before	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
3-9	611-614	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
3-10	615-623	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
3-11	624-634	assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
3-12	634-635	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
3-13	636-639	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
3-14	640-648	severity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
3-15	649-651	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
3-16	652-660	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
3-17	661-669	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
3-18	670-673	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
3-19	674-683	evaluated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
3-20	684-689	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
3-21	690-692	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
3-22	693-696	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
3-23	697-701	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
3-24	702-710	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
3-25	710-711	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
3-26	712-715	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
3-27	716-720	then	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
3-28	721-727	images	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
3-29	728-732	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
3-30	733-741	acquired	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
3-31	742-745	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
3-32	746-758	preprocessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
3-33	759-764	after	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
3-34	765-769	each	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
3-35	770-781	participant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
3-36	782-790	received	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
3-37	791-792	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
3-38	792-793	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
3-39	793-796	min	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
3-40	797-801	fRMI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[13]	
3-41	802-810	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[13]	
3-42	810-811	.	_	

#Text=The participants all underwent BOLD-fMRI scanning.
4-1	812-815	The	_	
4-2	816-828	participants	_	
4-3	829-832	all	_	
4-4	833-842	underwent	_	
4-5	843-852	BOLD-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[14]	
4-6	853-861	scanning	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[14]	
4-7	861-862	.	_	

#Text=Voxel-based morphometry was used to measure gray matter density (GMD).
5-1	863-874	Voxel-based	_	
5-2	875-886	morphometry	_	
5-3	887-890	was	_	
5-4	891-895	used	_	
5-5	896-898	to	_	
5-6	899-906	measure	_	
5-7	907-911	gray	_	
5-8	912-918	matter	_	
5-9	919-926	density	_	
5-10	927-928	(	_	
5-11	928-931	GMD	_	
5-12	931-932	)	_	
5-13	932-933	.	_	

#Text=Resting-state fMRI (rs-fMRI) was conducted to analyze functional MR, ReHo, and functional connectivity (FC).
6-1	934-947	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[15]	
6-2	948-952	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[15]	
6-3	953-954	(	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[15]	
6-4	954-961	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[15]	
6-5	961-962	)	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[15]	
6-6	963-966	was	_	
6-7	967-976	conducted	_	
6-8	977-979	to	_	
6-9	980-987	analyze	_	
6-10	988-998	functional	_	
6-11	999-1001	MR	_	
6-12	1001-1002	,	_	
6-13	1003-1007	ReHo	_	
6-14	1007-1008	,	_	
6-15	1009-1012	and	_	
6-16	1013-1023	functional	_	
6-17	1024-1036	connectivity	_	
6-18	1037-1038	(	_	
6-19	1038-1040	FC	_	
6-20	1040-1041	)	_	
6-21	1041-1042	.	_	

#Text=Results
#Text=GMD analysis results suggest that MAP patients, SCZ patients, and healthy volunteers show different GMDs within different brain regions.
7-1	1043-1050	Results	_	
7-2	1051-1054	GMD	_	
7-3	1055-1063	analysis	_	
7-4	1064-1071	results	_	
7-5	1072-1079	suggest	_	
7-6	1080-1084	that	_	
7-7	1085-1088	MAP	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[16]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[17]	
7-8	1089-1097	patients	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[16]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[17]	
7-9	1097-1098	,	_	
7-10	1099-1102	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[18]	
7-11	1103-1111	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[18]	
7-12	1111-1112	,	_	
7-13	1113-1116	and	_	
7-14	1117-1124	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[19]	
7-15	1125-1135	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[19]	
7-16	1136-1140	show	_	
7-17	1141-1150	different	_	
7-18	1151-1155	GMDs	_	
7-19	1156-1162	within	_	
7-20	1163-1172	different	_	
7-21	1173-1178	brain	_	
7-22	1179-1186	regions	_	
7-23	1186-1187	.	_	

#Text=Similarly, the ReHo analysis results suggest that MAP patients, SCZ patients, and healthy volunteers have different GMDs within different brain regions.
8-1	1188-1197	Similarly	_	
8-2	1197-1198	,	_	
8-3	1199-1202	the	_	
8-4	1203-1207	ReHo	_	
8-5	1208-1216	analysis	_	
8-6	1217-1224	results	_	
8-7	1225-1232	suggest	_	
8-8	1233-1237	that	_	
8-9	1238-1241	MAP	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[20]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[21]	
8-10	1242-1250	patients	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[20]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[21]	
8-11	1250-1251	,	_	
8-12	1252-1255	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[22]	
8-13	1256-1264	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[22]	
8-14	1264-1265	,	_	
8-15	1266-1269	and	_	
8-16	1270-1277	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[23]	
8-17	1278-1288	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[23]	
8-18	1289-1293	have	_	
8-19	1294-1303	different	_	
8-20	1304-1308	GMDs	_	
8-21	1309-1315	within	_	
8-22	1316-1325	different	_	
8-23	1326-1331	brain	_	
8-24	1332-1339	regions	_	
8-25	1339-1340	.	_	

#Text=Negative correlations were found between ReHo- and the PANSS-positive scores within the left orbital interior frontal gyrus (L-orb-IFG) of MAP patients.
9-1	1341-1349	Negative	_	
9-2	1350-1362	correlations	_	
9-3	1363-1367	were	_	
9-4	1368-1373	found	_	
9-5	1374-1381	between	_	
9-6	1382-1386	ReHo	_	
9-7	1386-1387	-	_	
9-8	1388-1391	and	_	
9-9	1392-1395	the	_	
9-10	1396-1410	PANSS-positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	
9-11	1411-1417	scores	_	
9-12	1418-1424	within	_	
9-13	1425-1428	the	_	
9-14	1429-1433	left	_	
9-15	1434-1441	orbital	_	
9-16	1442-1450	interior	_	
9-17	1451-1458	frontal	_	
9-18	1459-1464	gyrus	_	
9-19	1465-1466	(	_	
9-20	1466-1475	L-orb-IFG	_	
9-21	1475-1476	)	_	
9-22	1477-1479	of	_	
9-23	1480-1483	MAP	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[24]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[25]	
9-24	1484-1492	patients	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[24]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[25]	
9-25	1492-1493	.	_	

#Text=ReHo- and PANSS-negative scores of R-SFG were negatively correlated among SCZ patients.
10-1	1494-1498	ReHo	_	
10-2	1498-1499	-	_	
10-3	1500-1503	and	_	
10-4	1504-1518	PANSS-negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	
10-5	1519-1525	scores	_	
10-6	1526-1528	of	_	
10-7	1529-1534	R-SFG	_	
10-8	1535-1539	were	_	
10-9	1540-1550	negatively	_	
10-10	1551-1561	correlated	_	
10-11	1562-1567	among	_	
10-12	1568-1571	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[26]	
10-13	1572-1580	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[26]	
10-14	1580-1581	.	_	

#Text=The abnormal FC of R-MFG showed a negative correlation with the PANSS score among MAP patients.
11-1	1582-1585	The	_	
11-2	1586-1594	abnormal	_	
11-3	1595-1597	FC	_	
11-4	1598-1600	of	_	
11-5	1601-1606	R-MFG	_	
11-6	1607-1613	showed	_	
11-7	1614-1615	a	_	
11-8	1616-1624	negative	_	
11-9	1625-1636	correlation	_	
11-10	1637-1641	with	_	
11-11	1642-1645	the	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[27]	
11-12	1646-1651	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[27]	
11-13	1652-1657	score	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[27]	
11-14	1658-1663	among	_	
11-15	1664-1667	MAP	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[28]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[29]	
11-16	1668-1676	patients	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[28]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[29]	
11-17	1676-1677	.	_	

#Text=Conclusions
#Text=The abnormalities in brain structure and FC were associated with the development of MAP.
12-1	1678-1689	Conclusions	_	
12-2	1690-1693	The	_	
12-3	1694-1707	abnormalities	_	
12-4	1708-1710	in	_	
12-5	1711-1716	brain	_	
12-6	1717-1726	structure	_	
12-7	1727-1730	and	_	
12-8	1731-1733	FC	_	
12-9	1734-1738	were	_	
12-10	1739-1749	associated	_	
12-11	1750-1754	with	_	
12-12	1755-1758	the	_	
12-13	1759-1770	development	_	
12-14	1771-1773	of	_	
12-15	1774-1777	MAP	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[30]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[31]	
12-16	1777-1778	.	_	

#Text=Background
#Text=Methamphetamine (METH) is a member of amphetamine-type stimulants (ATS) family.
13-1	1779-1789	Background	_	
13-2	1790-1805	Methamphetamine	_	
13-3	1806-1807	(	_	
13-4	1807-1811	METH	_	
13-5	1811-1812	)	_	
13-6	1813-1815	is	_	
13-7	1816-1817	a	_	
13-8	1818-1824	member	_	
13-9	1825-1827	of	_	
13-10	1828-1844	amphetamine-type	_	
13-11	1845-1855	stimulants	_	
13-12	1856-1857	(	_	
13-13	1857-1860	ATS	_	
13-14	1860-1861	)	_	
13-15	1862-1868	family	_	
13-16	1868-1869	.	_	

#Text=According to the World Drug Report by the United Nations, ATS are the second most commonly used illegal drug in 2014, and it is abused as commonly as the opiate drugs in China.
14-1	1870-1879	According	_	
14-2	1880-1882	to	_	
14-3	1883-1886	the	_	
14-4	1887-1892	World	_	
14-5	1893-1897	Drug	_	
14-6	1898-1904	Report	_	
14-7	1905-1907	by	_	
14-8	1908-1911	the	_	
14-9	1912-1918	United	_	
14-10	1919-1926	Nations	_	
14-11	1926-1927	,	_	
14-12	1928-1931	ATS	_	
14-13	1932-1935	are	_	
14-14	1936-1939	the	_	
14-15	1940-1946	second	_	
14-16	1947-1951	most	_	
14-17	1952-1960	commonly	_	
14-18	1961-1965	used	_	
14-19	1966-1973	illegal	_	
14-20	1974-1978	drug	_	
14-21	1979-1981	in	_	
14-22	1982-1986	2014	_	
14-23	1986-1987	,	_	
14-24	1988-1991	and	_	
14-25	1992-1994	it	_	
14-26	1995-1997	is	_	
14-27	1998-2004	abused	_	
14-28	2005-2007	as	_	
14-29	2008-2016	commonly	_	
14-30	2017-2019	as	_	
14-31	2020-2023	the	_	
14-32	2024-2030	opiate	_	
14-33	2031-2036	drugs	_	
14-34	2037-2039	in	_	
14-35	2040-2045	China	_	
14-36	2045-2046	.	_	

#Text=According to a report of National Narcotic Control Commission (NNCC) of China, the cumulative number of registered drug users in China increased dramatically, from 0.07 million in 1990 to 2.09 million, by the end of 2012.
15-1	2047-2056	According	_	
15-2	2057-2059	to	_	
15-3	2060-2061	a	_	
15-4	2062-2068	report	_	
15-5	2069-2071	of	_	
15-6	2072-2080	National	_	
15-7	2081-2089	Narcotic	_	
15-8	2090-2097	Control	_	
15-9	2098-2108	Commission	_	
15-10	2109-2110	(	_	
15-11	2110-2114	NNCC	_	
15-12	2114-2115	)	_	
15-13	2116-2118	of	_	
15-14	2119-2124	China	_	
15-15	2124-2125	,	_	
15-16	2126-2129	the	_	
15-17	2130-2140	cumulative	_	
15-18	2141-2147	number	_	
15-19	2148-2150	of	_	
15-20	2151-2161	registered	_	
15-21	2162-2166	drug	_	
15-22	2167-2172	users	_	
15-23	2173-2175	in	_	
15-24	2176-2181	China	_	
15-25	2182-2191	increased	_	
15-26	2192-2204	dramatically	_	
15-27	2204-2205	,	_	
15-28	2206-2210	from	_	
15-29	2211-2215	0.07	_	
15-30	2216-2223	million	_	
15-31	2224-2226	in	_	
15-32	2227-2231	1990	_	
15-33	2232-2234	to	_	
15-34	2235-2239	2.09	_	
15-35	2240-2247	million	_	
15-36	2247-2248	,	_	
15-37	2249-2251	by	_	
15-38	2252-2255	the	_	
15-39	2256-2259	end	_	
15-40	2260-2262	of	_	
15-41	2263-2267	2012	_	
15-42	2267-2268	.	_	

#Text=Due to the epidemic of METH, the incidence rate of methamphetamine-associated psychosis (MAP) has increased dramatically.
16-1	2269-2272	Due	_	
16-2	2273-2275	to	_	
16-3	2276-2279	the	_	
16-4	2280-2288	epidemic	_	
16-5	2289-2291	of	_	
16-6	2292-2296	METH	_	
16-7	2296-2297	,	_	
16-8	2298-2301	the	_	
16-9	2302-2311	incidence	_	
16-10	2312-2316	rate	_	
16-11	2317-2319	of	_	
16-12	2320-2346	methamphetamine-associated	_	
16-13	2347-2356	psychosis	_	
16-14	2357-2358	(	_	
16-15	2358-2361	MAP	_	
16-16	2361-2362	)	_	
16-17	2363-2366	has	_	
16-18	2367-2376	increased	_	
16-19	2377-2389	dramatically	_	
16-20	2389-2390	.	_	

#Text=It has been proven that ATS can produce psychotic symptoms, such as persecutory delusions, auditory hallucinations, visual hallucinations, delusions of reference, and thought broadcasting.
17-1	2391-2393	It	_	
17-2	2394-2397	has	_	
17-3	2398-2402	been	_	
17-4	2403-2409	proven	_	
17-5	2410-2414	that	_	
17-6	2415-2418	ATS	_	
17-7	2419-2422	can	_	
17-8	2423-2430	produce	_	
17-9	2431-2440	psychotic	_	
17-10	2441-2449	symptoms	_	
17-11	2449-2450	,	_	
17-12	2451-2455	such	_	
17-13	2456-2458	as	_	
17-14	2459-2470	persecutory	_	
17-15	2471-2480	delusions	_	
17-16	2480-2481	,	_	
17-17	2482-2490	auditory	_	
17-18	2491-2505	hallucinations	_	
17-19	2505-2506	,	_	
17-20	2507-2513	visual	_	
17-21	2514-2528	hallucinations	_	
17-22	2528-2529	,	_	
17-23	2530-2539	delusions	_	
17-24	2540-2542	of	_	
17-25	2543-2552	reference	_	
17-26	2552-2553	,	_	
17-27	2554-2557	and	_	
17-28	2558-2565	thought	_	
17-29	2566-2578	broadcasting	_	
17-30	2578-2579	.	_	

#Text=The symptom of psychosis was generally present for an average of 5.2 years after METH was first used; therefore, MAP is hard to diagnose at early stages.
18-1	2580-2583	The	_	
18-2	2584-2591	symptom	_	
18-3	2592-2594	of	_	
18-4	2595-2604	psychosis	_	
18-5	2605-2608	was	_	
18-6	2609-2618	generally	_	
18-7	2619-2626	present	_	
18-8	2627-2630	for	_	
18-9	2631-2633	an	_	
18-10	2634-2641	average	_	
18-11	2642-2644	of	_	
18-12	2645-2648	5.2	_	
18-13	2649-2654	years	_	
18-14	2655-2660	after	_	
18-15	2661-2665	METH	_	
18-16	2666-2669	was	_	
18-17	2670-2675	first	_	
18-18	2676-2680	used	_	
18-19	2680-2681	;	_	
18-20	2682-2691	therefore	_	
18-21	2691-2692	,	_	
18-22	2693-2696	MAP	_	
18-23	2697-2699	is	_	
18-24	2700-2704	hard	_	
18-25	2705-2707	to	_	
18-26	2708-2716	diagnose	_	
18-27	2717-2719	at	_	
18-28	2720-2725	early	_	
18-29	2726-2732	stages	_	
18-30	2732-2733	.	_	

#Text=In addition, 25~50% of long-term METH-dependent subjects suffer from MAP during their lifetime.
19-1	2734-2736	In	_	
19-2	2737-2745	addition	_	
19-3	2745-2746	,	_	
19-4	2747-2749	25	_	
19-5	2749-2750	~	_	
19-6	2750-2753	50%	_	
19-7	2754-2756	of	_	
19-8	2757-2766	long-term	_	
19-9	2767-2781	METH-dependent	_	
19-10	2782-2790	subjects	_	
19-11	2791-2797	suffer	_	
19-12	2798-2802	from	_	
19-13	2803-2806	MAP	_	
19-14	2807-2813	during	_	
19-15	2814-2819	their	_	
19-16	2820-2828	lifetime	_	
19-17	2828-2829	.	_	

#Text=Since the incidence of psychotic disorders among drug addicts in southwest China reached 77.1%, MAP has recently become a clinical concern.
20-1	2830-2835	Since	_	
20-2	2836-2839	the	_	
20-3	2840-2849	incidence	_	
20-4	2850-2852	of	_	
20-5	2853-2862	psychotic	_	
20-6	2863-2872	disorders	_	
20-7	2873-2878	among	_	
20-8	2879-2883	drug	_	
20-9	2884-2891	addicts	_	
20-10	2892-2894	in	_	
20-11	2895-2904	southwest	_	
20-12	2905-2910	China	_	
20-13	2911-2918	reached	_	
20-14	2919-2924	77.1%	_	
20-15	2924-2925	,	_	
20-16	2926-2929	MAP	_	
20-17	2930-2933	has	_	
20-18	2934-2942	recently	_	
20-19	2943-2949	become	_	
20-20	2950-2951	a	_	
20-21	2952-2960	clinical	_	
20-22	2961-2968	concern	_	
20-23	2968-2969	.	_	

#Text=With the development of functional magnetic resonance imaging (fMRI), the structural MR and functional images of the brain became available.
21-1	2970-2974	With	_	
21-2	2975-2978	the	_	
21-3	2979-2990	development	_	
21-4	2991-2993	of	_	
21-5	2994-3004	functional	_	
21-6	3005-3013	magnetic	_	
21-7	3014-3023	resonance	_	
21-8	3024-3031	imaging	_	
21-9	3032-3033	(	_	
21-10	3033-3037	fMRI	_	
21-11	3037-3038	)	_	
21-12	3038-3039	,	_	
21-13	3040-3043	the	_	
21-14	3044-3054	structural	_	
21-15	3055-3057	MR	_	
21-16	3058-3061	and	_	
21-17	3062-3072	functional	_	
21-18	3073-3079	images	_	
21-19	3080-3082	of	_	
21-20	3083-3086	the	_	
21-21	3087-3092	brain	_	
21-22	3093-3099	became	_	
21-23	3100-3109	available	_	
21-24	3109-3110	.	_	

#Text=FMRI can describe the volumetric changes in patients with psychotic disorders.
22-1	3111-3115	FMRI	_	
22-2	3116-3119	can	_	
22-3	3120-3128	describe	_	
22-4	3129-3132	the	_	
22-5	3133-3143	volumetric	_	
22-6	3144-3151	changes	_	
22-7	3152-3154	in	_	
22-8	3155-3163	patients	_	
22-9	3164-3168	with	_	
22-10	3169-3178	psychotic	_	
22-11	3179-3188	disorders	_	
22-12	3188-3189	.	_	

#Text=Over the past few years, fMRI has been widely applied to a wide range of diseases, such as renal disease, Parkinson diseases, and neuro-Bechet’s disease.
23-1	3190-3194	Over	_	
23-2	3195-3198	the	_	
23-3	3199-3203	past	_	
23-4	3204-3207	few	_	
23-5	3208-3213	years	_	
23-6	3213-3214	,	_	
23-7	3215-3219	fMRI	_	
23-8	3220-3223	has	_	
23-9	3224-3228	been	_	
23-10	3229-3235	widely	_	
23-11	3236-3243	applied	_	
23-12	3244-3246	to	_	
23-13	3247-3248	a	_	
23-14	3249-3253	wide	_	
23-15	3254-3259	range	_	
23-16	3260-3262	of	_	
23-17	3263-3271	diseases	_	
23-18	3271-3272	,	_	
23-19	3273-3277	such	_	
23-20	3278-3280	as	_	
23-21	3281-3286	renal	_	
23-22	3287-3294	disease	_	
23-23	3294-3295	,	_	
23-24	3296-3305	Parkinson	_	
23-25	3306-3314	diseases	_	
23-26	3314-3315	,	_	
23-27	3316-3319	and	_	
23-28	3320-3332	neuro-Bechet	_	
23-29	3332-3333	’	_	
23-30	3333-3334	s	_	
23-31	3335-3342	disease	_	
23-32	3342-3343	.	_	

#Text=Resting-state fMRI (rs-fMRI) can present the functional connectivity, which provides us with a better understating of the disease pathophysiology.
24-1	3344-3357	Resting-state	_	
24-2	3358-3362	fMRI	_	
24-3	3363-3364	(	_	
24-4	3364-3371	rs-fMRI	_	
24-5	3371-3372	)	_	
24-6	3373-3376	can	_	
24-7	3377-3384	present	_	
24-8	3385-3388	the	_	
24-9	3389-3399	functional	_	
24-10	3400-3412	connectivity	_	
24-11	3412-3413	,	_	
24-12	3414-3419	which	_	
24-13	3420-3428	provides	_	
24-14	3429-3431	us	_	
24-15	3432-3436	with	_	
24-16	3437-3438	a	_	
24-17	3439-3445	better	_	
24-18	3446-3458	understating	_	
24-19	3459-3461	of	_	
24-20	3462-3465	the	_	
24-21	3466-3473	disease	_	
24-22	3474-3489	pathophysiology	_	
24-23	3489-3490	.	_	

#Text=Previous study results indicated that METH abusers often exhibited reduced reaction time adjustments and reduced activation in the prefrontal cortex.
25-1	3491-3499	Previous	_	
25-2	3500-3505	study	_	
25-3	3506-3513	results	_	
25-4	3514-3523	indicated	_	
25-5	3524-3528	that	_	
25-6	3529-3533	METH	_	
25-7	3534-3541	abusers	_	
25-8	3542-3547	often	_	
25-9	3548-3557	exhibited	_	
25-10	3558-3565	reduced	_	
25-11	3566-3574	reaction	_	
25-12	3575-3579	time	_	
25-13	3580-3591	adjustments	_	
25-14	3592-3595	and	_	
25-15	3596-3603	reduced	_	
25-16	3604-3614	activation	_	
25-17	3615-3617	in	_	
25-18	3618-3621	the	_	
25-19	3622-3632	prefrontal	_	
25-20	3633-3639	cortex	_	
25-21	3639-3640	.	_	

#Text=Salo et al. found impairment of prefrontal cortical function and disruption of adaptive cognitive control in METH users.
26-1	3641-3645	Salo	_	
26-2	3646-3648	et	_	
26-3	3649-3651	al	_	
26-4	3651-3652	.	_	
26-5	3653-3658	found	_	
26-6	3659-3669	impairment	_	
26-7	3670-3672	of	_	
26-8	3673-3683	prefrontal	_	
26-9	3684-3692	cortical	_	
26-10	3693-3701	function	_	
26-11	3702-3705	and	_	
26-12	3706-3716	disruption	_	
26-13	3717-3719	of	_	
26-14	3720-3728	adaptive	_	
26-15	3729-3738	cognitive	_	
26-16	3739-3746	control	_	
26-17	3747-3749	in	_	
26-18	3750-3754	METH	_	
26-19	3755-3760	users	_	
26-20	3760-3761	.	_	

#Text=Thus, the present study was performed to investigate the concentration of gray matter and functional alternations of the brain in MAP patients and schizophrenia (SCZ) patients by use of ReHo blood oxygen level-dependent functional MR (BOLD-fMRI) to explore the potential difference between MAP and SCZ patients.
27-1	3762-3766	Thus	_	
27-2	3766-3767	,	_	
27-3	3768-3771	the	_	
27-4	3772-3779	present	_	
27-5	3780-3785	study	_	
27-6	3786-3789	was	_	
27-7	3790-3799	performed	_	
27-8	3800-3802	to	_	
27-9	3803-3814	investigate	_	
27-10	3815-3818	the	_	
27-11	3819-3832	concentration	_	
27-12	3833-3835	of	_	
27-13	3836-3840	gray	_	
27-14	3841-3847	matter	_	
27-15	3848-3851	and	_	
27-16	3852-3862	functional	_	
27-17	3863-3875	alternations	_	
27-18	3876-3878	of	_	
27-19	3879-3882	the	_	
27-20	3883-3888	brain	_	
27-21	3889-3891	in	_	
27-22	3892-3895	MAP	_	
27-23	3896-3904	patients	_	
27-24	3905-3908	and	_	
27-25	3909-3922	schizophrenia	_	
27-26	3923-3924	(	_	
27-27	3924-3927	SCZ	_	
27-28	3927-3928	)	_	
27-29	3929-3937	patients	_	
27-30	3938-3940	by	_	
27-31	3941-3944	use	_	
27-32	3945-3947	of	_	
27-33	3948-3952	ReHo	_	
27-34	3953-3958	blood	_	
27-35	3959-3965	oxygen	_	
27-36	3966-3981	level-dependent	_	
27-37	3982-3992	functional	_	
27-38	3993-3995	MR	_	
27-39	3996-3997	(	_	
27-40	3997-4006	BOLD-fMRI	_	
27-41	4006-4007	)	_	
27-42	4008-4010	to	_	
27-43	4011-4018	explore	_	
27-44	4019-4022	the	_	
27-45	4023-4032	potential	_	
27-46	4033-4043	difference	_	
27-47	4044-4051	between	_	
27-48	4052-4055	MAP	_	
27-49	4056-4059	and	_	
27-50	4060-4063	SCZ	_	
27-51	4064-4072	patients	_	
27-52	4072-4073	.	_	

#Text=Material and Methods
#Text=Participants
#Text=We recruited right-handed men ages 18~45 years, and placed them into 3 groups: MAP (n=19), SCZ (n=19), and control (n=18).
28-1	4074-4082	Material	http://www.case.edu/ProvCaRe/provcare#StudyMethod[32]	
28-2	4083-4086	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[32]	
28-3	4087-4094	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[32]	
28-4	4095-4107	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-5	4108-4110	We	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-6	4111-4120	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-7	4121-4133	right-handed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-8	4134-4137	men	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-9	4138-4142	ages	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-10	4143-4145	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-11	4145-4146	~	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-12	4146-4148	45	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-13	4149-4154	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-14	4154-4155	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-15	4156-4159	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-16	4160-4166	placed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-17	4167-4171	them	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-18	4172-4176	into	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-19	4177-4178	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-20	4179-4185	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-21	4185-4186	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-22	4187-4190	MAP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[34]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[35]	
28-23	4191-4192	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-24	4192-4193	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-25	4193-4194	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-26	4194-4196	19	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-27	4196-4197	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-28	4197-4198	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-29	4199-4202	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[36]	
28-30	4203-4204	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-31	4204-4205	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-32	4205-4206	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-33	4206-4208	19	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-34	4208-4209	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-35	4209-4210	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-36	4211-4214	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-37	4215-4222	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[37]	
28-38	4223-4224	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-39	4224-4225	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-40	4225-4226	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-41	4226-4228	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-42	4228-4229	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	
28-43	4229-4230	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]	

#Text=MAP was diagnosed according to the International Classification of Diseases-10 (ICD-10) research criteria.
29-1	4231-4234	MAP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[39]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[40]	
29-2	4235-4238	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
29-3	4239-4248	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
29-4	4249-4258	according	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
29-5	4259-4261	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
29-6	4262-4265	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
29-7	4266-4279	International	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
29-8	4280-4294	Classification	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
29-9	4295-4297	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
29-10	4298-4306	Diseases	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
29-11	4306-4307	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
29-12	4307-4309	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
29-13	4310-4311	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
29-14	4311-4314	ICD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
29-15	4314-4315	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
29-16	4315-4317	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]	
29-17	4317-4318	)	_	
29-18	4319-4327	research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
29-19	4328-4336	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
29-20	4336-4337	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	

#Text=The inclusion criteria for the MAP group were as follows: (a) they volunteered to detox from METH; (b) they met the criteria of substance-associated psychosis of ICD-10, but their course standard could be more than 1 month; (c) direct laboratory evidence (urine, blood, and hair) proved that they had a history of METH abuse; (d) they achieved the medium or serious level in ≥t items of delusion, hallucinatory behavior, grandiosity, suspiciousness/persecution, and unusual thought content.
30-1	4338-4341	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
30-2	4342-4351	inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
30-3	4352-4360	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
30-4	4361-4364	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
30-5	4365-4368	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
30-6	4369-4372	MAP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[42]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[43]	
30-7	4373-4378	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
30-8	4379-4383	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
30-9	4384-4386	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
30-10	4387-4394	follows	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
30-11	4394-4395	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
30-12	4396-4397	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
30-13	4397-4398	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
30-14	4398-4399	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
30-15	4400-4404	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
30-16	4405-4416	volunteered	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
30-17	4417-4419	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
30-18	4420-4425	detox	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
30-19	4426-4430	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
30-20	4431-4435	METH	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
30-21	4435-4436	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
30-22	4437-4438	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
30-23	4438-4439	b	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
30-24	4439-4440	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
30-25	4441-4445	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
30-26	4446-4449	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
30-27	4450-4453	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
30-28	4454-4462	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
30-29	4463-4465	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[41]	
30-30	4466-4486	substance-associated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-31	4487-4496	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-32	4497-4499	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-33	4500-4503	ICD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]|http://maven.renci.org/NeuroBridge/neurobridge#ImpulseControlDisorder[45]	
30-34	4503-4504	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]|http://maven.renci.org/NeuroBridge/neurobridge#ImpulseControlDisorder[45]	
30-35	4504-4506	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]|http://maven.renci.org/NeuroBridge/neurobridge#ImpulseControlDisorder[45]	
30-36	4506-4507	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-37	4508-4511	but	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-38	4512-4517	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-39	4518-4524	course	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-40	4525-4533	standard	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-41	4534-4539	could	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-42	4540-4542	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-43	4543-4547	more	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-44	4548-4552	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-45	4553-4554	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-46	4555-4560	month	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-47	4560-4561	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-48	4562-4563	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-49	4563-4564	c	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-50	4564-4565	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-51	4566-4572	direct	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-52	4573-4583	laboratory	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-53	4584-4592	evidence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-54	4593-4594	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-55	4594-4599	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-56	4599-4600	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-57	4601-4606	blood	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-58	4606-4607	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-59	4608-4611	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-60	4612-4616	hair	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-61	4616-4617	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-62	4618-4624	proved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-63	4625-4629	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-64	4630-4634	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-65	4635-4638	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-66	4639-4640	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-67	4641-4648	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-68	4649-4651	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-69	4652-4656	METH	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-70	4657-4662	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-71	4662-4663	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-72	4664-4665	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-73	4665-4666	d	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-74	4666-4667	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-75	4668-4672	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-76	4673-4681	achieved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-77	4682-4685	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-78	4686-4692	medium	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-79	4693-4695	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-80	4696-4703	serious	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-81	4704-4709	level	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-82	4710-4712	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-83	4713-4714	≥	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-84	4714-4715	t	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-85	4716-4721	items	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-86	4722-4724	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-87	4725-4733	delusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-88	4733-4734	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-89	4735-4748	hallucinatory	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-90	4749-4757	behavior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-91	4757-4758	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-92	4759-4770	grandiosity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-93	4770-4771	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-94	4772-4786	suspiciousness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-95	4786-4787	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-96	4787-4798	persecution	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-97	4798-4799	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-98	4800-4803	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-99	4804-4811	unusual	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-100	4812-4819	thought	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-101	4820-4827	content	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
30-102	4827-4828	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	

#Text=The exclusion criteria were as follow: (a) subjects had a history of SCZ, mood disorders, neurosis, or mental retardation; (b) they had a history of serious somatic diseases or organic brain diseases, such as stroke or brain injury; (c) they presented a seropositive test for HIV; (d) they were incompatible for MRI; (e) they abused harmful substances other than METH and nicotine; (f) they were delirious; (g) they had a history of epileptic seizure or had a family history of epilepsy; (h) they had used benzodiazepines 1 week prior to fMRI examination; (i) their head translation or rotation was more than 3 mm/3°.
31-1	4829-4832	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-2	4833-4842	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-3	4843-4851	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-4	4852-4856	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-5	4857-4859	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-6	4860-4866	follow	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-7	4866-4867	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-8	4868-4869	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-9	4869-4870	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-10	4870-4871	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-11	4872-4880	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-12	4881-4884	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-13	4885-4886	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-14	4887-4894	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-15	4895-4897	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-16	4898-4901	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-17	4901-4902	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-18	4903-4907	mood	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-19	4908-4917	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-20	4917-4918	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-21	4919-4927	neurosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-22	4927-4928	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-23	4929-4931	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-24	4932-4938	mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-25	4939-4950	retardation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-26	4950-4951	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-27	4952-4953	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-28	4953-4954	b	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-29	4954-4955	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-30	4956-4960	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-31	4961-4964	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-32	4965-4966	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-33	4967-4974	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-34	4975-4977	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-35	4978-4985	serious	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-36	4986-4993	somatic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-37	4994-5002	diseases	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-38	5003-5005	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-39	5006-5013	organic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-40	5014-5019	brain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-41	5020-5028	diseases	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-42	5028-5029	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-43	5030-5034	such	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-44	5035-5037	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-45	5038-5044	stroke	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-46	5045-5047	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-47	5048-5053	brain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-48	5054-5060	injury	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-49	5060-5061	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-50	5062-5063	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-51	5063-5064	c	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-52	5064-5065	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-53	5066-5070	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-54	5071-5080	presented	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-55	5081-5082	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-56	5083-5095	seropositive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-57	5096-5100	test	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-58	5101-5104	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-59	5105-5108	HIV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-60	5108-5109	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-61	5110-5111	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-62	5111-5112	d	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-63	5112-5113	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-64	5114-5118	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-65	5119-5123	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-66	5124-5136	incompatible	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-67	5137-5140	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-68	5141-5144	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-69	5144-5145	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-70	5146-5147	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-71	5147-5148	e	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-72	5148-5149	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-73	5150-5154	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-74	5155-5161	abused	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-75	5162-5169	harmful	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-76	5170-5180	substances	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-77	5181-5186	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-78	5187-5191	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-79	5192-5196	METH	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-80	5197-5200	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-81	5201-5209	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-82	5209-5210	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-83	5211-5212	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-84	5212-5213	f	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-85	5213-5214	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-86	5215-5219	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-87	5220-5224	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-88	5225-5234	delirious	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-89	5234-5235	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-90	5236-5237	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-91	5237-5238	g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-92	5238-5239	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-93	5240-5244	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-94	5245-5248	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-95	5249-5250	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-96	5251-5258	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-97	5259-5261	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-98	5262-5271	epileptic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-99	5272-5279	seizure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-100	5280-5282	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-101	5283-5286	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-102	5287-5288	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-103	5289-5295	family	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-104	5296-5303	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-105	5304-5306	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-106	5307-5315	epilepsy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-107	5315-5316	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-108	5317-5318	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-109	5318-5319	h	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-110	5319-5320	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-111	5321-5325	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-112	5326-5329	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-113	5330-5334	used	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-114	5335-5350	benzodiazepines	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-115	5351-5352	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-116	5353-5357	week	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-117	5358-5363	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-118	5364-5366	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-119	5367-5371	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-120	5372-5383	examination	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-121	5383-5384	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-122	5385-5386	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-123	5386-5387	i	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-124	5387-5388	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-125	5389-5394	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-126	5395-5399	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-127	5400-5411	translation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-128	5412-5414	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-129	5415-5423	rotation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-130	5424-5427	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-131	5428-5432	more	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-132	5433-5437	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-133	5438-5439	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-134	5440-5442	mm	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-135	5442-5443	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-136	5443-5444	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-137	5444-5445	°	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
31-138	5445-5446	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	

#Text=The inclusion and exclusion criteria of SCZ patients were similar to the MAP group, except that they met the criteria for SCZ according to ICD-10.
32-1	5447-5450	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
32-2	5451-5460	inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
32-3	5461-5464	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
32-4	5465-5474	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
32-5	5475-5483	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
32-6	5484-5486	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
32-7	5487-5490	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[46]	
32-8	5491-5499	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
32-9	5500-5504	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
32-10	5505-5512	similar	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
32-11	5513-5515	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
32-12	5516-5519	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
32-13	5520-5523	MAP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[47]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[48]	
32-14	5524-5529	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[47]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[48]	
32-15	5529-5530	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
32-16	5531-5537	except	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
32-17	5538-5542	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
32-18	5543-5547	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
32-19	5548-5551	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
32-20	5552-5555	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
32-21	5556-5564	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
32-22	5565-5568	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
32-23	5569-5572	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[49]	
32-24	5573-5582	according	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
32-25	5583-5585	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
32-26	5586-5589	ICD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
32-27	5589-5590	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
32-28	5590-5592	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
32-29	5592-5593	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	

#Text=Informed consent from all participants was obtained before the neuroimaging and other clinical assessments.
33-1	5594-5602	Informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
33-2	5603-5610	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
33-3	5611-5615	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
33-4	5616-5619	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
33-5	5620-5632	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
33-6	5633-5636	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
33-7	5637-5645	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
33-8	5646-5652	before	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
33-9	5653-5656	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
33-10	5657-5669	neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
33-11	5670-5673	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
33-12	5674-5679	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
33-13	5680-5688	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
33-14	5689-5700	assessments	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	
33-15	5700-5701	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]	

#Text=This retrospective study was approved by the local Ethics Committee and the Institutional Review Board, and all participants signed the informed consent before participating in this study.
34-1	5702-5706	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
34-2	5707-5720	retrospective	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
34-3	5721-5726	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
34-4	5727-5730	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
34-5	5731-5739	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
34-6	5740-5742	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
34-7	5743-5746	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
34-8	5747-5752	local	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
34-9	5753-5759	Ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
34-10	5760-5769	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
34-11	5770-5773	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
34-12	5774-5777	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
34-13	5778-5791	Institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
34-14	5792-5798	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
34-15	5799-5804	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
34-16	5804-5805	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
34-17	5806-5809	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
34-18	5810-5813	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
34-19	5814-5826	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
34-20	5827-5833	signed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
34-21	5834-5837	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
34-22	5838-5846	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
34-23	5847-5854	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
34-24	5855-5861	before	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
34-25	5862-5875	participating	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
34-26	5876-5878	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
34-27	5879-5883	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
34-28	5884-5889	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	
34-29	5889-5890	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[50]	

#Text=Data collection and follow-up
#Text=Personal information on demographics, history of psychoactive drug use, and history of body/mental disease were collected.
35-1	5891-5895	Data	_	
35-2	5896-5906	collection	_	
35-3	5907-5910	and	_	
35-4	5911-5920	follow-up	_	
35-5	5921-5929	Personal	_	
35-6	5930-5941	information	_	
35-7	5942-5944	on	_	
35-8	5945-5957	demographics	_	
35-9	5957-5958	,	_	
35-10	5959-5966	history	_	
35-11	5967-5969	of	_	
35-12	5970-5982	psychoactive	_	
35-13	5983-5987	drug	_	
35-14	5988-5991	use	_	
35-15	5991-5992	,	_	
35-16	5993-5996	and	_	
35-17	5997-6004	history	_	
35-18	6005-6007	of	_	
35-19	6008-6012	body	_	
35-20	6012-6013	/	_	
35-21	6013-6019	mental	_	
35-22	6020-6027	disease	_	
35-23	6028-6032	were	_	
35-24	6033-6042	collected	_	
35-25	6042-6043	.	_	

#Text=In addition, detailed information on METH use and its relationship with onset and disappearance of psychotic symptoms was obtained after interviewing the patients.
36-1	6044-6046	In	_	
36-2	6047-6055	addition	_	
36-3	6055-6056	,	_	
36-4	6057-6065	detailed	_	
36-5	6066-6077	information	_	
36-6	6078-6080	on	_	
36-7	6081-6085	METH	_	
36-8	6086-6089	use	_	
36-9	6090-6093	and	_	
36-10	6094-6097	its	_	
36-11	6098-6110	relationship	_	
36-12	6111-6115	with	_	
36-13	6116-6121	onset	_	
36-14	6122-6125	and	_	
36-15	6126-6139	disappearance	_	
36-16	6140-6142	of	_	
36-17	6143-6152	psychotic	_	
36-18	6153-6161	symptoms	_	
36-19	6162-6165	was	_	
36-20	6166-6174	obtained	_	
36-21	6175-6180	after	_	
36-22	6181-6193	interviewing	_	
36-23	6194-6197	the	_	
36-24	6198-6206	patients	_	
36-25	6206-6207	.	_	

#Text=Moreover, the history of psychiatric disorders and serious somatic diseases were recorded.
37-1	6208-6216	Moreover	_	
37-2	6216-6217	,	_	
37-3	6218-6221	the	_	
37-4	6222-6229	history	_	
37-5	6230-6232	of	_	
37-6	6233-6244	psychiatric	_	
37-7	6245-6254	disorders	_	
37-8	6255-6258	and	_	
37-9	6259-6266	serious	_	
37-10	6267-6274	somatic	_	
37-11	6275-6283	diseases	_	
37-12	6284-6288	were	_	
37-13	6289-6297	recorded	_	
37-14	6297-6298	.	_	

#Text=Participants were followed up for 6 months after their first interview.
38-1	6299-6311	Participants	_	
38-2	6312-6316	were	_	
38-3	6317-6325	followed	_	
38-4	6326-6328	up	_	
38-5	6329-6332	for	_	
38-6	6333-6334	6	_	
38-7	6335-6341	months	_	
38-8	6342-6347	after	_	
38-9	6348-6353	their	_	
38-10	6354-6359	first	_	
38-11	6360-6369	interview	_	
38-12	6369-6370	.	_	

#Text=Clinical evaluation
#Text=The diagnoses of MAP and SCZ were confirmed by 2 senior attending psychiatrists, and the severity of the clinical symptoms was assessed prior to the fMRI scan using the Positive and Negative Syndrome Scale (PANSS) and the Mini International Neuropsychiatric Interview (MINI).
39-1	6371-6379	Clinical	_	
39-2	6380-6390	evaluation	_	
39-3	6391-6394	The	_	
39-4	6395-6404	diagnoses	_	
39-5	6405-6407	of	_	
39-6	6408-6411	MAP	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[51]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[52]	
39-7	6412-6415	and	_	
39-8	6416-6419	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
39-9	6420-6424	were	_	
39-10	6425-6434	confirmed	_	
39-11	6435-6437	by	_	
39-12	6438-6439	2	_	
39-13	6440-6446	senior	_	
39-14	6447-6456	attending	_	
39-15	6457-6470	psychiatrists	_	
39-16	6470-6471	,	_	
39-17	6472-6475	and	_	
39-18	6476-6479	the	_	
39-19	6480-6488	severity	_	
39-20	6489-6491	of	_	
39-21	6492-6495	the	_	
39-22	6496-6504	clinical	_	
39-23	6505-6513	symptoms	_	
39-24	6514-6517	was	_	
39-25	6518-6526	assessed	_	
39-26	6527-6532	prior	_	
39-27	6533-6535	to	_	
39-28	6536-6539	the	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[53]	
39-29	6540-6544	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[53]	
39-30	6545-6549	scan	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[53]	
39-31	6550-6555	using	_	
39-32	6556-6559	the	_	
39-33	6560-6568	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[54]	
39-34	6569-6572	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[54]	
39-35	6573-6581	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[54]	
39-36	6582-6590	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[54]	
39-37	6591-6596	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[54]	
39-38	6597-6598	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[54]	
39-39	6598-6603	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[54]	
39-40	6603-6604	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[54]	
39-41	6605-6608	and	_	
39-42	6609-6612	the	_	
39-43	6613-6617	Mini	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[55]	
39-44	6618-6631	International	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[55]	
39-45	6632-6648	Neuropsychiatric	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[55]	
39-46	6649-6658	Interview	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[55]	
39-47	6659-6660	(	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[55]	
39-48	6660-6664	MINI	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[55]	
39-49	6664-6665	)	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[55]	
39-50	6665-6666	.	_	

#Text=MRI acquisition
#Text=The MRI scans were performed on a 3.0T Signa HDxt scanner (GE Healthcare, America) with an 8-channel head coil MRI scanner at the Department of Psychology, Qiqihar Mental Health Center.
40-1	6667-6670	MRI	_	
40-2	6671-6682	acquisition	_	
40-3	6683-6686	The	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[56]	
40-4	6687-6690	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[56]	
40-5	6691-6696	scans	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[56]	
40-6	6697-6701	were	_	
40-7	6702-6711	performed	_	
40-8	6712-6714	on	_	
40-9	6715-6716	a	_	
40-10	6717-6721	3.0T	_	
40-11	6722-6727	Signa	_	
40-12	6728-6732	HDxt	_	
40-13	6733-6740	scanner	_	
40-14	6741-6742	(	_	
40-15	6742-6744	GE	_	
40-16	6745-6755	Healthcare	_	
40-17	6755-6756	,	_	
40-18	6757-6764	America	_	
40-19	6764-6765	)	_	
40-20	6766-6770	with	_	
40-21	6771-6773	an	_	
40-22	6774-6775	8	_	
40-23	6775-6776	-	_	
40-24	6776-6783	channel	_	
40-25	6784-6788	head	_	
40-26	6789-6793	coil	_	
40-27	6794-6797	MRI	_	
40-28	6798-6805	scanner	_	
40-29	6806-6808	at	_	
40-30	6809-6812	the	_	
40-31	6813-6823	Department	_	
40-32	6824-6826	of	_	
40-33	6827-6837	Psychology	_	
40-34	6837-6838	,	_	
40-35	6839-6846	Qiqihar	_	
40-36	6847-6853	Mental	_	
40-37	6854-6860	Health	_	
40-38	6861-6867	Center	_	
40-39	6867-6868	.	_	

#Text=The anatomical MRIs were administered with T1-weighted sequence for 300 s using the fast spin echo sequence.
41-1	6869-6872	The	_	
41-2	6873-6883	anatomical	_	
41-3	6884-6888	MRIs	_	
41-4	6889-6893	were	_	
41-5	6894-6906	administered	_	
41-6	6907-6911	with	_	
41-7	6912-6914	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[57]	
41-8	6914-6915	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[57]	
41-9	6915-6923	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[57]	
41-10	6924-6932	sequence	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[57]	
41-11	6933-6936	for	_	
41-12	6937-6940	300	_	
41-13	6941-6942	s	_	
41-14	6943-6948	using	_	
41-15	6949-6952	the	_	
41-16	6953-6957	fast	_	
41-17	6958-6962	spin	_	
41-18	6963-6967	echo	_	
41-19	6968-6976	sequence	_	
41-20	6976-6977	.	_	

#Text=Parameters for the OAx T1 FLAIR were shown as: repetition time (TR)=2300 ms, echo time (TE)=2.96 ms, field of vision (FOV)=256×256 cm, image matrix=256×256, voxel dimensions=1.0×1.0×1.0 cm, layer thickness=1.0 mm, layer gap=0.0 mm, and 192 layers in total.
42-1	6978-6988	Parameters	_	
42-2	6989-6992	for	_	
42-3	6993-6996	the	_	
42-4	6997-7000	OAx	_	
42-5	7001-7003	T1	_	
42-6	7004-7009	FLAIR	_	
42-7	7010-7014	were	_	
42-8	7015-7020	shown	_	
42-9	7021-7023	as	_	
42-10	7023-7024	:	_	
42-11	7025-7035	repetition	_	
42-12	7036-7040	time	_	
42-13	7041-7042	(	_	
42-14	7042-7044	TR	_	
42-15	7044-7045	)	_	
42-16	7045-7046	=	_	
42-17	7046-7050	2300	_	
42-18	7051-7053	ms	_	
42-19	7053-7054	,	_	
42-20	7055-7059	echo	_	
42-21	7060-7064	time	_	
42-22	7065-7066	(	_	
42-23	7066-7068	TE	_	
42-24	7068-7069	)	_	
42-25	7069-7070	=	_	
42-26	7070-7074	2.96	_	
42-27	7075-7077	ms	_	
42-28	7077-7078	,	_	
42-29	7079-7084	field	_	
42-30	7085-7087	of	_	
42-31	7088-7094	vision	_	
42-32	7095-7096	(	_	
42-33	7096-7099	FOV	_	
42-34	7099-7100	)	_	
42-35	7100-7101	=	_	
42-36	7101-7104	256	_	
42-37	7104-7105	×	_	
42-38	7105-7108	256	_	
42-39	7109-7111	cm	_	
42-40	7111-7112	,	_	
42-41	7113-7118	image	_	
42-42	7119-7125	matrix	_	
42-43	7125-7126	=	_	
42-44	7126-7129	256	_	
42-45	7129-7130	×	_	
42-46	7130-7133	256	_	
42-47	7133-7134	,	_	
42-48	7135-7140	voxel	_	
42-49	7141-7151	dimensions	_	
42-50	7151-7152	=	_	
42-51	7152-7155	1.0	_	
42-52	7155-7156	×	_	
42-53	7156-7159	1.0	_	
42-54	7159-7160	×	_	
42-55	7160-7163	1.0	_	
42-56	7164-7166	cm	_	
42-57	7166-7167	,	_	
42-58	7168-7173	layer	_	
42-59	7174-7183	thickness	_	
42-60	7183-7184	=	_	
42-61	7184-7187	1.0	_	
42-62	7188-7190	mm	_	
42-63	7190-7191	,	_	
42-64	7192-7197	layer	_	
42-65	7198-7201	gap	_	
42-66	7201-7202	=	_	
42-67	7202-7205	0.0	_	
42-68	7206-7208	mm	_	
42-69	7208-7209	,	_	
42-70	7210-7213	and	_	
42-71	7214-7217	192	_	
42-72	7218-7224	layers	_	
42-73	7225-7227	in	_	
42-74	7228-7233	total	_	
42-75	7233-7234	.	_	

#Text=Then, rs-fMRIs were obtained by 400-second-BOLD-fMRI scanning with echo planar imaging (EPI) sequence, and the scanning orientation was parallel to the anatomical MRI.
43-1	7235-7239	Then	_	
43-2	7239-7240	,	_	
43-3	7241-7249	rs-fMRIs	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	
43-4	7250-7254	were	_	
43-5	7255-7263	obtained	_	
43-6	7264-7266	by	_	
43-7	7267-7270	400	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[58]	
43-8	7270-7271	-	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[58]	
43-9	7271-7287	second-BOLD-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[58]	
43-10	7288-7296	scanning	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[58]	
43-11	7297-7301	with	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[58]	
43-12	7302-7306	echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[58]	
43-13	7307-7313	planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[58]	
43-14	7314-7321	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[58]	
43-15	7322-7323	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[58]	
43-16	7323-7326	EPI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[58]	
43-17	7326-7327	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[58]	
43-18	7328-7336	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[58]	
43-19	7336-7337	,	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[58]	
43-20	7338-7341	and	_	
43-21	7342-7345	the	_	
43-22	7346-7354	scanning	_	
43-23	7355-7366	orientation	_	
43-24	7367-7370	was	_	
43-25	7371-7379	parallel	_	
43-26	7380-7382	to	_	
43-27	7383-7386	the	_	
43-28	7387-7397	anatomical	_	
43-29	7398-7401	MRI	_	
43-30	7401-7402	.	_	

#Text=All participants were required to close their eyes, lie down, rest without thinking, and keep their head still.
44-1	7403-7406	All	_	
44-2	7407-7419	participants	_	
44-3	7420-7424	were	_	
44-4	7425-7433	required	_	
44-5	7434-7436	to	_	
44-6	7437-7442	close	_	
44-7	7443-7448	their	_	
44-8	7449-7453	eyes	_	
44-9	7453-7454	,	_	
44-10	7455-7458	lie	_	
44-11	7459-7463	down	_	
44-12	7463-7464	,	_	
44-13	7465-7469	rest	_	
44-14	7470-7477	without	_	
44-15	7478-7486	thinking	_	
44-16	7486-7487	,	_	
44-17	7488-7491	and	_	
44-18	7492-7496	keep	_	
44-19	7497-7502	their	_	
44-20	7503-7507	head	_	
44-21	7508-7513	still	_	
44-22	7513-7514	.	_	

#Text=The parameters were set as follow: TR=2000 ms, TE=30 ms, flip angle (FA)=90°, FOV=220×220 mm, image matrix=64×64, layer thickness=4.0 mm, and 33 layers in total.
45-1	7515-7518	The	_	
45-2	7519-7529	parameters	_	
45-3	7530-7534	were	_	
45-4	7535-7538	set	_	
45-5	7539-7541	as	_	
45-6	7542-7548	follow	_	
45-7	7548-7549	:	_	
45-8	7550-7552	TR	_	
45-9	7552-7553	=	_	
45-10	7553-7557	2000	_	
45-11	7558-7560	ms	_	
45-12	7560-7561	,	_	
45-13	7562-7564	TE	_	
45-14	7564-7565	=	_	
45-15	7565-7567	30	_	
45-16	7568-7570	ms	_	
45-17	7570-7571	,	_	
45-18	7572-7576	flip	_	
45-19	7577-7582	angle	_	
45-20	7583-7584	(	_	
45-21	7584-7586	FA	_	
45-22	7586-7587	)	_	
45-23	7587-7588	=	_	
45-24	7588-7590	90	_	
45-25	7590-7591	°	_	
45-26	7591-7592	,	_	
45-27	7593-7596	FOV	_	
45-28	7596-7597	=	_	
45-29	7597-7600	220	_	
45-30	7600-7601	×	_	
45-31	7601-7604	220	_	
45-32	7605-7607	mm	_	
45-33	7607-7608	,	_	
45-34	7609-7614	image	_	
45-35	7615-7621	matrix	_	
45-36	7621-7622	=	_	
45-37	7622-7624	64	_	
45-38	7624-7625	×	_	
45-39	7625-7627	64	_	
45-40	7627-7628	,	_	
45-41	7629-7634	layer	_	
45-42	7635-7644	thickness	_	
45-43	7644-7645	=	_	
45-44	7645-7648	4.0	_	
45-45	7649-7651	mm	_	
45-46	7651-7652	,	_	
45-47	7653-7656	and	_	
45-48	7657-7659	33	_	
45-49	7660-7666	layers	_	
45-50	7667-7669	in	_	
45-51	7670-7675	total	_	
45-52	7675-7676	.	_	

#Text=For each participant, the fMRI scanning lasted for approximately 6 min.
46-1	7677-7680	For	_	
46-2	7681-7685	each	_	
46-3	7686-7697	participant	_	
46-4	7697-7698	,	_	
46-5	7699-7702	the	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[59]	
46-6	7703-7707	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[59]	
46-7	7708-7716	scanning	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[59]	
46-8	7717-7723	lasted	_	
46-9	7724-7727	for	_	
46-10	7728-7741	approximately	_	
46-11	7742-7743	6	_	
46-12	7744-7747	min	_	
46-13	7747-7748	.	_	

#Text=Image preprocessing
#Text=All the images were reconstructed and transformed to NIFTI by using the software SPM8 (http://www.fil.ion.ucl.ac.uk/spm/software/spm8/) running on the MATLAB 2011b.
47-1	7749-7754	Image	_	
47-2	7755-7768	preprocessing	_	
47-3	7769-7772	All	_	
47-4	7773-7776	the	_	
47-5	7777-7783	images	_	
47-6	7784-7788	were	_	
47-7	7789-7802	reconstructed	_	
47-8	7803-7806	and	_	
47-9	7807-7818	transformed	_	
47-10	7819-7821	to	_	
47-11	7822-7827	NIFTI	_	
47-12	7828-7830	by	_	
47-13	7831-7836	using	_	
47-14	7837-7840	the	_	
47-15	7841-7849	software	_	
47-16	7850-7854	SPM8	_	
47-17	7855-7856	(	_	
47-18	7856-7860	http	_	
47-19	7860-7861	:	_	
47-20	7861-7862	/	_	
47-21	7862-7863	/	_	
47-22	7863-7884	www.fil.ion.ucl.ac.uk	_	
47-23	7884-7885	/	_	
47-24	7885-7888	spm	_	
47-25	7888-7889	/	_	
47-26	7889-7897	software	_	
47-27	7897-7898	/	_	
47-28	7898-7902	spm8	_	
47-29	7902-7903	/	_	
47-30	7903-7904	)	_	
47-31	7905-7912	running	_	
47-32	7913-7915	on	_	
47-33	7916-7919	the	_	
47-34	7920-7926	MATLAB	_	
47-35	7927-7932	2011b	_	
47-36	7932-7933	.	_	

#Text=Structural image preprocessing and the gray matter density (GMD) were performed using the same software, while the functional image preprocessing, individual ReHo calculation and whole-brain functional connectivity (FC) were analyzed using DPARSF 2.0 software (http://www.nitrc.org/projects/dparsf).
48-1	7934-7944	Structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[60]	
48-2	7945-7950	image	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[60]	
48-3	7951-7964	preprocessing	_	
48-4	7965-7968	and	_	
48-5	7969-7972	the	_	
48-6	7973-7977	gray	_	
48-7	7978-7984	matter	_	
48-8	7985-7992	density	_	
48-9	7993-7994	(	_	
48-10	7994-7997	GMD	_	
48-11	7997-7998	)	_	
48-12	7999-8003	were	_	
48-13	8004-8013	performed	_	
48-14	8014-8019	using	_	
48-15	8020-8023	the	_	
48-16	8024-8028	same	_	
48-17	8029-8037	software	_	
48-18	8037-8038	,	_	
48-19	8039-8044	while	_	
48-20	8045-8048	the	_	
48-21	8049-8059	functional	_	
48-22	8060-8065	image	_	
48-23	8066-8079	preprocessing	_	
48-24	8079-8080	,	_	
48-25	8081-8091	individual	_	
48-26	8092-8096	ReHo	_	
48-27	8097-8108	calculation	_	
48-28	8109-8112	and	_	
48-29	8113-8124	whole-brain	_	
48-30	8125-8135	functional	_	
48-31	8136-8148	connectivity	_	
48-32	8149-8150	(	_	
48-33	8150-8152	FC	_	
48-34	8152-8153	)	_	
48-35	8154-8158	were	_	
48-36	8159-8167	analyzed	_	
48-37	8168-8173	using	_	
48-38	8174-8180	DPARSF	_	
48-39	8181-8184	2.0	_	
48-40	8185-8193	software	_	
48-41	8194-8195	(	_	
48-42	8195-8199	http	_	
48-43	8199-8200	:	_	
48-44	8200-8201	/	_	
48-45	8201-8202	/	_	
48-46	8202-8215	www.nitrc.org	_	
48-47	8215-8216	/	_	
48-48	8216-8224	projects	_	
48-49	8224-8225	/	_	
48-50	8225-8231	dparsf	_	
48-51	8231-8232	)	_	
48-52	8232-8233	.	_	

#Text=GMD
#Text=The structural images were divided into cerebrospinal fluid, gray matter (GM), and white matter using the unified segment.
49-1	8234-8237	GMD	_	
49-2	8238-8241	The	_	
49-3	8242-8252	structural	_	
49-4	8253-8259	images	_	
49-5	8260-8264	were	_	
49-6	8265-8272	divided	_	
49-7	8273-8277	into	_	
49-8	8278-8291	cerebrospinal	_	
49-9	8292-8297	fluid	_	
49-10	8297-8298	,	_	
49-11	8299-8303	gray	_	
49-12	8304-8310	matter	_	
49-13	8311-8312	(	_	
49-14	8312-8314	GM	_	
49-15	8314-8315	)	_	
49-16	8315-8316	,	_	
49-17	8317-8320	and	_	
49-18	8321-8326	white	_	
49-19	8327-8333	matter	_	
49-20	8334-8339	using	_	
49-21	8340-8343	the	_	
49-22	8344-8351	unified	_	
49-23	8352-8359	segment	_	
49-24	8359-8360	.	_	

#Text=According to non-linear methods, the segmented subareas were spatially normalized to standard brain space, and were smoothed by a 6×6×6 FWHM Gaussian kernel to obtain a GM concentration map.
50-1	8361-8370	According	_	
50-2	8371-8373	to	_	
50-3	8374-8384	non-linear	_	
50-4	8385-8392	methods	_	
50-5	8392-8393	,	_	
50-6	8394-8397	the	_	
50-7	8398-8407	segmented	_	
50-8	8408-8416	subareas	_	
50-9	8417-8421	were	_	
50-10	8422-8431	spatially	_	
50-11	8432-8442	normalized	_	
50-12	8443-8445	to	_	
50-13	8446-8454	standard	_	
50-14	8455-8460	brain	_	
50-15	8461-8466	space	_	
50-16	8466-8467	,	_	
50-17	8468-8471	and	_	
50-18	8472-8476	were	_	
50-19	8477-8485	smoothed	_	
50-20	8486-8488	by	_	
50-21	8489-8490	a	_	
50-22	8491-8492	6	_	
50-23	8492-8493	×	_	
50-24	8493-8494	6	_	
50-25	8494-8495	×	_	
50-26	8495-8496	6	_	
50-27	8497-8501	FWHM	_	
50-28	8502-8510	Gaussian	_	
50-29	8511-8517	kernel	_	
50-30	8518-8520	to	_	
50-31	8521-8527	obtain	_	
50-32	8528-8529	a	_	
50-33	8530-8532	GM	_	
50-34	8533-8546	concentration	_	
50-35	8547-8550	map	_	
50-36	8550-8551	.	_	

#Text=The GMD density was analyzed using Marsbar software.
51-1	8552-8555	The	_	
51-2	8556-8559	GMD	_	
51-3	8560-8567	density	_	
51-4	8568-8571	was	_	
51-5	8572-8580	analyzed	_	
51-6	8581-8586	using	_	
51-7	8587-8594	Marsbar	_	
51-8	8595-8603	software	_	
51-9	8603-8604	.	_	

#Text=Individual ReHo
#Text=For functional image preprocessing, the first 10 volumes of the EPI sequence were discarded to avoid signal instability.
52-1	8605-8615	Individual	_	
52-2	8616-8620	ReHo	_	
52-3	8621-8624	For	_	
52-4	8625-8635	functional	_	
52-5	8636-8641	image	_	
52-6	8642-8655	preprocessing	_	
52-7	8655-8656	,	_	
52-8	8657-8660	the	_	
52-9	8661-8666	first	_	
52-10	8667-8669	10	_	
52-11	8670-8677	volumes	_	
52-12	8678-8680	of	_	
52-13	8681-8684	the	_	
52-14	8685-8688	EPI	_	
52-15	8689-8697	sequence	_	
52-16	8698-8702	were	_	
52-17	8703-8712	discarded	_	
52-18	8713-8715	to	_	
52-19	8716-8721	avoid	_	
52-20	8722-8728	signal	_	
52-21	8729-8740	instability	_	
52-22	8740-8741	.	_	

#Text=Slice timing was conducted to correct the remaining volumes, and head realign was used to reject abnormal participants who had more than 3 mm of motion or 3.0° of rotation.
53-1	8742-8747	Slice	_	
53-2	8748-8754	timing	_	
53-3	8755-8758	was	_	
53-4	8759-8768	conducted	_	
53-5	8769-8771	to	_	
53-6	8772-8779	correct	_	
53-7	8780-8783	the	_	
53-8	8784-8793	remaining	_	
53-9	8794-8801	volumes	_	
53-10	8801-8802	,	_	
53-11	8803-8806	and	_	
53-12	8807-8811	head	_	
53-13	8812-8819	realign	_	
53-14	8820-8823	was	_	
53-15	8824-8828	used	_	
53-16	8829-8831	to	_	
53-17	8832-8838	reject	_	
53-18	8839-8847	abnormal	_	
53-19	8848-8860	participants	_	
53-20	8861-8864	who	_	
53-21	8865-8868	had	_	
53-22	8869-8873	more	_	
53-23	8874-8878	than	_	
53-24	8879-8880	3	_	
53-25	8881-8883	mm	_	
53-26	8884-8886	of	_	
53-27	8887-8893	motion	_	
53-28	8894-8896	or	_	
53-29	8897-8900	3.0	_	
53-30	8900-8901	°	_	
53-31	8902-8904	of	_	
53-32	8905-8913	rotation	_	
53-33	8913-8914	.	_	

#Text=The realigned sequences were spatially normalized to the MNI (Montreal Neurological Institute) coordinate and voxels were resampled to 3×3×3 mm3.
54-1	8915-8918	The	_	
54-2	8919-8928	realigned	_	
54-3	8929-8938	sequences	_	
54-4	8939-8943	were	_	
54-5	8944-8953	spatially	_	
54-6	8954-8964	normalized	_	
54-7	8965-8967	to	_	
54-8	8968-8971	the	_	
54-9	8972-8975	MNI	_	
54-10	8976-8977	(	_	
54-11	8977-8985	Montreal	_	
54-12	8986-8998	Neurological	_	
54-13	8999-9008	Institute	_	
54-14	9008-9009	)	_	
54-15	9010-9020	coordinate	_	
54-16	9021-9024	and	_	
54-17	9025-9031	voxels	_	
54-18	9032-9036	were	_	
54-19	9037-9046	resampled	_	
54-20	9047-9049	to	_	
54-21	9050-9051	3	_	
54-22	9051-9052	×	_	
54-23	9052-9053	3	_	
54-24	9053-9054	×	_	
54-25	9054-9055	3	_	
54-26	9056-9059	mm3	_	
54-27	9059-9060	.	_	

#Text=Then, images were band-pass filtered (0.01–0.08 Hz) to reduce low-frequency drift and physiological high-frequency noise, including breath and heart beats.
55-1	9061-9065	Then	_	
55-2	9065-9066	,	_	
55-3	9067-9073	images	_	
55-4	9074-9078	were	_	
55-5	9079-9088	band-pass	_	
55-6	9089-9097	filtered	_	
55-7	9098-9099	(	_	
55-8	9099-9103	0.01	_	
55-9	9103-9104	–	_	
55-10	9104-9108	0.08	_	
55-11	9109-9111	Hz	_	
55-12	9111-9112	)	_	
55-13	9113-9115	to	_	
55-14	9116-9122	reduce	_	
55-15	9123-9136	low-frequency	_	
55-16	9137-9142	drift	_	
55-17	9143-9146	and	_	
55-18	9147-9160	physiological	_	
55-19	9161-9175	high-frequency	_	
55-20	9176-9181	noise	_	
55-21	9181-9182	,	_	
55-22	9183-9192	including	_	
55-23	9193-9199	breath	_	
55-24	9200-9203	and	_	
55-25	9204-9209	heart	_	
55-26	9210-9215	beats	_	
55-27	9215-9216	.	_	

#Text=Then, signals were regressed out before ReHo computation, including head parameter in 6 dimensions, white matter, cerebrospinal fluid (CSF), and global brain.
56-1	9217-9221	Then	_	
56-2	9221-9222	,	_	
56-3	9223-9230	signals	_	
56-4	9231-9235	were	_	
56-5	9236-9245	regressed	_	
56-6	9246-9249	out	_	
56-7	9250-9256	before	_	
56-8	9257-9261	ReHo	_	
56-9	9262-9273	computation	_	
56-10	9273-9274	,	_	
56-11	9275-9284	including	_	
56-12	9285-9289	head	_	
56-13	9290-9299	parameter	_	
56-14	9300-9302	in	_	
56-15	9303-9304	6	_	
56-16	9305-9315	dimensions	_	
56-17	9315-9316	,	_	
56-18	9317-9322	white	_	
56-19	9323-9329	matter	_	
56-20	9329-9330	,	_	
56-21	9331-9344	cerebrospinal	_	
56-22	9345-9350	fluid	_	
56-23	9351-9352	(	_	
56-24	9352-9355	CSF	_	
56-25	9355-9356	)	_	
56-26	9356-9357	,	_	
56-27	9358-9361	and	_	
56-28	9362-9368	global	_	
56-29	9369-9374	brain	_	
56-30	9374-9375	.	_	

#Text=Individual ReHo was calculated with the Kendall’s coefficient concordance (KCC) method.
57-1	9376-9386	Individual	_	
57-2	9387-9391	ReHo	_	
57-3	9392-9395	was	_	
57-4	9396-9406	calculated	_	
57-5	9407-9411	with	_	
57-6	9412-9415	the	_	
57-7	9416-9423	Kendall	_	
57-8	9423-9424	’	_	
57-9	9424-9425	s	_	
57-10	9426-9437	coefficient	_	
57-11	9438-9449	concordance	_	
57-12	9450-9451	(	_	
57-13	9451-9454	KCC	_	
57-14	9454-9455	)	_	
57-15	9456-9462	method	_	
57-16	9462-9463	.	_	

#Text=ReHo maps were normalized by dividing KCC among each voxel by the averaged ReHo of the entire brain and were smoothed by a 4×4×4 FWHM Gaussian kernel to avoid the spatial noise and the false data caused by spatial normalization.
58-1	9464-9468	ReHo	_	
58-2	9469-9473	maps	_	
58-3	9474-9478	were	_	
58-4	9479-9489	normalized	_	
58-5	9490-9492	by	_	
58-6	9493-9501	dividing	_	
58-7	9502-9505	KCC	_	
58-8	9506-9511	among	_	
58-9	9512-9516	each	_	
58-10	9517-9522	voxel	_	
58-11	9523-9525	by	_	
58-12	9526-9529	the	_	
58-13	9530-9538	averaged	_	
58-14	9539-9543	ReHo	_	
58-15	9544-9546	of	_	
58-16	9547-9550	the	_	
58-17	9551-9557	entire	_	
58-18	9558-9563	brain	_	
58-19	9564-9567	and	_	
58-20	9568-9572	were	_	
58-21	9573-9581	smoothed	_	
58-22	9582-9584	by	_	
58-23	9585-9586	a	_	
58-24	9587-9588	4	_	
58-25	9588-9589	×	_	
58-26	9589-9590	4	_	
58-27	9590-9591	×	_	
58-28	9591-9592	4	_	
58-29	9593-9597	FWHM	_	
58-30	9598-9606	Gaussian	_	
58-31	9607-9613	kernel	_	
58-32	9614-9616	to	_	
58-33	9617-9622	avoid	_	
58-34	9623-9626	the	_	
58-35	9627-9634	spatial	_	
58-36	9635-9640	noise	_	
58-37	9641-9644	and	_	
58-38	9645-9648	the	_	
58-39	9649-9654	false	_	
58-40	9655-9659	data	_	
58-41	9660-9666	caused	_	
58-42	9667-9669	by	_	
58-43	9670-9677	spatial	_	
58-44	9678-9691	normalization	_	
58-45	9691-9692	.	_	

#Text=Seed ROI FCM
#Text=According to the analysis of ReHo, group differences in ReHo were found, and points with peak values in sub-regions were defined as seeds.
59-1	9693-9697	Seed	_	
59-2	9698-9701	ROI	_	
59-3	9702-9705	FCM	_	
59-4	9706-9715	According	_	
59-5	9716-9718	to	_	
59-6	9719-9722	the	_	
59-7	9723-9731	analysis	_	
59-8	9732-9734	of	_	
59-9	9735-9739	ReHo	_	
59-10	9739-9740	,	_	
59-11	9741-9746	group	_	
59-12	9747-9758	differences	_	
59-13	9759-9761	in	_	
59-14	9762-9766	ReHo	_	
59-15	9767-9771	were	_	
59-16	9772-9777	found	_	
59-17	9777-9778	,	_	
59-18	9779-9782	and	_	
59-19	9783-9789	points	_	
59-20	9790-9794	with	_	
59-21	9795-9799	peak	_	
59-22	9800-9806	values	_	
59-23	9807-9809	in	_	
59-24	9810-9821	sub-regions	_	
59-25	9822-9826	were	_	
59-26	9827-9834	defined	_	
59-27	9835-9837	as	_	
59-28	9838-9843	seeds	_	
59-29	9843-9844	.	_	

#Text=Spheres with a 6-mm radius and with the seeds as the center were designated as the regions of interest (ROIs).
60-1	9845-9852	Spheres	_	
60-2	9853-9857	with	_	
60-3	9858-9859	a	_	
60-4	9860-9861	6	_	
60-5	9861-9862	-	_	
60-6	9862-9864	mm	_	
60-7	9865-9871	radius	_	
60-8	9872-9875	and	_	
60-9	9876-9880	with	_	
60-10	9881-9884	the	_	
60-11	9885-9890	seeds	_	
60-12	9891-9893	as	_	
60-13	9894-9897	the	_	
60-14	9898-9904	center	_	
60-15	9905-9909	were	_	
60-16	9910-9920	designated	_	
60-17	9921-9923	as	_	
60-18	9924-9927	the	_	
60-19	9928-9935	regions	_	
60-20	9936-9938	of	_	
60-21	9939-9947	interest	_	
60-22	9948-9949	(	_	
60-23	9949-9953	ROIs	_	
60-24	9953-9954	)	_	
60-25	9954-9955	.	_	

#Text=Each voxel in an ROI was calculated as the mean value according to the time sequence.
61-1	9956-9960	Each	_	
61-2	9961-9966	voxel	_	
61-3	9967-9969	in	_	
61-4	9970-9972	an	_	
61-5	9973-9976	ROI	_	
61-6	9977-9980	was	_	
61-7	9981-9991	calculated	_	
61-8	9992-9994	as	_	
61-9	9995-9998	the	_	
61-10	9999-10003	mean	_	
61-11	10004-10009	value	_	
61-12	10010-10019	according	_	
61-13	10020-10022	to	_	
61-14	10023-10026	the	_	
61-15	10027-10031	time	_	
61-16	10032-10040	sequence	_	
61-17	10040-10041	.	_	

#Text=Pearson’s correlation analysis was performed to obtain the whole-brain correlation maps, and Fisher Z translation was calculated to receive whole-brain functional connectivity maps (FCM).
62-1	10042-10049	Pearson	_	
62-2	10049-10050	’	_	
62-3	10050-10051	s	_	
62-4	10052-10063	correlation	_	
62-5	10064-10072	analysis	_	
62-6	10073-10076	was	_	
62-7	10077-10086	performed	_	
62-8	10087-10089	to	_	
62-9	10090-10096	obtain	_	
62-10	10097-10100	the	_	
62-11	10101-10112	whole-brain	_	
62-12	10113-10124	correlation	_	
62-13	10125-10129	maps	_	
62-14	10129-10130	,	_	
62-15	10131-10134	and	_	
62-16	10135-10141	Fisher	_	
62-17	10142-10143	Z	_	
62-18	10144-10155	translation	_	
62-19	10156-10159	was	_	
62-20	10160-10170	calculated	_	
62-21	10171-10173	to	_	
62-22	10174-10181	receive	_	
62-23	10182-10193	whole-brain	_	
62-24	10194-10204	functional	_	
62-25	10205-10217	connectivity	_	
62-26	10218-10222	maps	_	
62-27	10223-10224	(	_	
62-28	10224-10227	FCM	_	
62-29	10227-10228	)	_	
62-30	10228-10229	.	_	

#Text=Statistical analysis
#Text=For GMD, ReHo, and FC analyses, one-way ANOVA was initially conducted in the SPM8 to explore whether there were significant differences among the 3 groups: MAP, SCZ, and controls.
63-1	10230-10241	Statistical	_	
63-2	10242-10250	analysis	_	
63-3	10251-10254	For	_	
63-4	10255-10258	GMD	_	
63-5	10258-10259	,	_	
63-6	10260-10264	ReHo	_	
63-7	10264-10265	,	_	
63-8	10266-10269	and	_	
63-9	10270-10272	FC	_	
63-10	10273-10281	analyses	_	
63-11	10281-10282	,	_	
63-12	10283-10290	one-way	_	
63-13	10291-10296	ANOVA	_	
63-14	10297-10300	was	_	
63-15	10301-10310	initially	_	
63-16	10311-10320	conducted	_	
63-17	10321-10323	in	_	
63-18	10324-10327	the	_	
63-19	10328-10332	SPM8	_	
63-20	10333-10335	to	_	
63-21	10336-10343	explore	_	
63-22	10344-10351	whether	_	
63-23	10352-10357	there	_	
63-24	10358-10362	were	_	
63-25	10363-10374	significant	_	
63-26	10375-10386	differences	_	
63-27	10387-10392	among	_	
63-28	10393-10396	the	_	
63-29	10397-10398	3	_	
63-30	10399-10405	groups	_	
63-31	10405-10406	:	_	
63-32	10407-10410	MAP	_	
63-33	10410-10411	,	_	
63-34	10412-10415	SCZ	_	
63-35	10415-10416	,	_	
63-36	10417-10420	and	_	
63-37	10421-10429	controls	_	
63-38	10429-10430	.	_	

#Text=Post hoc analysis was performed in SPSS 18.0 to detect the group differences within ROIs between paired subgroups.
64-1	10431-10435	Post	_	
64-2	10436-10439	hoc	_	
64-3	10440-10448	analysis	_	
64-4	10449-10452	was	_	
64-5	10453-10462	performed	_	
64-6	10463-10465	in	_	
64-7	10466-10470	SPSS	_	
64-8	10471-10475	18.0	_	
64-9	10476-10478	to	_	
64-10	10479-10485	detect	_	
64-11	10486-10489	the	_	
64-12	10490-10495	group	_	
64-13	10496-10507	differences	_	
64-14	10508-10514	within	_	
64-15	10515-10519	ROIs	_	
64-16	10520-10527	between	_	
64-17	10528-10534	paired	_	
64-18	10535-10544	subgroups	_	
64-19	10544-10545	.	_	

#Text=At last, correlation analysis was administrated for 3 parameters and PANSS score in patient groups.
65-1	10546-10548	At	_	
65-2	10549-10553	last	_	
65-3	10553-10554	,	_	
65-4	10555-10566	correlation	_	
65-5	10567-10575	analysis	_	
65-6	10576-10579	was	_	
65-7	10580-10593	administrated	_	
65-8	10594-10597	for	_	
65-9	10598-10599	3	_	
65-10	10600-10610	parameters	_	
65-11	10611-10614	and	_	
65-12	10615-10620	PANSS	_	
65-13	10621-10626	score	_	
65-14	10627-10629	in	_	
65-15	10630-10637	patient	_	
65-16	10638-10644	groups	_	
65-17	10644-10645	.	_	

#Text=The statistical threshold for one-way ANOVA in GMD analysis was set at P<0.001 and clusters size >40.
66-1	10646-10649	The	_	
66-2	10650-10661	statistical	_	
66-3	10662-10671	threshold	_	
66-4	10672-10675	for	_	
66-5	10676-10683	one-way	_	
66-6	10684-10689	ANOVA	_	
66-7	10690-10692	in	_	
66-8	10693-10696	GMD	_	
66-9	10697-10705	analysis	_	
66-10	10706-10709	was	_	
66-11	10710-10713	set	_	
66-12	10714-10716	at	_	
66-13	10717-10718	P	_	
66-14	10718-10719	<	_	
66-15	10719-10724	0.001	_	
66-16	10725-10728	and	_	
66-17	10729-10737	clusters	_	
66-18	10738-10742	size	_	
66-19	10743-10744	>	_	
66-20	10744-10746	40	_	
66-21	10746-10747	.	_	

#Text=For ReHo comparison, the corrected data according with a combination criterion of voxel-wise P value less than 0.001 and cluster sized greater than 6 voxels were regarded as statistically significant, which was the same in the FC analysis.
67-1	10748-10751	For	_	
67-2	10752-10756	ReHo	_	
67-3	10757-10767	comparison	_	
67-4	10767-10768	,	_	
67-5	10769-10772	the	_	
67-6	10773-10782	corrected	_	
67-7	10783-10787	data	_	
67-8	10788-10797	according	_	
67-9	10798-10802	with	_	
67-10	10803-10804	a	_	
67-11	10805-10816	combination	_	
67-12	10817-10826	criterion	_	
67-13	10827-10829	of	_	
67-14	10830-10840	voxel-wise	_	
67-15	10841-10842	P	_	
67-16	10843-10848	value	_	
67-17	10849-10853	less	_	
67-18	10854-10858	than	_	
67-19	10859-10864	0.001	_	
67-20	10865-10868	and	_	
67-21	10869-10876	cluster	_	
67-22	10877-10882	sized	_	
67-23	10883-10890	greater	_	
67-24	10891-10895	than	_	
67-25	10896-10897	6	_	
67-26	10898-10904	voxels	_	
67-27	10905-10909	were	_	
67-28	10910-10918	regarded	_	
67-29	10919-10921	as	_	
67-30	10922-10935	statistically	_	
67-31	10936-10947	significant	_	
67-32	10947-10948	,	_	
67-33	10949-10954	which	_	
67-34	10955-10958	was	_	
67-35	10959-10962	the	_	
67-36	10963-10967	same	_	
67-37	10968-10970	in	_	
67-38	10971-10974	the	_	
67-39	10975-10977	FC	_	
67-40	10978-10986	analysis	_	
67-41	10986-10987	.	_	

#Text=Results
#Text=Subjects
#Text=We excluded 2 MAP participants and 3 SCZ participants because their head motion/rotation was >3 mm/3°.
68-1	10988-10995	Results	_	
68-2	10996-11004	Subjects	_	
68-3	11005-11007	We	_	
68-4	11008-11016	excluded	_	
68-5	11017-11018	2	_	
68-6	11019-11022	MAP	_	
68-7	11023-11035	participants	_	
68-8	11036-11039	and	_	
68-9	11040-11041	3	_	
68-10	11042-11045	SCZ	_	
68-11	11046-11058	participants	_	
68-12	11059-11066	because	_	
68-13	11067-11072	their	_	
68-14	11073-11077	head	_	
68-15	11078-11084	motion	_	
68-16	11084-11085	/	_	
68-17	11085-11093	rotation	_	
68-18	11094-11097	was	_	
68-19	11098-11099	>	_	
68-20	11099-11100	3	_	
68-21	11101-11103	mm	_	
68-22	11103-11104	/	_	
68-23	11104-11105	3	_	
68-24	11105-11106	°	_	
68-25	11106-11107	.	_	

#Text=Finally, there were 17 MAP recruits, 16 SCZ recruits, and 18 healthy volunteers involved in this study.
69-1	11108-11115	Finally	_	
69-2	11115-11116	,	_	
69-3	11117-11122	there	_	
69-4	11123-11127	were	_	
69-5	11128-11130	17	_	
69-6	11131-11134	MAP	_	
69-7	11135-11143	recruits	_	
69-8	11143-11144	,	_	
69-9	11145-11147	16	_	
69-10	11148-11151	SCZ	_	
69-11	11152-11160	recruits	_	
69-12	11160-11161	,	_	
69-13	11162-11165	and	_	
69-14	11166-11168	18	_	
69-15	11169-11176	healthy	_	
69-16	11177-11187	volunteers	_	
69-17	11188-11196	involved	_	
69-18	11197-11199	in	_	
69-19	11200-11204	this	_	
69-20	11205-11210	study	_	
69-21	11210-11211	.	_	

#Text=No significant differences were shown among the MAP, SCZ, and control groups regarding age, years of education, sex distribution, alcohol consumption history, smoking history, and positive and negative PANSS scores (P>0.05).
70-1	11212-11214	No	_	
70-2	11215-11226	significant	_	
70-3	11227-11238	differences	_	
70-4	11239-11243	were	_	
70-5	11244-11249	shown	_	
70-6	11250-11255	among	_	
70-7	11256-11259	the	_	
70-8	11260-11263	MAP	_	
70-9	11263-11264	,	_	
70-10	11265-11268	SCZ	_	
70-11	11268-11269	,	_	
70-12	11270-11273	and	_	
70-13	11274-11281	control	_	
70-14	11282-11288	groups	_	
70-15	11289-11298	regarding	_	
70-16	11299-11302	age	_	
70-17	11302-11303	,	_	
70-18	11304-11309	years	_	
70-19	11310-11312	of	_	
70-20	11313-11322	education	_	
70-21	11322-11323	,	_	
70-22	11324-11327	sex	_	
70-23	11328-11340	distribution	_	
70-24	11340-11341	,	_	
70-25	11342-11349	alcohol	_	
70-26	11350-11361	consumption	_	
70-27	11362-11369	history	_	
70-28	11369-11370	,	_	
70-29	11371-11378	smoking	_	
70-30	11379-11386	history	_	
70-31	11386-11387	,	_	
70-32	11388-11391	and	_	
70-33	11392-11400	positive	_	
70-34	11401-11404	and	_	
70-35	11405-11413	negative	_	
70-36	11414-11419	PANSS	_	
70-37	11420-11426	scores	_	
70-38	11427-11428	(	_	
70-39	11428-11429	P	_	
70-40	11429-11430	>	_	
70-41	11430-11434	0.05	_	
70-42	11434-11435	)	_	
70-43	11435-11436	.	_	

#Text=However, the total PANSS score in the SCZ group was significantly higher than in the MAP group (P<0.05) (Table 1).
71-1	11437-11444	However	_	
71-2	11444-11445	,	_	
71-3	11446-11449	the	_	
71-4	11450-11455	total	_	
71-5	11456-11461	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	
71-6	11462-11467	score	_	
71-7	11468-11470	in	_	
71-8	11471-11474	the	_	
71-9	11475-11478	SCZ	_	
71-10	11479-11484	group	_	
71-11	11485-11488	was	_	
71-12	11489-11502	significantly	_	
71-13	11503-11509	higher	_	
71-14	11510-11514	than	_	
71-15	11515-11517	in	_	
71-16	11518-11521	the	_	
71-17	11522-11525	MAP	_	
71-18	11526-11531	group	_	
71-19	11532-11533	(	_	
71-20	11533-11534	P	_	
71-21	11534-11535	<	_	
71-22	11535-11539	0.05	_	
71-23	11539-11540	)	_	
71-24	11541-11542	(	_	
71-25	11542-11547	Table	_	
71-26	11548-11549	1	_	
71-27	11549-11550	)	_	
71-28	11550-11551	.	_	

#Text=GMD analysis
#Text=Compared with the control group, higher GMD was observed in the bilateral anterior cingulate (B-AC), bilateral medial superior frontal gyrus (B-MSFG), and left operculum inferior frontal gyrus (L-opr-IFG), whereas lower GMD was observed in right middle frontal gyrus (R-MFG) of the MAP group.
72-1	11552-11555	GMD	_	
72-2	11556-11564	analysis	_	
72-3	11565-11573	Compared	_	
72-4	11574-11578	with	_	
72-5	11579-11582	the	_	
72-6	11583-11590	control	_	
72-7	11591-11596	group	_	
72-8	11596-11597	,	_	
72-9	11598-11604	higher	_	
72-10	11605-11608	GMD	_	
72-11	11609-11612	was	_	
72-12	11613-11621	observed	_	
72-13	11622-11624	in	_	
72-14	11625-11628	the	_	
72-15	11629-11638	bilateral	_	
72-16	11639-11647	anterior	_	
72-17	11648-11657	cingulate	_	
72-18	11658-11659	(	_	
72-19	11659-11663	B-AC	_	
72-20	11663-11664	)	_	
72-21	11664-11665	,	_	
72-22	11666-11675	bilateral	_	
72-23	11676-11682	medial	_	
72-24	11683-11691	superior	_	
72-25	11692-11699	frontal	_	
72-26	11700-11705	gyrus	_	
72-27	11706-11707	(	_	
72-28	11707-11713	B-MSFG	_	
72-29	11713-11714	)	_	
72-30	11714-11715	,	_	
72-31	11716-11719	and	_	
72-32	11720-11724	left	_	
72-33	11725-11734	operculum	_	
72-34	11735-11743	inferior	_	
72-35	11744-11751	frontal	_	
72-36	11752-11757	gyrus	_	
72-37	11758-11759	(	_	
72-38	11759-11768	L-opr-IFG	_	
72-39	11768-11769	)	_	
72-40	11769-11770	,	_	
72-41	11771-11778	whereas	_	
72-42	11779-11784	lower	_	
72-43	11785-11788	GMD	_	
72-44	11789-11792	was	_	
72-45	11793-11801	observed	_	
72-46	11802-11804	in	_	
72-47	11805-11810	right	_	
72-48	11811-11817	middle	_	
72-49	11818-11825	frontal	_	
72-50	11826-11831	gyrus	_	
72-51	11832-11833	(	_	
72-52	11833-11838	R-MFG	_	
72-53	11838-11839	)	_	
72-54	11840-11842	of	_	
72-55	11843-11846	the	_	
72-56	11847-11850	MAP	_	
72-57	11851-11856	group	_	
72-58	11856-11857	.	_	

#Text=In comparison with the control group, the SCZ group presented lower GMD values in L-opr-IFG, B-AC, and R-MFG regions but higher GMD within the B-MSFG region.
73-1	11858-11860	In	_	
73-2	11861-11871	comparison	_	
73-3	11872-11876	with	_	
73-4	11877-11880	the	_	
73-5	11881-11888	control	_	
73-6	11889-11894	group	_	
73-7	11894-11895	,	_	
73-8	11896-11899	the	_	
73-9	11900-11903	SCZ	_	
73-10	11904-11909	group	_	
73-11	11910-11919	presented	_	
73-12	11920-11925	lower	_	
73-13	11926-11929	GMD	_	
73-14	11930-11936	values	_	
73-15	11937-11939	in	_	
73-16	11940-11949	L-opr-IFG	_	
73-17	11949-11950	,	_	
73-18	11951-11955	B-AC	_	
73-19	11955-11956	,	_	
73-20	11957-11960	and	_	
73-21	11961-11966	R-MFG	_	
73-22	11967-11974	regions	_	
73-23	11975-11978	but	_	
73-24	11979-11985	higher	_	
73-25	11986-11989	GMD	_	
73-26	11990-11996	within	_	
73-27	11997-12000	the	_	
73-28	12001-12007	B-MSFG	_	
73-29	12008-12014	region	_	
73-30	12014-12015	.	_	

#Text=Compared with the SCZ group, the MAP group showed significantly higher GMD in the L-opr-IFG, B-MSFG, B-AC, and R-MFG regions (Figure 1, Table 2).
74-1	12016-12024	Compared	_	
74-2	12025-12029	with	_	
74-3	12030-12033	the	_	
74-4	12034-12037	SCZ	_	
74-5	12038-12043	group	_	
74-6	12043-12044	,	_	
74-7	12045-12048	the	_	
74-8	12049-12052	MAP	_	
74-9	12053-12058	group	_	
74-10	12059-12065	showed	_	
74-11	12066-12079	significantly	_	
74-12	12080-12086	higher	_	
74-13	12087-12090	GMD	_	
74-14	12091-12093	in	_	
74-15	12094-12097	the	_	
74-16	12098-12107	L-opr-IFG	_	
74-17	12107-12108	,	_	
74-18	12109-12115	B-MSFG	_	
74-19	12115-12116	,	_	
74-20	12117-12121	B-AC	_	
74-21	12121-12122	,	_	
74-22	12123-12126	and	_	
74-23	12127-12132	R-MFG	_	
74-24	12133-12140	regions	_	
74-25	12141-12142	(	_	
74-26	12142-12148	Figure	_	
74-27	12149-12150	1	_	
74-28	12150-12151	,	_	
74-29	12152-12157	Table	_	
74-30	12158-12159	2	_	
74-31	12159-12160	)	_	
74-32	12160-12161	.	_	

#Text=Individual ReHo analysis
#Text=Post hoc analysis revealed that in comparison to healthy volunteers, higher ReHo was detected in the right hippocampus (R-HPC) and left orbital inferior frontal gyrus (L-orb-IFG) regions, whereas significant lower ReHo was observed in left medial superior frontal gyrus (L-MSFG), right angular gyrus (R-ANG), and R-MFG/superior frontal gyrus (SFG) of MAP patients.
75-1	12162-12172	Individual	_	
75-2	12173-12177	ReHo	_	
75-3	12178-12186	analysis	_	
75-4	12187-12191	Post	_	
75-5	12192-12195	hoc	_	
75-6	12196-12204	analysis	_	
75-7	12205-12213	revealed	_	
75-8	12214-12218	that	_	
75-9	12219-12221	in	_	
75-10	12222-12232	comparison	_	
75-11	12233-12235	to	_	
75-12	12236-12243	healthy	_	
75-13	12244-12254	volunteers	_	
75-14	12254-12255	,	_	
75-15	12256-12262	higher	_	
75-16	12263-12267	ReHo	_	
75-17	12268-12271	was	_	
75-18	12272-12280	detected	_	
75-19	12281-12283	in	_	
75-20	12284-12287	the	_	
75-21	12288-12293	right	_	
75-22	12294-12305	hippocampus	_	
75-23	12306-12307	(	_	
75-24	12307-12312	R-HPC	_	
75-25	12312-12313	)	_	
75-26	12314-12317	and	_	
75-27	12318-12322	left	_	
75-28	12323-12330	orbital	_	
75-29	12331-12339	inferior	_	
75-30	12340-12347	frontal	_	
75-31	12348-12353	gyrus	_	
75-32	12354-12355	(	_	
75-33	12355-12364	L-orb-IFG	_	
75-34	12364-12365	)	_	
75-35	12366-12373	regions	_	
75-36	12373-12374	,	_	
75-37	12375-12382	whereas	_	
75-38	12383-12394	significant	_	
75-39	12395-12400	lower	_	
75-40	12401-12405	ReHo	_	
75-41	12406-12409	was	_	
75-42	12410-12418	observed	_	
75-43	12419-12421	in	_	
75-44	12422-12426	left	_	
75-45	12427-12433	medial	_	
75-46	12434-12442	superior	_	
75-47	12443-12450	frontal	_	
75-48	12451-12456	gyrus	_	
75-49	12457-12458	(	_	
75-50	12458-12464	L-MSFG	_	
75-51	12464-12465	)	_	
75-52	12465-12466	,	_	
75-53	12467-12472	right	_	
75-54	12473-12480	angular	_	
75-55	12481-12486	gyrus	_	
75-56	12487-12488	(	_	
75-57	12488-12493	R-ANG	_	
75-58	12493-12494	)	_	
75-59	12494-12495	,	_	
75-60	12496-12499	and	_	
75-61	12500-12505	R-MFG	_	
75-62	12505-12506	/	_	
75-63	12506-12514	superior	_	
75-64	12515-12522	frontal	_	
75-65	12523-12528	gyrus	_	
75-66	12529-12530	(	_	
75-67	12530-12533	SFG	_	
75-68	12533-12534	)	_	
75-69	12535-12537	of	_	
75-70	12538-12541	MAP	_	
75-71	12542-12550	patients	_	
75-72	12550-12551	.	_	

#Text=Similarly, compared with the healthy volunteers, SCZ patients showed higher ReHo in R-HPC, left triangular part (L-TRP)/opr-IFG, and L-LTN regions, but these levels were lower in other tested brain regions.
76-1	12552-12561	Similarly	_	
76-2	12561-12562	,	_	
76-3	12563-12571	compared	_	
76-4	12572-12576	with	_	
76-5	12577-12580	the	_	
76-6	12581-12588	healthy	_	
76-7	12589-12599	volunteers	_	
76-8	12599-12600	,	_	
76-9	12601-12604	SCZ	_	
76-10	12605-12613	patients	_	
76-11	12614-12620	showed	_	
76-12	12621-12627	higher	_	
76-13	12628-12632	ReHo	_	
76-14	12633-12635	in	_	
76-15	12636-12641	R-HPC	_	
76-16	12641-12642	,	_	
76-17	12643-12647	left	_	
76-18	12648-12658	triangular	_	
76-19	12659-12663	part	_	
76-20	12664-12665	(	_	
76-21	12665-12670	L-TRP	_	
76-22	12670-12671	)	_	
76-23	12671-12672	/	_	
76-24	12672-12679	opr-IFG	_	
76-25	12679-12680	,	_	
76-26	12681-12684	and	_	
76-27	12685-12690	L-LTN	_	
76-28	12691-12698	regions	_	
76-29	12698-12699	,	_	
76-30	12700-12703	but	_	
76-31	12704-12709	these	_	
76-32	12710-12716	levels	_	
76-33	12717-12721	were	_	
76-34	12722-12727	lower	_	
76-35	12728-12730	in	_	
76-36	12731-12736	other	_	
76-37	12737-12743	tested	_	
76-38	12744-12749	brain	_	
76-39	12750-12757	regions	_	
76-40	12757-12758	.	_	

#Text=Quite differently, MAP patients demonstrated significantly stronger ReHo in L-orb-IFG, R-STG, L-MSFG, right precuneus (R-PC), and R-SFG regions compared to SCZ patients (Figure 2, Table 3).
77-1	12759-12764	Quite	_	
77-2	12765-12776	differently	_	
77-3	12776-12777	,	_	
77-4	12778-12781	MAP	_	
77-5	12782-12790	patients	_	
77-6	12791-12803	demonstrated	_	
77-7	12804-12817	significantly	_	
77-8	12818-12826	stronger	_	
77-9	12827-12831	ReHo	_	
77-10	12832-12834	in	_	
77-11	12835-12844	L-orb-IFG	_	
77-12	12844-12845	,	_	
77-13	12846-12851	R-STG	_	
77-14	12851-12852	,	_	
77-15	12853-12859	L-MSFG	_	
77-16	12859-12860	,	_	
77-17	12861-12866	right	_	
77-18	12867-12876	precuneus	_	
77-19	12877-12878	(	_	
77-20	12878-12882	R-PC	_	
77-21	12882-12883	)	_	
77-22	12883-12884	,	_	
77-23	12885-12888	and	_	
77-24	12889-12894	R-SFG	_	
77-25	12895-12902	regions	_	
77-26	12903-12911	compared	_	
77-27	12912-12914	to	_	
77-28	12915-12918	SCZ	_	
77-29	12919-12927	patients	_	
77-30	12928-12929	(	_	
77-31	12929-12935	Figure	_	
77-32	12936-12937	2	_	
77-33	12937-12938	,	_	
77-34	12939-12944	Table	_	
77-35	12945-12946	3	_	
77-36	12946-12947	)	_	
77-37	12947-12948	.	_	

#Text=Functional connectivity (FC) analysis of participants
#Text=The peak points of R-HPC, L-MSFG, R-ANG, and R-MFG/SFG were chosen as seeds.
78-1	12949-12959	Functional	_	
78-2	12960-12972	connectivity	_	
78-3	12973-12974	(	_	
78-4	12974-12976	FC	_	
78-5	12976-12977	)	_	
78-6	12978-12986	analysis	_	
78-7	12987-12989	of	_	
78-8	12990-13002	participants	_	
78-9	13003-13006	The	_	
78-10	13007-13011	peak	_	
78-11	13012-13018	points	_	
78-12	13019-13021	of	_	
78-13	13022-13027	R-HPC	_	
78-14	13027-13028	,	_	
78-15	13029-13035	L-MSFG	_	
78-16	13035-13036	,	_	
78-17	13037-13042	R-ANG	_	
78-18	13042-13043	,	_	
78-19	13044-13047	and	_	
78-20	13048-13053	R-MFG	_	
78-21	13053-13054	/	_	
78-22	13054-13057	SFG	_	
78-23	13058-13062	were	_	
78-24	13063-13069	chosen	_	
78-25	13070-13072	as	_	
78-26	13073-13078	seeds	_	
78-27	13078-13079	.	_	

#Text=The seed regions were specifically shown as: R-HPC (MNI coordinates x=27, y=−18, z=−9), L-MSFG (MNI coordinates x=−3, y=63, z=18), R-ANG (MNI coordinates x=39, y=−63, z=48), and R-MFG/SFG (MNI coordinates x=30, y=30, z=51) (Table 4).
79-1	13080-13083	The	_	
79-2	13084-13088	seed	_	
79-3	13089-13096	regions	_	
79-4	13097-13101	were	_	
79-5	13102-13114	specifically	_	
79-6	13115-13120	shown	_	
79-7	13121-13123	as	_	
79-8	13123-13124	:	_	
79-9	13125-13130	R-HPC	_	
79-10	13131-13132	(	_	
79-11	13132-13135	MNI	_	
79-12	13136-13147	coordinates	_	
79-13	13148-13149	x	_	
79-14	13149-13150	=	_	
79-15	13150-13152	27	_	
79-16	13152-13153	,	_	
79-17	13154-13155	y	_	
79-18	13155-13156	=	_	
79-19	13156-13157	−	_	
79-20	13157-13159	18	_	
79-21	13159-13160	,	_	
79-22	13161-13162	z	_	
79-23	13162-13163	=	_	
79-24	13163-13164	−	_	
79-25	13164-13165	9	_	
79-26	13165-13166	)	_	
79-27	13166-13167	,	_	
79-28	13168-13174	L-MSFG	_	
79-29	13175-13176	(	_	
79-30	13176-13179	MNI	_	
79-31	13180-13191	coordinates	_	
79-32	13192-13193	x	_	
79-33	13193-13194	=	_	
79-34	13194-13195	−	_	
79-35	13195-13196	3	_	
79-36	13196-13197	,	_	
79-37	13198-13199	y	_	
79-38	13199-13200	=	_	
79-39	13200-13202	63	_	
79-40	13202-13203	,	_	
79-41	13204-13205	z	_	
79-42	13205-13206	=	_	
79-43	13206-13208	18	_	
79-44	13208-13209	)	_	
79-45	13209-13210	,	_	
79-46	13211-13216	R-ANG	_	
79-47	13217-13218	(	_	
79-48	13218-13221	MNI	_	
79-49	13222-13233	coordinates	_	
79-50	13234-13235	x	_	
79-51	13235-13236	=	_	
79-52	13236-13238	39	_	
79-53	13238-13239	,	_	
79-54	13240-13241	y	_	
79-55	13241-13242	=	_	
79-56	13242-13243	−	_	
79-57	13243-13245	63	_	
79-58	13245-13246	,	_	
79-59	13247-13248	z	_	
79-60	13248-13249	=	_	
79-61	13249-13251	48	_	
79-62	13251-13252	)	_	
79-63	13252-13253	,	_	
79-64	13254-13257	and	_	
79-65	13258-13263	R-MFG	_	
79-66	13263-13264	/	_	
79-67	13264-13267	SFG	_	
79-68	13268-13269	(	_	
79-69	13269-13272	MNI	_	
79-70	13273-13284	coordinates	_	
79-71	13285-13286	x	_	
79-72	13286-13287	=	_	
79-73	13287-13289	30	_	
79-74	13289-13290	,	_	
79-75	13291-13292	y	_	
79-76	13292-13293	=	_	
79-77	13293-13295	30	_	
79-78	13295-13296	,	_	
79-79	13297-13298	z	_	
79-80	13298-13299	=	_	
79-81	13299-13301	51	_	
79-82	13301-13302	)	_	
79-83	13303-13304	(	_	
79-84	13304-13309	Table	_	
79-85	13310-13311	4	_	
79-86	13311-13312	)	_	
79-87	13312-13313	.	_	

#Text=When the R-HPC was set as the seed region, MAP patients showed no significant difference from the controls (Table 4, Figure 3).
80-1	13314-13318	When	_	
80-2	13319-13322	the	_	
80-3	13323-13328	R-HPC	_	
80-4	13329-13332	was	_	
80-5	13333-13336	set	_	
80-6	13337-13339	as	_	
80-7	13340-13343	the	_	
80-8	13344-13348	seed	_	
80-9	13349-13355	region	_	
80-10	13355-13356	,	_	
80-11	13357-13360	MAP	_	
80-12	13361-13369	patients	_	
80-13	13370-13376	showed	_	
80-14	13377-13379	no	_	
80-15	13380-13391	significant	_	
80-16	13392-13402	difference	_	
80-17	13403-13407	from	_	
80-18	13408-13411	the	_	
80-19	13412-13420	controls	_	
80-20	13421-13422	(	_	
80-21	13422-13427	Table	_	
80-22	13428-13429	4	_	
80-23	13429-13430	,	_	
80-24	13431-13437	Figure	_	
80-25	13438-13439	3	_	
80-26	13439-13440	)	_	
80-27	13440-13441	.	_	

#Text=When the L-MSFG was set as the seed region, L-SFG/MFG and L-SFG were significantly higher GMD in controls compared with the MAP group (Table 4, Figure 4).
81-1	13442-13446	When	_	
81-2	13447-13450	the	_	
81-3	13451-13457	L-MSFG	_	
81-4	13458-13461	was	_	
81-5	13462-13465	set	_	
81-6	13466-13468	as	_	
81-7	13469-13472	the	_	
81-8	13473-13477	seed	_	
81-9	13478-13484	region	_	
81-10	13484-13485	,	_	
81-11	13486-13491	L-SFG	_	
81-12	13491-13492	/	_	
81-13	13492-13495	MFG	_	
81-14	13496-13499	and	_	
81-15	13500-13505	L-SFG	_	
81-16	13506-13510	were	_	
81-17	13511-13524	significantly	_	
81-18	13525-13531	higher	_	
81-19	13532-13535	GMD	_	
81-20	13536-13538	in	_	
81-21	13539-13547	controls	_	
81-22	13548-13556	compared	_	
81-23	13557-13561	with	_	
81-24	13562-13565	the	_	
81-25	13566-13569	MAP	_	
81-26	13570-13575	group	_	
81-27	13576-13577	(	_	
81-28	13577-13582	Table	_	
81-29	13583-13584	4	_	
81-30	13584-13585	,	_	
81-31	13586-13592	Figure	_	
81-32	13593-13594	4	_	
81-33	13594-13595	)	_	
81-34	13595-13596	.	_	

#Text=When R-ANG region was set as the seed, MAP patients showed significantly lower GMD in R-ITG compared with the control group (Table 4, Figure 5).
82-1	13597-13601	When	_	
82-2	13602-13607	R-ANG	_	
82-3	13608-13614	region	_	
82-4	13615-13618	was	_	
82-5	13619-13622	set	_	
82-6	13623-13625	as	_	
82-7	13626-13629	the	_	
82-8	13630-13634	seed	_	
82-9	13634-13635	,	_	
82-10	13636-13639	MAP	_	
82-11	13640-13648	patients	_	
82-12	13649-13655	showed	_	
82-13	13656-13669	significantly	_	
82-14	13670-13675	lower	_	
82-15	13676-13679	GMD	_	
82-16	13680-13682	in	_	
82-17	13683-13688	R-ITG	_	
82-18	13689-13697	compared	_	
82-19	13698-13702	with	_	
82-20	13703-13706	the	_	
82-21	13707-13714	control	_	
82-22	13715-13720	group	_	
82-23	13721-13722	(	_	
82-24	13722-13727	Table	_	
82-25	13728-13729	4	_	
82-26	13729-13730	,	_	
82-27	13731-13737	Figure	_	
82-28	13738-13739	5	_	
82-29	13739-13740	)	_	
82-30	13740-13741	.	_	

#Text=When the R-MFG/SFG was set as the seed region, MAP patients showed significantly lower GMD within L-PC and L-ANG regions but higher GMD within R-MFG, L-opr-IFG, and L-MFG regions than control volunteers (Table 4, Figure 6).
83-1	13742-13746	When	_	
83-2	13747-13750	the	_	
83-3	13751-13756	R-MFG	_	
83-4	13756-13757	/	_	
83-5	13757-13760	SFG	_	
83-6	13761-13764	was	_	
83-7	13765-13768	set	_	
83-8	13769-13771	as	_	
83-9	13772-13775	the	_	
83-10	13776-13780	seed	_	
83-11	13781-13787	region	_	
83-12	13787-13788	,	_	
83-13	13789-13792	MAP	_	
83-14	13793-13801	patients	_	
83-15	13802-13808	showed	_	
83-16	13809-13822	significantly	_	
83-17	13823-13828	lower	_	
83-18	13829-13832	GMD	_	
83-19	13833-13839	within	_	
83-20	13840-13844	L-PC	_	
83-21	13845-13848	and	_	
83-22	13849-13854	L-ANG	_	
83-23	13855-13862	regions	_	
83-24	13863-13866	but	_	
83-25	13867-13873	higher	_	
83-26	13874-13877	GMD	_	
83-27	13878-13884	within	_	
83-28	13885-13890	R-MFG	_	
83-29	13890-13891	,	_	
83-30	13892-13901	L-opr-IFG	_	
83-31	13901-13902	,	_	
83-32	13903-13906	and	_	
83-33	13907-13912	L-MFG	_	
83-34	13913-13920	regions	_	
83-35	13921-13925	than	_	
83-36	13926-13933	control	_	
83-37	13934-13944	volunteers	_	
83-38	13945-13946	(	_	
83-39	13946-13951	Table	_	
83-40	13952-13953	4	_	
83-41	13953-13954	,	_	
83-42	13955-13961	Figure	_	
83-43	13962-13963	6	_	
83-44	13963-13964	)	_	
83-45	13964-13965	.	_	

#Text=High GMD suggests strong FC with the seed region within the brain.
84-1	13966-13970	High	_	
84-2	13971-13974	GMD	_	
84-3	13975-13983	suggests	_	
84-4	13984-13990	strong	_	
84-5	13991-13993	FC	_	
84-6	13994-13998	with	_	
84-7	13999-14002	the	_	
84-8	14003-14007	seed	_	
84-9	14008-14014	region	_	
84-10	14015-14021	within	_	
84-11	14022-14025	the	_	
84-12	14026-14031	brain	_	
84-13	14031-14032	.	_	

#Text=In the SCZ group, there were strong FCs between the R-HPC seed region and the left insula (L-INS) (Figure 3, Table 4) between LM-SFG seed and the R-MSFG (Figure 4, Table 4), the L-SFG/MFG and the left superior frontal gyrus (L-SFG), between the R-ANG seed region and the right inferior temporal gyrus (R-ITG) (Figure 5, Table 4), and between the R-MFG/SFG seed region and the right thalamus (R-THL), left precuneus (L-PC), R-MFG, L-opr-IFG, left middle frontal gyrus (L-MFG), and L-ANG regions (Figure 6, Table 4).
85-1	14033-14035	In	_	
85-2	14036-14039	the	_	
85-3	14040-14043	SCZ	_	
85-4	14044-14049	group	_	
85-5	14049-14050	,	_	
85-6	14051-14056	there	_	
85-7	14057-14061	were	_	
85-8	14062-14068	strong	_	
85-9	14069-14072	FCs	_	
85-10	14073-14080	between	_	
85-11	14081-14084	the	_	
85-12	14085-14090	R-HPC	_	
85-13	14091-14095	seed	_	
85-14	14096-14102	region	_	
85-15	14103-14106	and	_	
85-16	14107-14110	the	_	
85-17	14111-14115	left	_	
85-18	14116-14122	insula	_	
85-19	14123-14124	(	_	
85-20	14124-14129	L-INS	_	
85-21	14129-14130	)	_	
85-22	14131-14132	(	_	
85-23	14132-14138	Figure	_	
85-24	14139-14140	3	_	
85-25	14140-14141	,	_	
85-26	14142-14147	Table	_	
85-27	14148-14149	4	_	
85-28	14149-14150	)	_	
85-29	14151-14158	between	_	
85-30	14159-14165	LM-SFG	_	
85-31	14166-14170	seed	_	
85-32	14171-14174	and	_	
85-33	14175-14178	the	_	
85-34	14179-14185	R-MSFG	_	
85-35	14186-14187	(	_	
85-36	14187-14193	Figure	_	
85-37	14194-14195	4	_	
85-38	14195-14196	,	_	
85-39	14197-14202	Table	_	
85-40	14203-14204	4	_	
85-41	14204-14205	)	_	
85-42	14205-14206	,	_	
85-43	14207-14210	the	_	
85-44	14211-14216	L-SFG	_	
85-45	14216-14217	/	_	
85-46	14217-14220	MFG	_	
85-47	14221-14224	and	_	
85-48	14225-14228	the	_	
85-49	14229-14233	left	_	
85-50	14234-14242	superior	_	
85-51	14243-14250	frontal	_	
85-52	14251-14256	gyrus	_	
85-53	14257-14258	(	_	
85-54	14258-14263	L-SFG	_	
85-55	14263-14264	)	_	
85-56	14264-14265	,	_	
85-57	14266-14273	between	_	
85-58	14274-14277	the	_	
85-59	14278-14283	R-ANG	_	
85-60	14284-14288	seed	_	
85-61	14289-14295	region	_	
85-62	14296-14299	and	_	
85-63	14300-14303	the	_	
85-64	14304-14309	right	_	
85-65	14310-14318	inferior	_	
85-66	14319-14327	temporal	_	
85-67	14328-14333	gyrus	_	
85-68	14334-14335	(	_	
85-69	14335-14340	R-ITG	_	
85-70	14340-14341	)	_	
85-71	14342-14343	(	_	
85-72	14343-14349	Figure	_	
85-73	14350-14351	5	_	
85-74	14351-14352	,	_	
85-75	14353-14358	Table	_	
85-76	14359-14360	4	_	
85-77	14360-14361	)	_	
85-78	14361-14362	,	_	
85-79	14363-14366	and	_	
85-80	14367-14374	between	_	
85-81	14375-14378	the	_	
85-82	14379-14384	R-MFG	_	
85-83	14384-14385	/	_	
85-84	14385-14388	SFG	_	
85-85	14389-14393	seed	_	
85-86	14394-14400	region	_	
85-87	14401-14404	and	_	
85-88	14405-14408	the	_	
85-89	14409-14414	right	_	
85-90	14415-14423	thalamus	_	
85-91	14424-14425	(	_	
85-92	14425-14430	R-THL	_	
85-93	14430-14431	)	_	
85-94	14431-14432	,	_	
85-95	14433-14437	left	_	
85-96	14438-14447	precuneus	_	
85-97	14448-14449	(	_	
85-98	14449-14453	L-PC	_	
85-99	14453-14454	)	_	
85-100	14454-14455	,	_	
85-101	14456-14461	R-MFG	_	
85-102	14461-14462	,	_	
85-103	14463-14472	L-opr-IFG	_	
85-104	14472-14473	,	_	
85-105	14474-14478	left	_	
85-106	14479-14485	middle	_	
85-107	14486-14493	frontal	_	
85-108	14494-14499	gyrus	_	
85-109	14500-14501	(	_	
85-110	14501-14506	L-MFG	_	
85-111	14506-14507	)	_	
85-112	14507-14508	,	_	
85-113	14509-14512	and	_	
85-114	14513-14518	L-ANG	_	
85-115	14519-14526	regions	_	
85-116	14527-14528	(	_	
85-117	14528-14534	Figure	_	
85-118	14535-14536	6	_	
85-119	14536-14537	,	_	
85-120	14538-14543	Table	_	
85-121	14544-14545	4	_	
85-122	14545-14546	)	_	
85-123	14546-14547	.	_	

#Text=MAP patients showed significantly weaker FC with R-HPC seed region within the L-INS region than SCZ patients.
86-1	14548-14551	MAP	_	
86-2	14552-14560	patients	_	
86-3	14561-14567	showed	_	
86-4	14568-14581	significantly	_	
86-5	14582-14588	weaker	_	
86-6	14589-14591	FC	_	
86-7	14592-14596	with	_	
86-8	14597-14602	R-HPC	_	
86-9	14603-14607	seed	_	
86-10	14608-14614	region	_	
86-11	14615-14621	within	_	
86-12	14622-14625	the	_	
86-13	14626-14631	L-INS	_	
86-14	14632-14638	region	_	
86-15	14639-14643	than	_	
86-16	14644-14647	SCZ	_	
86-17	14648-14656	patients	_	
86-18	14656-14657	.	_	

#Text=MAP patients showed significantly stronger FCs with L-MSFG seed region within R-MSFG and L-SFG regions.
87-1	14658-14661	MAP	_	
87-2	14662-14670	patients	_	
87-3	14671-14677	showed	_	
87-4	14678-14691	significantly	_	
87-5	14692-14700	stronger	_	
87-6	14701-14704	FCs	_	
87-7	14705-14709	with	_	
87-8	14710-14716	L-MSFG	_	
87-9	14717-14721	seed	_	
87-10	14722-14728	region	_	
87-11	14729-14735	within	_	
87-12	14736-14742	R-MSFG	_	
87-13	14743-14746	and	_	
87-14	14747-14752	L-SFG	_	
87-15	14753-14760	regions	_	
87-16	14760-14761	.	_	

#Text=There was no significantly different FC with R-ANG seed region within the R-ITG region.
88-1	14762-14767	There	_	
88-2	14768-14771	was	_	
88-3	14772-14774	no	_	
88-4	14775-14788	significantly	_	
88-5	14789-14798	different	_	
88-6	14799-14801	FC	_	
88-7	14802-14806	with	_	
88-8	14807-14812	R-ANG	_	
88-9	14813-14817	seed	_	
88-10	14818-14824	region	_	
88-11	14825-14831	within	_	
88-12	14832-14835	the	_	
88-13	14836-14841	R-ITG	_	
88-14	14842-14848	region	_	
88-15	14848-14849	.	_	

#Text=In addition, when R-MFG/SFG was set as the seed region, MAP patients had significantly stronger FC within the R-THL region than SCZ patients (Figure 6, Table 4).
89-1	14850-14852	In	_	
89-2	14853-14861	addition	_	
89-3	14861-14862	,	_	
89-4	14863-14867	when	_	
89-5	14868-14873	R-MFG	_	
89-6	14873-14874	/	_	
89-7	14874-14877	SFG	_	
89-8	14878-14881	was	_	
89-9	14882-14885	set	_	
89-10	14886-14888	as	_	
89-11	14889-14892	the	_	
89-12	14893-14897	seed	_	
89-13	14898-14904	region	_	
89-14	14904-14905	,	_	
89-15	14906-14909	MAP	_	
89-16	14910-14918	patients	_	
89-17	14919-14922	had	_	
89-18	14923-14936	significantly	_	
89-19	14937-14945	stronger	_	
89-20	14946-14948	FC	_	
89-21	14949-14955	within	_	
89-22	14956-14959	the	_	
89-23	14960-14965	R-THL	_	
89-24	14966-14972	region	_	
89-25	14973-14977	than	_	
89-26	14978-14981	SCZ	_	
89-27	14982-14990	patients	_	
89-28	14991-14992	(	_	
89-29	14992-14998	Figure	_	
89-30	14999-15000	6	_	
89-31	15000-15001	,	_	
89-32	15002-15007	Table	_	
89-33	15008-15009	4	_	
89-34	15009-15010	)	_	
89-35	15010-15011	.	_	

#Text=Correlation between ReHo or FC in abnormal regions and PANSS scores
#Text=A statistically significant correlation was found between the PANSS-positive scores and ReHo value in the L-orb-IFG (r=−0.505, P = 0.039) of the MAP patients.
90-1	15012-15023	Correlation	_	
90-2	15024-15031	between	_	
90-3	15032-15036	ReHo	_	
90-4	15037-15039	or	_	
90-5	15040-15042	FC	_	
90-6	15043-15045	in	_	
90-7	15046-15054	abnormal	_	
90-8	15055-15062	regions	_	
90-9	15063-15066	and	_	
90-10	15067-15072	PANSS	_	
90-11	15073-15079	scores	_	
90-12	15080-15081	A	_	
90-13	15082-15095	statistically	_	
90-14	15096-15107	significant	_	
90-15	15108-15119	correlation	_	
90-16	15120-15123	was	_	
90-17	15124-15129	found	_	
90-18	15130-15137	between	_	
90-19	15138-15141	the	_	
90-20	15142-15156	PANSS-positive	_	
90-21	15157-15163	scores	_	
90-22	15164-15167	and	_	
90-23	15168-15172	ReHo	_	
90-24	15173-15178	value	_	
90-25	15179-15181	in	_	
90-26	15182-15185	the	_	
90-27	15186-15195	L-orb-IFG	_	
90-28	15196-15197	(	_	
90-29	15197-15198	r	_	
90-30	15198-15199	=	_	
90-31	15199-15200	−	_	
90-32	15200-15205	0.505	_	
90-33	15205-15206	,	_	
90-34	15207-15208	P	_	
90-35	15209-15210	=	_	
90-36	15211-15216	0.039	_	
90-37	15216-15217	)	_	
90-38	15218-15220	of	_	
90-39	15221-15224	the	_	
90-40	15225-15228	MAP	_	
90-41	15229-15237	patients	_	
90-42	15237-15238	.	_	

#Text=The ReHo value in the R-MFG was negatively correlated with the PANSS-negative scores (r=−0.522, P=0.038) of the SCZ patients.
91-1	15239-15242	The	_	
91-2	15243-15247	ReHo	_	
91-3	15248-15253	value	_	
91-4	15254-15256	in	_	
91-5	15257-15260	the	_	
91-6	15261-15266	R-MFG	_	
91-7	15267-15270	was	_	
91-8	15271-15281	negatively	_	
91-9	15282-15292	correlated	_	
91-10	15293-15297	with	_	
91-11	15298-15301	the	_	
91-12	15302-15316	PANSS-negative	_	
91-13	15317-15323	scores	_	
91-14	15324-15325	(	_	
91-15	15325-15326	r	_	
91-16	15326-15327	=	_	
91-17	15327-15328	−	_	
91-18	15328-15333	0.522	_	
91-19	15333-15334	,	_	
91-20	15335-15336	P	_	
91-21	15336-15337	=	_	
91-22	15337-15342	0.038	_	
91-23	15342-15343	)	_	
91-24	15344-15346	of	_	
91-25	15347-15350	the	_	
91-26	15351-15354	SCZ	_	
91-27	15355-15363	patients	_	
91-28	15363-15364	.	_	

#Text=In addition, the abnormal FC in the R-MFG also showed a significant negative correlation with the PANSS scores (r=−0.483, P=0.049) in the MAP group (Figure 7).
92-1	15365-15367	In	_	
92-2	15368-15376	addition	_	
92-3	15376-15377	,	_	
92-4	15378-15381	the	_	
92-5	15382-15390	abnormal	_	
92-6	15391-15393	FC	_	
92-7	15394-15396	in	_	
92-8	15397-15400	the	_	
92-9	15401-15406	R-MFG	_	
92-10	15407-15411	also	_	
92-11	15412-15418	showed	_	
92-12	15419-15420	a	_	
92-13	15421-15432	significant	_	
92-14	15433-15441	negative	_	
92-15	15442-15453	correlation	_	
92-16	15454-15458	with	_	
92-17	15459-15462	the	_	
92-18	15463-15468	PANSS	_	
92-19	15469-15475	scores	_	
92-20	15476-15477	(	_	
92-21	15477-15478	r	_	
92-22	15478-15479	=	_	
92-23	15479-15480	−	_	
92-24	15480-15485	0.483	_	
92-25	15485-15486	,	_	
92-26	15487-15488	P	_	
92-27	15488-15489	=	_	
92-28	15489-15494	0.049	_	
92-29	15494-15495	)	_	
92-30	15496-15498	in	_	
92-31	15499-15502	the	_	
92-32	15503-15506	MAP	_	
92-33	15507-15512	group	_	
92-34	15513-15514	(	_	
92-35	15514-15520	Figure	_	
92-36	15521-15522	7	_	
92-37	15522-15523	)	_	
92-38	15523-15524	.	_	

#Text=Discussion
#Text=MAP is a type of substance abuse-associated psychosis among METH addicts.
93-1	15525-15535	Discussion	_	
93-2	15536-15539	MAP	_	
93-3	15540-15542	is	_	
93-4	15543-15544	a	_	
93-5	15545-15549	type	_	
93-6	15550-15552	of	_	
93-7	15553-15562	substance	_	
93-8	15563-15579	abuse-associated	_	
93-9	15580-15589	psychosis	_	
93-10	15590-15595	among	_	
93-11	15596-15600	METH	_	
93-12	15601-15608	addicts	_	
93-13	15608-15609	.	_	

#Text=Power et al. revealed that the mean duration of premorbid exposure to MAP is 5.3 years after the abuse of METH.
94-1	15610-15615	Power	_	
94-2	15616-15618	et	_	
94-3	15619-15621	al	_	
94-4	15621-15622	.	_	
94-5	15623-15631	revealed	_	
94-6	15632-15636	that	_	
94-7	15637-15640	the	_	
94-8	15641-15645	mean	_	
94-9	15646-15654	duration	_	
94-10	15655-15657	of	_	
94-11	15658-15667	premorbid	_	
94-12	15668-15676	exposure	_	
94-13	15677-15679	to	_	
94-14	15680-15683	MAP	_	
94-15	15684-15686	is	_	
94-16	15687-15690	5.3	_	
94-17	15691-15696	years	_	
94-18	15697-15702	after	_	
94-19	15703-15706	the	_	
94-20	15707-15712	abuse	_	
94-21	15713-15715	of	_	
94-22	15716-15720	METH	_	
94-23	15720-15721	.	_	

#Text=In our studied groups, the average duration of premorbid exposure to MAP was 5 years.
95-1	15722-15724	In	_	
95-2	15725-15728	our	_	
95-3	15729-15736	studied	_	
95-4	15737-15743	groups	_	
95-5	15743-15744	,	_	
95-6	15745-15748	the	_	
95-7	15749-15756	average	_	
95-8	15757-15765	duration	_	
95-9	15766-15768	of	_	
95-10	15769-15778	premorbid	_	
95-11	15779-15787	exposure	_	
95-12	15788-15790	to	_	
95-13	15791-15794	MAP	_	
95-14	15795-15798	was	_	
95-15	15799-15800	5	_	
95-16	15801-15806	years	_	
95-17	15806-15807	.	_	

#Text=The top 3 synthetic drug-reduced mental disorders are psychotic disorders, mood disorders, and anxiety disorders, and their prevalences are 77.1%, 28.0%, and 39.7%, respectively.
96-1	15808-15811	The	_	
96-2	15812-15815	top	_	
96-3	15816-15817	3	_	
96-4	15818-15827	synthetic	_	
96-5	15828-15840	drug-reduced	_	
96-6	15841-15847	mental	_	
96-7	15848-15857	disorders	_	
96-8	15858-15861	are	_	
96-9	15862-15871	psychotic	_	
96-10	15872-15881	disorders	_	
96-11	15881-15882	,	_	
96-12	15883-15887	mood	_	
96-13	15888-15897	disorders	_	
96-14	15897-15898	,	_	
96-15	15899-15902	and	_	
96-16	15903-15910	anxiety	_	
96-17	15911-15920	disorders	_	
96-18	15920-15921	,	_	
96-19	15922-15925	and	_	
96-20	15926-15931	their	_	
96-21	15932-15943	prevalences	_	
96-22	15944-15947	are	_	
96-23	15948-15953	77.1%	_	
96-24	15953-15954	,	_	
96-25	15955-15960	28.0%	_	
96-26	15960-15961	,	_	
96-27	15962-15965	and	_	
96-28	15966-15971	39.7%	_	
96-29	15971-15972	,	_	
96-30	15973-15985	respectively	_	
96-31	15985-15986	.	_	

#Text=MAP is easily misdiagnosed as SCZ.
97-1	15987-15990	MAP	_	
97-2	15991-15993	is	_	
97-3	15994-16000	easily	_	
97-4	16001-16013	misdiagnosed	_	
97-5	16014-16016	as	_	
97-6	16017-16020	SCZ	_	
97-7	16020-16021	.	_	

#Text=Only a few functional MR studies have investigated the alternation of brain structure and functional connectivity in MAP patients, and most research has focused on SCZ.
98-1	16022-16026	Only	_	
98-2	16027-16028	a	_	
98-3	16029-16032	few	_	
98-4	16033-16043	functional	_	
98-5	16044-16046	MR	_	
98-6	16047-16054	studies	_	
98-7	16055-16059	have	_	
98-8	16060-16072	investigated	_	
98-9	16073-16076	the	_	
98-10	16077-16088	alternation	_	
98-11	16089-16091	of	_	
98-12	16092-16097	brain	_	
98-13	16098-16107	structure	_	
98-14	16108-16111	and	_	
98-15	16112-16122	functional	_	
98-16	16123-16135	connectivity	_	
98-17	16136-16138	in	_	
98-18	16139-16142	MAP	_	
98-19	16143-16151	patients	_	
98-20	16151-16152	,	_	
98-21	16153-16156	and	_	
98-22	16157-16161	most	_	
98-23	16162-16170	research	_	
98-24	16171-16174	has	_	
98-25	16175-16182	focused	_	
98-26	16183-16185	on	_	
98-27	16186-16189	SCZ	_	
98-28	16189-16190	.	_	

#Text=This study is the first to investigated the GMD differences of MAP individuals and compare the abnormal FCs between MAP and SCZ based on 4 seed ROIs.
99-1	16191-16195	This	_	
99-2	16196-16201	study	_	
99-3	16202-16204	is	_	
99-4	16205-16208	the	_	
99-5	16209-16214	first	_	
99-6	16215-16217	to	_	
99-7	16218-16230	investigated	_	
99-8	16231-16234	the	_	
99-9	16235-16238	GMD	_	
99-10	16239-16250	differences	_	
99-11	16251-16253	of	_	
99-12	16254-16257	MAP	_	
99-13	16258-16269	individuals	_	
99-14	16270-16273	and	_	
99-15	16274-16281	compare	_	
99-16	16282-16285	the	_	
99-17	16286-16294	abnormal	_	
99-18	16295-16298	FCs	_	
99-19	16299-16306	between	_	
99-20	16307-16310	MAP	_	
99-21	16311-16314	and	_	
99-22	16315-16318	SCZ	_	
99-23	16319-16324	based	_	
99-24	16325-16327	on	_	
99-25	16328-16329	4	_	
99-26	16330-16334	seed	_	
99-27	16335-16339	ROIs	_	
99-28	16339-16340	.	_	

#Text=We found increased GMD in B-AC, B-MSFG, and L-opr-IFG of the MAP group, while decreased GMD was found in the L-opr-IFG and R-MFG of the SCZ group.
100-1	16341-16343	We	_	
100-2	16344-16349	found	_	
100-3	16350-16359	increased	_	
100-4	16360-16363	GMD	_	
100-5	16364-16366	in	_	
100-6	16367-16371	B-AC	_	
100-7	16371-16372	,	_	
100-8	16373-16379	B-MSFG	_	
100-9	16379-16380	,	_	
100-10	16381-16384	and	_	
100-11	16385-16394	L-opr-IFG	_	
100-12	16395-16397	of	_	
100-13	16398-16401	the	_	
100-14	16402-16405	MAP	_	
100-15	16406-16411	group	_	
100-16	16411-16412	,	_	
100-17	16413-16418	while	_	
100-18	16419-16428	decreased	_	
100-19	16429-16432	GMD	_	
100-20	16433-16436	was	_	
100-21	16437-16442	found	_	
100-22	16443-16445	in	_	
100-23	16446-16449	the	_	
100-24	16450-16459	L-opr-IFG	_	
100-25	16460-16463	and	_	
100-26	16464-16469	R-MFG	_	
100-27	16470-16472	of	_	
100-28	16473-16476	the	_	
100-29	16477-16480	SCZ	_	
100-30	16481-16486	group	_	
100-31	16486-16487	.	_	

#Text=Although the symptoms of the 2 diseases are quite similar, it is interesting that their GMD exhibited opposite trends in the present study.
101-1	16488-16496	Although	_	
101-2	16497-16500	the	_	
101-3	16501-16509	symptoms	_	
101-4	16510-16512	of	_	
101-5	16513-16516	the	_	
101-6	16517-16518	2	_	
101-7	16519-16527	diseases	_	
101-8	16528-16531	are	_	
101-9	16532-16537	quite	_	
101-10	16538-16545	similar	_	
101-11	16545-16546	,	_	
101-12	16547-16549	it	_	
101-13	16550-16552	is	_	
101-14	16553-16564	interesting	_	
101-15	16565-16569	that	_	
101-16	16570-16575	their	_	
101-17	16576-16579	GMD	_	
101-18	16580-16589	exhibited	_	
101-19	16590-16598	opposite	_	
101-20	16599-16605	trends	_	
101-21	16606-16608	in	_	
101-22	16609-16612	the	_	
101-23	16613-16620	present	_	
101-24	16621-16626	study	_	
101-25	16626-16627	.	_	

#Text=Our result is contradictory to studies that investigated the role of gray matter volumetric alternations in psychiatric disorders.
102-1	16628-16631	Our	_	
102-2	16632-16638	result	_	
102-3	16639-16641	is	_	
102-4	16642-16655	contradictory	_	
102-5	16656-16658	to	_	
102-6	16659-16666	studies	_	
102-7	16667-16671	that	_	
102-8	16672-16684	investigated	_	
102-9	16685-16688	the	_	
102-10	16689-16693	role	_	
102-11	16694-16696	of	_	
102-12	16697-16701	gray	_	
102-13	16702-16708	matter	_	
102-14	16709-16719	volumetric	_	
102-15	16720-16732	alternations	_	
102-16	16733-16735	in	_	
102-17	16736-16747	psychiatric	_	
102-18	16748-16757	disorders	_	
102-19	16757-16758	.	_	

#Text=To be specific, many studies reported that gray matter volume is significantly smaller in MAP individuals than in healthy controls.
103-1	16759-16761	To	_	
103-2	16762-16764	be	_	
103-3	16765-16773	specific	_	
103-4	16773-16774	,	_	
103-5	16775-16779	many	_	
103-6	16780-16787	studies	_	
103-7	16788-16796	reported	_	
103-8	16797-16801	that	_	
103-9	16802-16806	gray	_	
103-10	16807-16813	matter	_	
103-11	16814-16820	volume	_	
103-12	16821-16823	is	_	
103-13	16824-16837	significantly	_	
103-14	16838-16845	smaller	_	
103-15	16846-16848	in	_	
103-16	16849-16852	MAP	_	
103-17	16853-16864	individuals	_	
103-18	16865-16869	than	_	
103-19	16870-16872	in	_	
103-20	16873-16880	healthy	_	
103-21	16881-16889	controls	_	
103-22	16889-16890	.	_	

#Text=The difference may be due to the fact that the altered brain regions are different.
104-1	16891-16894	The	_	
104-2	16895-16905	difference	_	
104-3	16906-16909	may	_	
104-4	16910-16912	be	_	
104-5	16913-16916	due	_	
104-6	16917-16919	to	_	
104-7	16920-16923	the	_	
104-8	16924-16928	fact	_	
104-9	16929-16933	that	_	
104-10	16934-16937	the	_	
104-11	16938-16945	altered	_	
104-12	16946-16951	brain	_	
104-13	16952-16959	regions	_	
104-14	16960-16963	are	_	
104-15	16964-16973	different	_	
104-16	16973-16974	.	_	

#Text=Moreover, increased ReHo was found in L-orb-IFG and R-HPC of the MAP group, and decreased ReHo was found in L-MSFT, R-ANG, and R-MFG/SFG in MAP patients.
105-1	16975-16983	Moreover	_	
105-2	16983-16984	,	_	
105-3	16985-16994	increased	_	
105-4	16995-16999	ReHo	_	
105-5	17000-17003	was	_	
105-6	17004-17009	found	_	
105-7	17010-17012	in	_	
105-8	17013-17022	L-orb-IFG	_	
105-9	17023-17026	and	_	
105-10	17027-17032	R-HPC	_	
105-11	17033-17035	of	_	
105-12	17036-17039	the	_	
105-13	17040-17043	MAP	_	
105-14	17044-17049	group	_	
105-15	17049-17050	,	_	
105-16	17051-17054	and	_	
105-17	17055-17064	decreased	_	
105-18	17065-17069	ReHo	_	
105-19	17070-17073	was	_	
105-20	17074-17079	found	_	
105-21	17080-17082	in	_	
105-22	17083-17089	L-MSFT	_	
105-23	17089-17090	,	_	
105-24	17091-17096	R-ANG	_	
105-25	17096-17097	,	_	
105-26	17098-17101	and	_	
105-27	17102-17107	R-MFG	_	
105-28	17107-17108	/	_	
105-29	17108-17111	SFG	_	
105-30	17112-17114	in	_	
105-31	17115-17118	MAP	_	
105-32	17119-17127	patients	_	
105-33	17127-17128	.	_	

#Text=For the SCZ group, the ReHo value in the R-HPC, L-LTN, and L-TRP/opr-IFG increased, and it decreased in the L-SFG, R-STG, R-PC, R-ANZ, R-MFG/SFG, and R-SFG.
106-1	17129-17132	For	_	
106-2	17133-17136	the	_	
106-3	17137-17140	SCZ	_	
106-4	17141-17146	group	_	
106-5	17146-17147	,	_	
106-6	17148-17151	the	_	
106-7	17152-17156	ReHo	_	
106-8	17157-17162	value	_	
106-9	17163-17165	in	_	
106-10	17166-17169	the	_	
106-11	17170-17175	R-HPC	_	
106-12	17175-17176	,	_	
106-13	17177-17182	L-LTN	_	
106-14	17182-17183	,	_	
106-15	17184-17187	and	_	
106-16	17188-17193	L-TRP	_	
106-17	17193-17194	/	_	
106-18	17194-17201	opr-IFG	_	
106-19	17202-17211	increased	_	
106-20	17211-17212	,	_	
106-21	17213-17216	and	_	
106-22	17217-17219	it	_	
106-23	17220-17229	decreased	_	
106-24	17230-17232	in	_	
106-25	17233-17236	the	_	
106-26	17237-17242	L-SFG	_	
106-27	17242-17243	,	_	
106-28	17244-17249	R-STG	_	
106-29	17249-17250	,	_	
106-30	17251-17255	R-PC	_	
106-31	17255-17256	,	_	
106-32	17257-17262	R-ANZ	_	
106-33	17262-17263	,	_	
106-34	17264-17269	R-MFG	_	
106-35	17269-17270	/	_	
106-36	17270-17273	SFG	_	
106-37	17273-17274	,	_	
106-38	17275-17278	and	_	
106-39	17279-17284	R-SFG	_	
106-40	17284-17285	.	_	

#Text=There were significant differences between MAP and SCZ groups regarding R-STG, R-PC, R-SFG, L-LTN, and L-TRP/opr-IFG.
107-1	17286-17291	There	_	
107-2	17292-17296	were	_	
107-3	17297-17308	significant	_	
107-4	17309-17320	differences	_	
107-5	17321-17328	between	_	
107-6	17329-17332	MAP	_	
107-7	17333-17336	and	_	
107-8	17337-17340	SCZ	_	
107-9	17341-17347	groups	_	
107-10	17348-17357	regarding	_	
107-11	17358-17363	R-STG	_	
107-12	17363-17364	,	_	
107-13	17365-17369	R-PC	_	
107-14	17369-17370	,	_	
107-15	17371-17376	R-SFG	_	
107-16	17376-17377	,	_	
107-17	17378-17383	L-LTN	_	
107-18	17383-17384	,	_	
107-19	17385-17388	and	_	
107-20	17389-17394	L-TRP	_	
107-21	17394-17395	/	_	
107-22	17395-17402	opr-IFG	_	
107-23	17402-17403	.	_	

#Text=We also found a negative correlation between the mean ReHo of the R-orb-IFG and the PANSS-positive scores, as well as between the mean ReHo of the R-SFG and the PANSS-negative scores among MAP patients.
108-1	17404-17406	We	_	
108-2	17407-17411	also	_	
108-3	17412-17417	found	_	
108-4	17418-17419	a	_	
108-5	17420-17428	negative	_	
108-6	17429-17440	correlation	_	
108-7	17441-17448	between	_	
108-8	17449-17452	the	_	
108-9	17453-17457	mean	_	
108-10	17458-17462	ReHo	_	
108-11	17463-17465	of	_	
108-12	17466-17469	the	_	
108-13	17470-17479	R-orb-IFG	_	
108-14	17480-17483	and	_	
108-15	17484-17487	the	_	
108-16	17488-17502	PANSS-positive	_	
108-17	17503-17509	scores	_	
108-18	17509-17510	,	_	
108-19	17511-17513	as	_	
108-20	17514-17518	well	_	
108-21	17519-17521	as	_	
108-22	17522-17529	between	_	
108-23	17530-17533	the	_	
108-24	17534-17538	mean	_	
108-25	17539-17543	ReHo	_	
108-26	17544-17546	of	_	
108-27	17547-17550	the	_	
108-28	17551-17556	R-SFG	_	
108-29	17557-17560	and	_	
108-30	17561-17564	the	_	
108-31	17565-17579	PANSS-negative	_	
108-32	17580-17586	scores	_	
108-33	17587-17592	among	_	
108-34	17593-17596	MAP	_	
108-35	17597-17605	patients	_	
108-36	17605-17606	.	_	

#Text=Certain results agree with a previous study reporting that SCZ patients had decreased ReHo in the STG compared with the control subjects.
109-1	17607-17614	Certain	_	
109-2	17615-17622	results	_	
109-3	17623-17628	agree	_	
109-4	17629-17633	with	_	
109-5	17634-17635	a	_	
109-6	17636-17644	previous	_	
109-7	17645-17650	study	_	
109-8	17651-17660	reporting	_	
109-9	17661-17665	that	_	
109-10	17666-17669	SCZ	_	
109-11	17670-17678	patients	_	
109-12	17679-17682	had	_	
109-13	17683-17692	decreased	_	
109-14	17693-17697	ReHo	_	
109-15	17698-17700	in	_	
109-16	17701-17704	the	_	
109-17	17705-17708	STG	_	
109-18	17709-17717	compared	_	
109-19	17718-17722	with	_	
109-20	17723-17726	the	_	
109-21	17727-17734	control	_	
109-22	17735-17743	subjects	_	
109-23	17743-17744	.	_	

#Text=As the ReHo method is sensitive in detecting the brain alternations of SCZ, it was suggested that MAP and SCZ indeed could cause distinct structural and functional changes.
110-1	17745-17747	As	_	
110-2	17748-17751	the	_	
110-3	17752-17756	ReHo	_	
110-4	17757-17763	method	_	
110-5	17764-17766	is	_	
110-6	17767-17776	sensitive	_	
110-7	17777-17779	in	_	
110-8	17780-17789	detecting	_	
110-9	17790-17793	the	_	
110-10	17794-17799	brain	_	
110-11	17800-17812	alternations	_	
110-12	17813-17815	of	_	
110-13	17816-17819	SCZ	_	
110-14	17819-17820	,	_	
110-15	17821-17823	it	_	
110-16	17824-17827	was	_	
110-17	17828-17837	suggested	_	
110-18	17838-17842	that	_	
110-19	17843-17846	MAP	_	
110-20	17847-17850	and	_	
110-21	17851-17854	SCZ	_	
110-22	17855-17861	indeed	_	
110-23	17862-17867	could	_	
110-24	17868-17873	cause	_	
110-25	17874-17882	distinct	_	
110-26	17883-17893	structural	_	
110-27	17894-17897	and	_	
110-28	17898-17908	functional	_	
110-29	17909-17916	changes	_	
110-30	17916-17917	.	_	

#Text=When R-HPC or R-ANZ was selected as the seed ROI, the changed strength of whole-brain FC was similar between SCZ and MAP groups.
111-1	17918-17922	When	_	
111-2	17923-17928	R-HPC	_	
111-3	17929-17931	or	_	
111-4	17932-17937	R-ANZ	_	
111-5	17938-17941	was	_	
111-6	17942-17950	selected	_	
111-7	17951-17953	as	_	
111-8	17954-17957	the	_	
111-9	17958-17962	seed	_	
111-10	17963-17966	ROI	_	
111-11	17966-17967	,	_	
111-12	17968-17971	the	_	
111-13	17972-17979	changed	_	
111-14	17980-17988	strength	_	
111-15	17989-17991	of	_	
111-16	17992-18003	whole-brain	_	
111-17	18004-18006	FC	_	
111-18	18007-18010	was	_	
111-19	18011-18018	similar	_	
111-20	18019-18026	between	_	
111-21	18027-18030	SCZ	_	
111-22	18031-18034	and	_	
111-23	18035-18038	MAP	_	
111-24	18039-18045	groups	_	
111-25	18045-18046	.	_	

#Text=However, abnormal FC was found in the SCZ group but not in the MAP group, when the L-MSFG or R-MFG/SFG was considered as the seed, indicating that abnormal FC in SCZ was quite specific.
112-1	18047-18054	However	_	
112-2	18054-18055	,	_	
112-3	18056-18064	abnormal	_	
112-4	18065-18067	FC	_	
112-5	18068-18071	was	_	
112-6	18072-18077	found	_	
112-7	18078-18080	in	_	
112-8	18081-18084	the	_	
112-9	18085-18088	SCZ	_	
112-10	18089-18094	group	_	
112-11	18095-18098	but	_	
112-12	18099-18102	not	_	
112-13	18103-18105	in	_	
112-14	18106-18109	the	_	
112-15	18110-18113	MAP	_	
112-16	18114-18119	group	_	
112-17	18119-18120	,	_	
112-18	18121-18125	when	_	
112-19	18126-18129	the	_	
112-20	18130-18136	L-MSFG	_	
112-21	18137-18139	or	_	
112-22	18140-18145	R-MFG	_	
112-23	18145-18146	/	_	
112-24	18146-18149	SFG	_	
112-25	18150-18153	was	_	
112-26	18154-18164	considered	_	
112-27	18165-18167	as	_	
112-28	18168-18171	the	_	
112-29	18172-18176	seed	_	
112-30	18176-18177	,	_	
112-31	18178-18188	indicating	_	
112-32	18189-18193	that	_	
112-33	18194-18202	abnormal	_	
112-34	18203-18205	FC	_	
112-35	18206-18208	in	_	
112-36	18209-18212	SCZ	_	
112-37	18213-18216	was	_	
112-38	18217-18222	quite	_	
112-39	18223-18231	specific	_	
112-40	18231-18232	.	_	

#Text=Furthermore, the abnormal FC of the R-MFG in MAP was found to be negatively correlated with PANSS scores, which also suggests the specificity of abnormal FC in MAP.
113-1	18233-18244	Furthermore	_	
113-2	18244-18245	,	_	
113-3	18246-18249	the	_	
113-4	18250-18258	abnormal	_	
113-5	18259-18261	FC	_	
113-6	18262-18264	of	_	
113-7	18265-18268	the	_	
113-8	18269-18274	R-MFG	_	
113-9	18275-18277	in	_	
113-10	18278-18281	MAP	_	
113-11	18282-18285	was	_	
113-12	18286-18291	found	_	
113-13	18292-18294	to	_	
113-14	18295-18297	be	_	
113-15	18298-18308	negatively	_	
113-16	18309-18319	correlated	_	
113-17	18320-18324	with	_	
113-18	18325-18330	PANSS	_	
113-19	18331-18337	scores	_	
113-20	18337-18338	,	_	
113-21	18339-18344	which	_	
113-22	18345-18349	also	_	
113-23	18350-18358	suggests	_	
113-24	18359-18362	the	_	
113-25	18363-18374	specificity	_	
113-26	18375-18377	of	_	
113-27	18378-18386	abnormal	_	
113-28	18387-18389	FC	_	
113-29	18390-18392	in	_	
113-30	18393-18396	MAP	_	
113-31	18396-18397	.	_	

#Text=Overall, 3 features of MAP and SCZ were different – the increased GMD, the altered ReHo in the L-orb-IFG, and the negative correlation between the abnormal FC with the R-MFG and the PANSS scores – but this conclusion warrants further exploration with a more rigorous study design.
114-1	18398-18405	Overall	_	
114-2	18405-18406	,	_	
114-3	18407-18408	3	_	
114-4	18409-18417	features	_	
114-5	18418-18420	of	_	
114-6	18421-18424	MAP	_	
114-7	18425-18428	and	_	
114-8	18429-18432	SCZ	_	
114-9	18433-18437	were	_	
114-10	18438-18447	different	_	
114-11	18448-18449	–	_	
114-12	18450-18453	the	_	
114-13	18454-18463	increased	_	
114-14	18464-18467	GMD	_	
114-15	18467-18468	,	_	
114-16	18469-18472	the	_	
114-17	18473-18480	altered	_	
114-18	18481-18485	ReHo	_	
114-19	18486-18488	in	_	
114-20	18489-18492	the	_	
114-21	18493-18502	L-orb-IFG	_	
114-22	18502-18503	,	_	
114-23	18504-18507	and	_	
114-24	18508-18511	the	_	
114-25	18512-18520	negative	_	
114-26	18521-18532	correlation	_	
114-27	18533-18540	between	_	
114-28	18541-18544	the	_	
114-29	18545-18553	abnormal	_	
114-30	18554-18556	FC	_	
114-31	18557-18561	with	_	
114-32	18562-18565	the	_	
114-33	18566-18571	R-MFG	_	
114-34	18572-18575	and	_	
114-35	18576-18579	the	_	
114-36	18580-18585	PANSS	_	
114-37	18586-18592	scores	_	
114-38	18593-18594	–	_	
114-39	18595-18598	but	_	
114-40	18599-18603	this	_	
114-41	18604-18614	conclusion	_	
114-42	18615-18623	warrants	_	
114-43	18624-18631	further	_	
114-44	18632-18643	exploration	_	
114-45	18644-18648	with	_	
114-46	18649-18650	a	_	
114-47	18651-18655	more	_	
114-48	18656-18664	rigorous	_	
114-49	18665-18670	study	_	
114-50	18671-18677	design	_	
114-51	18677-18678	.	_	

#Text=The present study was also limited in that the duration of exposure was unknown in both patient groups, and female METH addicts were excluded.
115-1	18679-18682	The	_	
115-2	18683-18690	present	_	
115-3	18691-18696	study	_	
115-4	18697-18700	was	_	
115-5	18701-18705	also	_	
115-6	18706-18713	limited	_	
115-7	18714-18716	in	_	
115-8	18717-18721	that	_	
115-9	18722-18725	the	_	
115-10	18726-18734	duration	_	
115-11	18735-18737	of	_	
115-12	18738-18746	exposure	_	
115-13	18747-18750	was	_	
115-14	18751-18758	unknown	_	
115-15	18759-18761	in	_	
115-16	18762-18766	both	_	
115-17	18767-18774	patient	_	
115-18	18775-18781	groups	_	
115-19	18781-18782	,	_	
115-20	18783-18786	and	_	
115-21	18787-18793	female	_	
115-22	18794-18798	METH	_	
115-23	18799-18806	addicts	_	
115-24	18807-18811	were	_	
115-25	18812-18820	excluded	_	
115-26	18820-18821	.	_	

#Text=Moreover, the MNI coordinate may be a potential disturbance for this study, because the template was constructed based on a white population, which might not be applicable for the Chinese subjects in the present study.
116-1	18822-18830	Moreover	_	
116-2	18830-18831	,	_	
116-3	18832-18835	the	_	
116-4	18836-18839	MNI	_	
116-5	18840-18850	coordinate	_	
116-6	18851-18854	may	_	
116-7	18855-18857	be	_	
116-8	18858-18859	a	_	
116-9	18860-18869	potential	_	
116-10	18870-18881	disturbance	_	
116-11	18882-18885	for	_	
116-12	18886-18890	this	_	
116-13	18891-18896	study	_	
116-14	18896-18897	,	_	
116-15	18898-18905	because	_	
116-16	18906-18909	the	_	
116-17	18910-18918	template	_	
116-18	18919-18922	was	_	
116-19	18923-18934	constructed	_	
116-20	18935-18940	based	_	
116-21	18941-18943	on	_	
116-22	18944-18945	a	_	
116-23	18946-18951	white	_	
116-24	18952-18962	population	_	
116-25	18962-18963	,	_	
116-26	18964-18969	which	_	
116-27	18970-18975	might	_	
116-28	18976-18979	not	_	
116-29	18980-18982	be	_	
116-30	18983-18993	applicable	_	
116-31	18994-18997	for	_	
116-32	18998-19001	the	_	
116-33	19002-19009	Chinese	_	
116-34	19010-19018	subjects	_	
116-35	19019-19021	in	_	
116-36	19022-19025	the	_	
116-37	19026-19033	present	_	
116-38	19034-19039	study	_	
116-39	19039-19040	.	_	

#Text=In addition, another limitation of our study is a relatively small number of participants examined.
117-1	19041-19043	In	_	
117-2	19044-19052	addition	_	
117-3	19052-19053	,	_	
117-4	19054-19061	another	_	
117-5	19062-19072	limitation	_	
117-6	19073-19075	of	_	
117-7	19076-19079	our	_	
117-8	19080-19085	study	_	
117-9	19086-19088	is	_	
117-10	19089-19090	a	_	
117-11	19091-19101	relatively	_	
117-12	19102-19107	small	_	
117-13	19108-19114	number	_	
117-14	19115-19117	of	_	
117-15	19118-19130	participants	_	
117-16	19131-19139	examined	_	
117-17	19139-19140	.	_	

#Text=Although the study data are not sufficient to fully substantiate the results, they provide some valuable evidence for the intensive study of neurophysiological mechanism underlying MAP and help lay a foundation for further study.
118-1	19141-19149	Although	_	
118-2	19150-19153	the	_	
118-3	19154-19159	study	_	
118-4	19160-19164	data	_	
118-5	19165-19168	are	_	
118-6	19169-19172	not	_	
118-7	19173-19183	sufficient	_	
118-8	19184-19186	to	_	
118-9	19187-19192	fully	_	
118-10	19193-19205	substantiate	_	
118-11	19206-19209	the	_	
118-12	19210-19217	results	_	
118-13	19217-19218	,	_	
118-14	19219-19223	they	_	
118-15	19224-19231	provide	_	
118-16	19232-19236	some	_	
118-17	19237-19245	valuable	_	
118-18	19246-19254	evidence	_	
118-19	19255-19258	for	_	
118-20	19259-19262	the	_	
118-21	19263-19272	intensive	_	
118-22	19273-19278	study	_	
118-23	19279-19281	of	_	
118-24	19282-19300	neurophysiological	_	
118-25	19301-19310	mechanism	_	
118-26	19311-19321	underlying	_	
118-27	19322-19325	MAP	_	
118-28	19326-19329	and	_	
118-29	19330-19334	help	_	
118-30	19335-19338	lay	_	
118-31	19339-19340	a	_	
118-32	19341-19351	foundation	_	
118-33	19352-19355	for	_	
118-34	19356-19363	further	_	
118-35	19364-19369	study	_	
118-36	19369-19370	.	_	

#Text=Conclusions
#Text=The present study investigated the GMD changes and rs-fMRI changes of MAP, which provides evidence of the neurophysiological mechanisms underlying MAP.
119-1	19371-19382	Conclusions	_	
119-2	19383-19386	The	_	
119-3	19387-19394	present	_	
119-4	19395-19400	study	_	
119-5	19401-19413	investigated	_	
119-6	19414-19417	the	_	
119-7	19418-19421	GMD	_	
119-8	19422-19429	changes	_	
119-9	19430-19433	and	_	
119-10	19434-19441	rs-fMRI	_	
119-11	19442-19449	changes	_	
119-12	19450-19452	of	_	
119-13	19453-19456	MAP	_	
119-14	19456-19457	,	_	
119-15	19458-19463	which	_	
119-16	19464-19472	provides	_	
119-17	19473-19481	evidence	_	
119-18	19482-19484	of	_	
119-19	19485-19488	the	_	
119-20	19489-19507	neurophysiological	_	
119-21	19508-19518	mechanisms	_	
119-22	19519-19529	underlying	_	
119-23	19530-19533	MAP	_	
119-24	19533-19534	.	_	

#Text=Conflict of Interest
#Text=None.
120-1	19535-19543	Conflict	_	
120-2	19544-19546	of	_	
120-3	19547-19555	Interest	_	
120-4	19556-19560	None	_	
120-5	19560-19561	.	_	

#Text=Source of support: Departmental sources
#Text=References
#Text=The new pattern of drug abuse in China
#Text=Volume reductions in frontopolar and left perisylvian cortices in methamphetamine induced psychosis
#Text=Longitudinal clinical course following pharmacological treatment of methamphetamine psychosis which persists after long-term abstinence
#Text=Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis
#Text=Distinct intrinsic functional brain network abnormalities in methamphetamine-dependent patients with and without a history of psychosis
#Text=Gender differences in abusers of amphetamine-type stimulants and ketamine in southwestern China
#Text=Abuse of amphetamines and structural abnormalities in the brain
#Text=Reduced regional homogeneity in bilateral frontostriatal system relates to higher impulsivity behavior in codeine-containing cough syrups dependent individuals
#Text=Age at initiation of amphetamine use and age at onset of psychosis: The Australian Survey of High Impact Psychosis
#Text=
#Text=Mediated plastid RNA editing in plant immunity
#Text=Comparative study of regional homogeneity in schizophrenia and major depressive disorder
#Text=First-rank symptoms in methamphetamine psychosis and schizophrenia
#Text=Subcortical grey matter alterations in cocaine dependent individuals with substance-induced psychosis compared to non-psychotic cocaine users
#Text=Reduced amygdala and hippocampal volumes in patients with methamphetamine psychosis
#Text=Frequency dependent alterations in regional homogeneity of baseline brain activity in schizophrenia
#Text=The brain regions that were distinct in gray matter density among MAP, SCZ, and control groups.
121-1	19562-19568	Source	_	
121-2	19569-19571	of	_	
121-3	19572-19579	support	_	
121-4	19579-19580	:	_	
121-5	19581-19593	Departmental	_	
121-6	19594-19601	sources	_	
121-7	19602-19612	References	_	
121-8	19613-19616	The	_	
121-9	19617-19620	new	_	
121-10	19621-19628	pattern	_	
121-11	19629-19631	of	_	
121-12	19632-19636	drug	_	
121-13	19637-19642	abuse	_	
121-14	19643-19645	in	_	
121-15	19646-19651	China	_	
121-16	19652-19658	Volume	_	
121-17	19659-19669	reductions	_	
121-18	19670-19672	in	_	
121-19	19673-19684	frontopolar	_	
121-20	19685-19688	and	_	
121-21	19689-19693	left	_	
121-22	19694-19705	perisylvian	_	
121-23	19706-19714	cortices	_	
121-24	19715-19717	in	_	
121-25	19718-19733	methamphetamine	_	
121-26	19734-19741	induced	_	
121-27	19742-19751	psychosis	_	
121-28	19752-19764	Longitudinal	_	
121-29	19765-19773	clinical	_	
121-30	19774-19780	course	_	
121-31	19781-19790	following	_	
121-32	19791-19806	pharmacological	_	
121-33	19807-19816	treatment	_	
121-34	19817-19819	of	_	
121-35	19820-19835	methamphetamine	_	
121-36	19836-19845	psychosis	_	
121-37	19846-19851	which	_	
121-38	19852-19860	persists	_	
121-39	19861-19866	after	_	
121-40	19867-19876	long-term	_	
121-41	19877-19887	abstinence	_	
121-42	19888-19896	Clinical	_	
121-43	19897-19905	features	_	
121-44	19906-19908	of	_	
121-45	19909-19922	sensitization	_	
121-46	19923-19925	to	_	
121-47	19926-19941	methamphetamine	_	
121-48	19942-19950	observed	_	
121-49	19951-19953	in	_	
121-50	19954-19962	patients	_	
121-51	19963-19967	with	_	
121-52	19968-19983	methamphetamine	_	
121-53	19984-19994	dependence	_	
121-54	19995-19998	and	_	
121-55	19999-20008	psychosis	_	
121-56	20009-20017	Distinct	_	
121-57	20018-20027	intrinsic	_	
121-58	20028-20038	functional	_	
121-59	20039-20044	brain	_	
121-60	20045-20052	network	_	
121-61	20053-20066	abnormalities	_	
121-62	20067-20069	in	_	
121-63	20070-20095	methamphetamine-dependent	_	
121-64	20096-20104	patients	_	
121-65	20105-20109	with	_	
121-66	20110-20113	and	_	
121-67	20114-20121	without	_	
121-68	20122-20123	a	_	
121-69	20124-20131	history	_	
121-70	20132-20134	of	_	
121-71	20135-20144	psychosis	_	
121-72	20145-20151	Gender	_	
121-73	20152-20163	differences	_	
121-74	20164-20166	in	_	
121-75	20167-20174	abusers	_	
121-76	20175-20177	of	_	
121-77	20178-20194	amphetamine-type	_	
121-78	20195-20205	stimulants	_	
121-79	20206-20209	and	_	
121-80	20210-20218	ketamine	_	
121-81	20219-20221	in	_	
121-82	20222-20234	southwestern	_	
121-83	20235-20240	China	_	
121-84	20241-20246	Abuse	_	
121-85	20247-20249	of	_	
121-86	20250-20262	amphetamines	_	
121-87	20263-20266	and	_	
121-88	20267-20277	structural	_	
121-89	20278-20291	abnormalities	_	
121-90	20292-20294	in	_	
121-91	20295-20298	the	_	
121-92	20299-20304	brain	_	
121-93	20305-20312	Reduced	_	
121-94	20313-20321	regional	_	
121-95	20322-20333	homogeneity	_	
121-96	20334-20336	in	_	
121-97	20337-20346	bilateral	_	
121-98	20347-20361	frontostriatal	_	
121-99	20362-20368	system	_	
121-100	20369-20376	relates	_	
121-101	20377-20379	to	_	
121-102	20380-20386	higher	_	
121-103	20387-20398	impulsivity	_	
121-104	20399-20407	behavior	_	
121-105	20408-20410	in	_	
121-106	20411-20429	codeine-containing	_	
121-107	20430-20435	cough	_	
121-108	20436-20442	syrups	_	
121-109	20443-20452	dependent	_	
121-110	20453-20464	individuals	_	
121-111	20465-20468	Age	_	
121-112	20469-20471	at	_	
121-113	20472-20482	initiation	_	
121-114	20483-20485	of	_	
121-115	20486-20497	amphetamine	_	
121-116	20498-20501	use	_	
121-117	20502-20505	and	_	
121-118	20506-20509	age	_	
121-119	20510-20512	at	_	
121-120	20513-20518	onset	_	
121-121	20519-20521	of	_	
121-122	20522-20531	psychosis	_	
121-123	20531-20532	:	_	
121-124	20533-20536	The	_	
121-125	20537-20547	Australian	_	
121-126	20548-20554	Survey	_	
121-127	20555-20557	of	_	
121-128	20558-20562	High	_	
121-129	20563-20569	Impact	_	
121-130	20570-20579	Psychosis	_	
121-131	20581-20589	Mediated	_	
121-132	20590-20597	plastid	_	
121-133	20598-20601	RNA	_	
121-134	20602-20609	editing	_	
121-135	20610-20612	in	_	
121-136	20613-20618	plant	_	
121-137	20619-20627	immunity	_	
121-138	20628-20639	Comparative	_	
121-139	20640-20645	study	_	
121-140	20646-20648	of	_	
121-141	20649-20657	regional	_	
121-142	20658-20669	homogeneity	_	
121-143	20670-20672	in	_	
121-144	20673-20686	schizophrenia	_	
121-145	20687-20690	and	_	
121-146	20691-20696	major	_	
121-147	20697-20707	depressive	_	
121-148	20708-20716	disorder	_	
121-149	20717-20727	First-rank	_	
121-150	20728-20736	symptoms	_	
121-151	20737-20739	in	_	
121-152	20740-20755	methamphetamine	_	
121-153	20756-20765	psychosis	_	
121-154	20766-20769	and	_	
121-155	20770-20783	schizophrenia	_	
121-156	20784-20795	Subcortical	_	
121-157	20796-20800	grey	_	
121-158	20801-20807	matter	_	
121-159	20808-20819	alterations	_	
121-160	20820-20822	in	_	
121-161	20823-20830	cocaine	_	
121-162	20831-20840	dependent	_	
121-163	20841-20852	individuals	_	
121-164	20853-20857	with	_	
121-165	20858-20875	substance-induced	_	
121-166	20876-20885	psychosis	_	
121-167	20886-20894	compared	_	
121-168	20895-20897	to	_	
121-169	20898-20911	non-psychotic	_	
121-170	20912-20919	cocaine	_	
121-171	20920-20925	users	_	
121-172	20926-20933	Reduced	_	
121-173	20934-20942	amygdala	_	
121-174	20943-20946	and	_	
121-175	20947-20958	hippocampal	_	
121-176	20959-20966	volumes	_	
121-177	20967-20969	in	_	
121-178	20970-20978	patients	_	
121-179	20979-20983	with	_	
121-180	20984-20999	methamphetamine	_	
121-181	21000-21009	psychosis	_	
121-182	21010-21019	Frequency	_	
121-183	21020-21029	dependent	_	
121-184	21030-21041	alterations	_	
121-185	21042-21044	in	_	
121-186	21045-21053	regional	_	
121-187	21054-21065	homogeneity	_	
121-188	21066-21068	of	_	
121-189	21069-21077	baseline	_	
121-190	21078-21083	brain	_	
121-191	21084-21092	activity	_	
121-192	21093-21095	in	_	
121-193	21096-21109	schizophrenia	_	
121-194	21110-21113	The	_	
121-195	21114-21119	brain	_	
121-196	21120-21127	regions	_	
121-197	21128-21132	that	_	
121-198	21133-21137	were	_	
121-199	21138-21146	distinct	_	
121-200	21147-21149	in	_	
121-201	21150-21154	gray	_	
121-202	21155-21161	matter	_	
121-203	21162-21169	density	_	
121-204	21170-21175	among	_	
121-205	21176-21179	MAP	_	
121-206	21179-21180	,	_	
121-207	21181-21184	SCZ	_	
121-208	21184-21185	,	_	
121-209	21186-21189	and	_	
121-210	21190-21197	control	_	
121-211	21198-21204	groups	_	
121-212	21204-21205	.	_	

#Text=(A) Left operculum inferior frontal gyrus; (B) right middle frontal gyrus; (C) bilateral anterior cingulate; (D) bilateral medial superior frontal gyrus.
122-1	21206-21207	(	_	
122-2	21207-21208	A	_	
122-3	21208-21209	)	_	
122-4	21210-21214	Left	_	
122-5	21215-21224	operculum	_	
122-6	21225-21233	inferior	_	
122-7	21234-21241	frontal	_	
122-8	21242-21247	gyrus	_	
122-9	21247-21248	;	_	
122-10	21249-21250	(	_	
122-11	21250-21251	B	_	
122-12	21251-21252	)	_	
122-13	21253-21258	right	_	
122-14	21259-21265	middle	_	
122-15	21266-21273	frontal	_	
122-16	21274-21279	gyrus	_	
122-17	21279-21280	;	_	
122-18	21281-21282	(	_	
122-19	21282-21283	C	_	
122-20	21283-21284	)	_	
122-21	21285-21294	bilateral	_	
122-22	21295-21303	anterior	_	
122-23	21304-21313	cingulate	_	
122-24	21313-21314	;	_	
122-25	21315-21316	(	_	
122-26	21316-21317	D	_	
122-27	21317-21318	)	_	
122-28	21319-21328	bilateral	_	
122-29	21329-21335	medial	_	
122-30	21336-21344	superior	_	
122-31	21345-21352	frontal	_	
122-32	21353-21358	gyrus	_	
122-33	21358-21359	.	_	

#Text=The brain regions that were distinct in ReHo among MAP, SCZ, and control groups.
123-1	21360-21363	The	_	
123-2	21364-21369	brain	_	
123-3	21370-21377	regions	_	
123-4	21378-21382	that	_	
123-5	21383-21387	were	_	
123-6	21388-21396	distinct	_	
123-7	21397-21399	in	_	
123-8	21400-21404	ReHo	_	
123-9	21405-21410	among	_	
123-10	21411-21414	MAP	_	
123-11	21414-21415	,	_	
123-12	21416-21419	SCZ	_	
123-13	21419-21420	,	_	
123-14	21421-21424	and	_	
123-15	21425-21432	control	_	
123-16	21433-21439	groups	_	
123-17	21439-21440	.	_	

#Text=I – left orbital inferior frontal gyrus; II – right hippocampus; III – left lenticular nucleus; IV – left triangular part/opercular part inferior frontal gyrus; V – right superior temporal gyrus; VI – left medial superior frontal gyrus; VII – right precuneus; VIII – right angular gyrus; IX – right middle frontal gyrus/superior frontal gyrus; X – right superior frontal gyrus.
124-1	21441-21442	I	_	
124-2	21443-21444	–	_	
124-3	21445-21449	left	_	
124-4	21450-21457	orbital	_	
124-5	21458-21466	inferior	_	
124-6	21467-21474	frontal	_	
124-7	21475-21480	gyrus	_	
124-8	21480-21481	;	_	
124-9	21482-21484	II	_	
124-10	21485-21486	–	_	
124-11	21487-21492	right	_	
124-12	21493-21504	hippocampus	_	
124-13	21504-21505	;	_	
124-14	21506-21509	III	_	
124-15	21510-21511	–	_	
124-16	21512-21516	left	_	
124-17	21517-21527	lenticular	_	
124-18	21528-21535	nucleus	_	
124-19	21535-21536	;	_	
124-20	21537-21539	IV	_	
124-21	21540-21541	–	_	
124-22	21542-21546	left	_	
124-23	21547-21557	triangular	_	
124-24	21558-21562	part	_	
124-25	21562-21563	/	_	
124-26	21563-21572	opercular	_	
124-27	21573-21577	part	_	
124-28	21578-21586	inferior	_	
124-29	21587-21594	frontal	_	
124-30	21595-21600	gyrus	_	
124-31	21600-21601	;	_	
124-32	21602-21603	V	_	
124-33	21604-21605	–	_	
124-34	21606-21611	right	_	
124-35	21612-21620	superior	_	
124-36	21621-21629	temporal	_	
124-37	21630-21635	gyrus	_	
124-38	21635-21636	;	_	
124-39	21637-21639	VI	_	
124-40	21640-21641	–	_	
124-41	21642-21646	left	_	
124-42	21647-21653	medial	_	
124-43	21654-21662	superior	_	
124-44	21663-21670	frontal	_	
124-45	21671-21676	gyrus	_	
124-46	21676-21677	;	_	
124-47	21678-21681	VII	_	
124-48	21682-21683	–	_	
124-49	21684-21689	right	_	
124-50	21690-21699	precuneus	_	
124-51	21699-21700	;	_	
124-52	21701-21705	VIII	_	
124-53	21706-21707	–	_	
124-54	21708-21713	right	_	
124-55	21714-21721	angular	_	
124-56	21722-21727	gyrus	_	
124-57	21727-21728	;	_	
124-58	21729-21731	IX	_	
124-59	21732-21733	–	_	
124-60	21734-21739	right	_	
124-61	21740-21746	middle	_	
124-62	21747-21754	frontal	_	
124-63	21755-21760	gyrus	_	
124-64	21760-21761	/	_	
124-65	21761-21769	superior	_	
124-66	21770-21777	frontal	_	
124-67	21778-21783	gyrus	_	
124-68	21783-21784	;	_	
124-69	21785-21786	X	_	
124-70	21787-21788	–	_	
124-71	21789-21794	right	_	
124-72	21795-21803	superior	_	
124-73	21804-21811	frontal	_	
124-74	21812-21817	gyrus	_	
124-75	21817-21818	.	_	

#Text=The brain regions that were distinct in the functional connectivity of right hippocampus (27, −18, −9) among MAP, SCZ, and control groups.
125-1	21819-21822	The	_	
125-2	21823-21828	brain	_	
125-3	21829-21836	regions	_	
125-4	21837-21841	that	_	
125-5	21842-21846	were	_	
125-6	21847-21855	distinct	_	
125-7	21856-21858	in	_	
125-8	21859-21862	the	_	
125-9	21863-21873	functional	_	
125-10	21874-21886	connectivity	_	
125-11	21887-21889	of	_	
125-12	21890-21895	right	_	
125-13	21896-21907	hippocampus	_	
125-14	21908-21909	(	_	
125-15	21909-21911	27	_	
125-16	21911-21912	,	_	
125-17	21913-21914	−	_	
125-18	21914-21916	18	_	
125-19	21916-21917	,	_	
125-20	21918-21919	−	_	
125-21	21919-21920	9	_	
125-22	21920-21921	)	_	
125-23	21922-21927	among	_	
125-24	21928-21931	MAP	_	
125-25	21931-21932	,	_	
125-26	21933-21936	SCZ	_	
125-27	21936-21937	,	_	
125-28	21938-21941	and	_	
125-29	21942-21949	control	_	
125-30	21950-21956	groups	_	
125-31	21956-21957	.	_	

#Text=The brain regions that were distinct in the functional connectivity of left medial superior frontal gyrus (−3, 63, 18) among MAP, SCZ and control groups.
126-1	21958-21961	The	_	
126-2	21962-21967	brain	_	
126-3	21968-21975	regions	_	
126-4	21976-21980	that	_	
126-5	21981-21985	were	_	
126-6	21986-21994	distinct	_	
126-7	21995-21997	in	_	
126-8	21998-22001	the	_	
126-9	22002-22012	functional	_	
126-10	22013-22025	connectivity	_	
126-11	22026-22028	of	_	
126-12	22029-22033	left	_	
126-13	22034-22040	medial	_	
126-14	22041-22049	superior	_	
126-15	22050-22057	frontal	_	
126-16	22058-22063	gyrus	_	
126-17	22064-22065	(	_	
126-18	22065-22066	−	_	
126-19	22066-22067	3	_	
126-20	22067-22068	,	_	
126-21	22069-22071	63	_	
126-22	22071-22072	,	_	
126-23	22073-22075	18	_	
126-24	22075-22076	)	_	
126-25	22077-22082	among	_	
126-26	22083-22086	MAP	_	
126-27	22086-22087	,	_	
126-28	22088-22091	SCZ	_	
126-29	22092-22095	and	_	
126-30	22096-22103	control	_	
126-31	22104-22110	groups	_	
126-32	22110-22111	.	_	

#Text=The brain regions that were distinct in the functional connectivity of right angular gyrus (39, −63, 48) among MAP, SCZ, and control groups.
127-1	22112-22115	The	_	
127-2	22116-22121	brain	_	
127-3	22122-22129	regions	_	
127-4	22130-22134	that	_	
127-5	22135-22139	were	_	
127-6	22140-22148	distinct	_	
127-7	22149-22151	in	_	
127-8	22152-22155	the	_	
127-9	22156-22166	functional	_	
127-10	22167-22179	connectivity	_	
127-11	22180-22182	of	_	
127-12	22183-22188	right	_	
127-13	22189-22196	angular	_	
127-14	22197-22202	gyrus	_	
127-15	22203-22204	(	_	
127-16	22204-22206	39	_	
127-17	22206-22207	,	_	
127-18	22208-22209	−	_	
127-19	22209-22211	63	_	
127-20	22211-22212	,	_	
127-21	22213-22215	48	_	
127-22	22215-22216	)	_	
127-23	22217-22222	among	_	
127-24	22223-22226	MAP	_	
127-25	22226-22227	,	_	
127-26	22228-22231	SCZ	_	
127-27	22231-22232	,	_	
127-28	22233-22236	and	_	
127-29	22237-22244	control	_	
127-30	22245-22251	groups	_	
127-31	22251-22252	.	_	

#Text=The brain regions that were distinct in the functional connectivity of right middle frontal gyrus/superior frontal gyrus (30, 30, 51) among MAP, SCZ, and control groups.
128-1	22253-22256	The	_	
128-2	22257-22262	brain	_	
128-3	22263-22270	regions	_	
128-4	22271-22275	that	_	
128-5	22276-22280	were	_	
128-6	22281-22289	distinct	_	
128-7	22290-22292	in	_	
128-8	22293-22296	the	_	
128-9	22297-22307	functional	_	
128-10	22308-22320	connectivity	_	
128-11	22321-22323	of	_	
128-12	22324-22329	right	_	
128-13	22330-22336	middle	_	
128-14	22337-22344	frontal	_	
128-15	22345-22350	gyrus	_	
128-16	22350-22351	/	_	
128-17	22351-22359	superior	_	
128-18	22360-22367	frontal	_	
128-19	22368-22373	gyrus	_	
128-20	22374-22375	(	_	
128-21	22375-22377	30	_	
128-22	22377-22378	,	_	
128-23	22379-22381	30	_	
128-24	22381-22382	,	_	
128-25	22383-22385	51	_	
128-26	22385-22386	)	_	
128-27	22387-22392	among	_	
128-28	22393-22396	MAP	_	
128-29	22396-22397	,	_	
128-30	22398-22401	SCZ	_	
128-31	22401-22402	,	_	
128-32	22403-22406	and	_	
128-33	22407-22414	control	_	
128-34	22415-22421	groups	_	
128-35	22421-22422	.	_	

#Text=Correlation between ReHo values of left orbital inferior gyrus and PANSS-positive symptoms among MAP patients, correlation between ReHo values, and functional connectivity in right middle frontal gyrus and PANSS-negative symptoms among MAP patients.
129-1	22423-22434	Correlation	_	
129-2	22435-22442	between	_	
129-3	22443-22447	ReHo	_	
129-4	22448-22454	values	_	
129-5	22455-22457	of	_	
129-6	22458-22462	left	_	
129-7	22463-22470	orbital	_	
129-8	22471-22479	inferior	_	
129-9	22480-22485	gyrus	_	
129-10	22486-22489	and	_	
129-11	22490-22504	PANSS-positive	_	
129-12	22505-22513	symptoms	_	
129-13	22514-22519	among	_	
129-14	22520-22523	MAP	_	
129-15	22524-22532	patients	_	
129-16	22532-22533	,	_	
129-17	22534-22545	correlation	_	
129-18	22546-22553	between	_	
129-19	22554-22558	ReHo	_	
129-20	22559-22565	values	_	
129-21	22565-22566	,	_	
129-22	22567-22570	and	_	
129-23	22571-22581	functional	_	
129-24	22582-22594	connectivity	_	
129-25	22595-22597	in	_	
129-26	22598-22603	right	_	
129-27	22604-22610	middle	_	
129-28	22611-22618	frontal	_	
129-29	22619-22624	gyrus	_	
129-30	22625-22628	and	_	
129-31	22629-22643	PANSS-negative	_	
129-32	22644-22652	symptoms	_	
129-33	22653-22658	among	_	
129-34	22659-22662	MAP	_	
129-35	22663-22671	patients	_	
129-36	22671-22672	.	_	

#Text=Recorded clinical characteristics and PANSS score for participants.
130-1	22673-22681	Recorded	_	
130-2	22682-22690	clinical	_	
130-3	22691-22706	characteristics	_	
130-4	22707-22710	and	_	
130-5	22711-22716	PANSS	_	
130-6	22717-22722	score	_	
130-7	22723-22726	for	_	
130-8	22727-22739	participants	_	
130-9	22739-22740	.	_	

#Text=Characteristics\tMAP patients (n=17)\tSCZ patients (n=16)\tHeathy controls(n=18)\tχ2/F/t value\tP value\t \tAge (years)\t21.0±4.0\t23.8±4.3\t23.2±2.3\t3.015b\t0.058\t \tEducation (years)\t11.4±1.4\t10.8±1.6\t11.1±1.7\t0.550b\t0.58\t \tSex\t \t Male\t9\t7\t9\t0.289a\t0.865\t \t Female\t8\t9\t9\t\t\t \tAlcohol\t\t\t\t0.216a\t0.897\t \t Yes\t6\t5\t7\t\t\t \t No\t11\t11\t11\t\t\t \tSmoking\t\t\t\t1.316a\t0.518\t \t Yes\t3\t2\t5\t\t\t \t No\t14\t14\t13\t\t\t \tPANSS total\t48.76±3.01\t76.00±6.00\t–\t20.35b\t<0.0001\t \tPANSS positive\t14.59±1.54\t14.19±2.07\t–\t0.299b\t0.638\t \tPANSS negative\t17.0±4.67\t18.69±3.98\t–\t1.262b\t0.416\t \t
#Text=MAP – methamphetamine-associated psychosis; SCZ – schizophrenia; PANSS – Positive and Negative Syndrome Scale.
#Text=χ2 value;
#Text=F/t value.
131-1	22741-22756	Characteristics	_	
131-2	22757-22760	MAP	_	
131-3	22761-22769	patients	_	
131-4	22770-22771	(	_	
131-5	22771-22772	n	_	
131-6	22772-22773	=	_	
131-7	22773-22775	17	_	
131-8	22775-22776	)	_	
131-9	22777-22780	SCZ	_	
131-10	22781-22789	patients	_	
131-11	22790-22791	(	_	
131-12	22791-22792	n	_	
131-13	22792-22793	=	_	
131-14	22793-22795	16	_	
131-15	22795-22796	)	_	
131-16	22797-22803	Heathy	_	
131-17	22804-22812	controls	_	
131-18	22812-22813	(	_	
131-19	22813-22814	n	_	
131-20	22814-22815	=	_	
131-21	22815-22817	18	_	
131-22	22817-22818	)	_	
131-23	22819-22821	χ2	_	
131-24	22821-22822	/	_	
131-25	22822-22823	F	_	
131-26	22823-22824	/	_	
131-27	22824-22825	t	_	
131-28	22826-22831	value	_	
131-29	22832-22833	P	_	
131-30	22834-22839	value	_	
131-31	22842-22845	Age	_	
131-32	22846-22847	(	_	
131-33	22847-22852	years	_	
131-34	22852-22853	)	_	
131-35	22854-22858	21.0	_	
131-36	22858-22859	±	_	
131-37	22859-22862	4.0	_	
131-38	22863-22867	23.8	_	
131-39	22867-22868	±	_	
131-40	22868-22871	4.3	_	
131-41	22872-22876	23.2	_	
131-42	22876-22877	±	_	
131-43	22877-22880	2.3	_	
131-44	22881-22887	3.015b	_	
131-45	22888-22893	0.058	_	
131-46	22896-22905	Education	_	
131-47	22906-22907	(	_	
131-48	22907-22912	years	_	
131-49	22912-22913	)	_	
131-50	22914-22918	11.4	_	
131-51	22918-22919	±	_	
131-52	22919-22922	1.4	_	
131-53	22923-22927	10.8	_	
131-54	22927-22928	±	_	
131-55	22928-22931	1.6	_	
131-56	22932-22936	11.1	_	
131-57	22936-22937	±	_	
131-58	22937-22940	1.7	_	
131-59	22941-22947	0.550b	_	
131-60	22948-22952	0.58	_	
131-61	22955-22958	Sex	_	
131-62	22962-22966	Male	_	
131-63	22967-22968	9	_	
131-64	22969-22970	7	_	
131-65	22971-22972	9	_	
131-66	22973-22979	0.289a	_	
131-67	22980-22985	0.865	_	
131-68	22989-22995	Female	_	
131-69	22996-22997	8	_	
131-70	22998-22999	9	_	
131-71	23000-23001	9	_	
131-72	23006-23013	Alcohol	_	
131-73	23017-23023	0.216a	_	
131-74	23024-23029	0.897	_	
131-75	23033-23036	Yes	_	
131-76	23037-23038	6	_	
131-77	23039-23040	5	_	
131-78	23041-23042	7	_	
131-79	23048-23050	No	_	
131-80	23051-23053	11	_	
131-81	23054-23056	11	_	
131-82	23057-23059	11	_	
131-83	23064-23071	Smoking	_	
131-84	23075-23081	1.316a	_	
131-85	23082-23087	0.518	_	
131-86	23091-23094	Yes	_	
131-87	23095-23096	3	_	
131-88	23097-23098	2	_	
131-89	23099-23100	5	_	
131-90	23106-23108	No	_	
131-91	23109-23111	14	_	
131-92	23112-23114	14	_	
131-93	23115-23117	13	_	
131-94	23122-23127	PANSS	_	
131-95	23128-23133	total	_	
131-96	23134-23139	48.76	_	
131-97	23139-23140	±	_	
131-98	23140-23144	3.01	_	
131-99	23145-23150	76.00	_	
131-100	23150-23151	±	_	
131-101	23151-23155	6.00	_	
131-102	23156-23157	–	_	
131-103	23158-23164	20.35b	_	
131-104	23165-23166	<	_	
131-105	23166-23172	0.0001	_	
131-106	23175-23180	PANSS	_	
131-107	23181-23189	positive	_	
131-108	23190-23195	14.59	_	
131-109	23195-23196	±	_	
131-110	23196-23200	1.54	_	
131-111	23201-23206	14.19	_	
131-112	23206-23207	±	_	
131-113	23207-23211	2.07	_	
131-114	23212-23213	–	_	
131-115	23214-23220	0.299b	_	
131-116	23221-23226	0.638	_	
131-117	23229-23234	PANSS	_	
131-118	23235-23243	negative	_	
131-119	23244-23248	17.0	_	
131-120	23248-23249	±	_	
131-121	23249-23253	4.67	_	
131-122	23254-23259	18.69	_	
131-123	23259-23260	±	_	
131-124	23260-23264	3.98	_	
131-125	23265-23266	–	_	
131-126	23267-23273	1.262b	_	
131-127	23274-23279	0.416	_	
131-128	23283-23286	MAP	_	
131-129	23287-23288	–	_	
131-130	23289-23315	methamphetamine-associated	_	
131-131	23316-23325	psychosis	_	
131-132	23325-23326	;	_	
131-133	23327-23330	SCZ	_	
131-134	23331-23332	–	_	
131-135	23333-23346	schizophrenia	_	
131-136	23346-23347	;	_	
131-137	23348-23353	PANSS	_	
131-138	23354-23355	–	_	
131-139	23356-23364	Positive	_	
131-140	23365-23368	and	_	
131-141	23369-23377	Negative	_	
131-142	23378-23386	Syndrome	_	
131-143	23387-23392	Scale	_	
131-144	23392-23393	.	_	
131-145	23394-23396	χ2	_	
131-146	23397-23402	value	_	
131-147	23402-23403	;	_	
131-148	23404-23405	F	_	
131-149	23405-23406	/	_	
131-150	23406-23407	t	_	
131-151	23408-23413	value	_	
131-152	23413-23414	.	_	

#Text=GMD difference analysis among MAP, SCZ and control recruits.
132-1	23415-23418	GMD	_	
132-2	23419-23429	difference	_	
132-3	23430-23438	analysis	_	
132-4	23439-23444	among	_	
132-5	23445-23448	MAP	_	
132-6	23448-23449	,	_	
132-7	23450-23453	SCZ	_	
132-8	23454-23457	and	_	
132-9	23458-23465	control	_	
132-10	23466-23474	recruits	_	
132-11	23474-23475	.	_	

#Text=Brain region\tThe mean GMD\tBA\tVoxels\tMNI coordinates (x, y, z)\tPeak F value\tGroup mean difference/significance\t \tMAP patients\tSCZ patients\tControl\tMAP-control/P\tSCZ-control/P\tMAP-SCZ/P\t \tL-opr-IFG\t0.45\t0.38\t0.42\t45\t46\t−57, 9, 23\t10.63\t0.03/ P=0.036\t−0.04/P=0.014\t0.07/ P<0.001\t \tB-MSFG\t0.63\t0.53\t0.52\t9\t67\t3, 53, 27\t12.57\t0.11/ P<0.001\t0.01/ P=1.000\t0.10/ P<0.001\t \tB-AC\t0.53\t0.43\t0.47\t24\t606\t2, 9, 30\t20.85\t0.06/ P=0.032\t−0.04/P=0.197\t0.10/ P<0.001\t \tR-MFG\t0.71\t0.53\t0.72\t9\t132\t38, 18, 44\t14.85\t−0.01/P=1.000\t−0.19/P<0.001\t0.18/ P<0.001\t \t
#Text=GMD – gray matter density; MAP – methamphetamine-associated psychosis; SCZ – schizophrenia; BA – bradmann; MNI – Montreal Neurological Institute; B – bilateral; opr-IFG – operculum inferior frontal gyrus; MSFG – medial superior frontal gyrus; AC – anterior cingulate; MFG – middle frontal gyrus.
133-1	23476-23481	Brain	_	
133-2	23482-23488	region	_	
133-3	23489-23492	The	_	
133-4	23493-23497	mean	_	
133-5	23498-23501	GMD	_	
133-6	23502-23504	BA	_	
133-7	23505-23511	Voxels	_	
133-8	23512-23515	MNI	_	
133-9	23516-23527	coordinates	_	
133-10	23528-23529	(	_	
133-11	23529-23530	x	_	
133-12	23530-23531	,	_	
133-13	23532-23533	y	_	
133-14	23533-23534	,	_	
133-15	23535-23536	z	_	
133-16	23536-23537	)	_	
133-17	23538-23542	Peak	_	
133-18	23543-23544	F	_	
133-19	23545-23550	value	_	
133-20	23551-23556	Group	_	
133-21	23557-23561	mean	_	
133-22	23562-23572	difference	_	
133-23	23572-23573	/	_	
133-24	23573-23585	significance	_	
133-25	23588-23591	MAP	_	
133-26	23592-23600	patients	_	
133-27	23601-23604	SCZ	_	
133-28	23605-23613	patients	_	
133-29	23614-23621	Control	_	
133-30	23622-23633	MAP-control	_	
133-31	23633-23634	/	_	
133-32	23634-23635	P	_	
133-33	23636-23647	SCZ-control	_	
133-34	23647-23648	/	_	
133-35	23648-23649	P	_	
133-36	23650-23657	MAP-SCZ	_	
133-37	23657-23658	/	_	
133-38	23658-23659	P	_	
133-39	23662-23671	L-opr-IFG	_	
133-40	23672-23676	0.45	_	
133-41	23677-23681	0.38	_	
133-42	23682-23686	0.42	_	
133-43	23687-23689	45	_	
133-44	23690-23692	46	_	
133-45	23693-23694	−	_	
133-46	23694-23696	57	_	
133-47	23696-23697	,	_	
133-48	23698-23699	9	_	
133-49	23699-23700	,	_	
133-50	23701-23703	23	_	
133-51	23704-23709	10.63	_	
133-52	23710-23714	0.03	_	
133-53	23714-23715	/	_	
133-54	23716-23717	P	_	
133-55	23717-23718	=	_	
133-56	23718-23723	0.036	_	
133-57	23724-23725	−	_	
133-58	23725-23729	0.04	_	
133-59	23729-23730	/	_	
133-60	23730-23731	P	_	
133-61	23731-23732	=	_	
133-62	23732-23737	0.014	_	
133-63	23738-23742	0.07	_	
133-64	23742-23743	/	_	
133-65	23744-23745	P	_	
133-66	23745-23746	<	_	
133-67	23746-23751	0.001	_	
133-68	23754-23760	B-MSFG	_	
133-69	23761-23765	0.63	_	
133-70	23766-23770	0.53	_	
133-71	23771-23775	0.52	_	
133-72	23776-23777	9	_	
133-73	23778-23780	67	_	
133-74	23781-23782	3	_	
133-75	23782-23783	,	_	
133-76	23784-23786	53	_	
133-77	23786-23787	,	_	
133-78	23788-23790	27	_	
133-79	23791-23796	12.57	_	
133-80	23797-23801	0.11	_	
133-81	23801-23802	/	_	
133-82	23803-23804	P	_	
133-83	23804-23805	<	_	
133-84	23805-23810	0.001	_	
133-85	23811-23815	0.01	_	
133-86	23815-23816	/	_	
133-87	23817-23818	P	_	
133-88	23818-23819	=	_	
133-89	23819-23824	1.000	_	
133-90	23825-23829	0.10	_	
133-91	23829-23830	/	_	
133-92	23831-23832	P	_	
133-93	23832-23833	<	_	
133-94	23833-23838	0.001	_	
133-95	23841-23845	B-AC	_	
133-96	23846-23850	0.53	_	
133-97	23851-23855	0.43	_	
133-98	23856-23860	0.47	_	
133-99	23861-23863	24	_	
133-100	23864-23867	606	_	
133-101	23868-23869	2	_	
133-102	23869-23870	,	_	
133-103	23871-23872	9	_	
133-104	23872-23873	,	_	
133-105	23874-23876	30	_	
133-106	23877-23882	20.85	_	
133-107	23883-23887	0.06	_	
133-108	23887-23888	/	_	
133-109	23889-23890	P	_	
133-110	23890-23891	=	_	
133-111	23891-23896	0.032	_	
133-112	23897-23898	−	_	
133-113	23898-23902	0.04	_	
133-114	23902-23903	/	_	
133-115	23903-23904	P	_	
133-116	23904-23905	=	_	
133-117	23905-23910	0.197	_	
133-118	23911-23915	0.10	_	
133-119	23915-23916	/	_	
133-120	23917-23918	P	_	
133-121	23918-23919	<	_	
133-122	23919-23924	0.001	_	
133-123	23927-23932	R-MFG	_	
133-124	23933-23937	0.71	_	
133-125	23938-23942	0.53	_	
133-126	23943-23947	0.72	_	
133-127	23948-23949	9	_	
133-128	23950-23953	132	_	
133-129	23954-23956	38	_	
133-130	23956-23957	,	_	
133-131	23958-23960	18	_	
133-132	23960-23961	,	_	
133-133	23962-23964	44	_	
133-134	23965-23970	14.85	_	
133-135	23971-23972	−	_	
133-136	23972-23976	0.01	_	
133-137	23976-23977	/	_	
133-138	23977-23978	P	_	
133-139	23978-23979	=	_	
133-140	23979-23984	1.000	_	
133-141	23985-23986	−	_	
133-142	23986-23990	0.19	_	
133-143	23990-23991	/	_	
133-144	23991-23992	P	_	
133-145	23992-23993	<	_	
133-146	23993-23998	0.001	_	
133-147	23999-24003	0.18	_	
133-148	24003-24004	/	_	
133-149	24005-24006	P	_	
133-150	24006-24007	<	_	
133-151	24007-24012	0.001	_	
133-152	24016-24019	GMD	_	
133-153	24020-24021	–	_	
133-154	24022-24026	gray	_	
133-155	24027-24033	matter	_	
133-156	24034-24041	density	_	
133-157	24041-24042	;	_	
133-158	24043-24046	MAP	_	
133-159	24047-24048	–	_	
133-160	24049-24075	methamphetamine-associated	_	
133-161	24076-24085	psychosis	_	
133-162	24085-24086	;	_	
133-163	24087-24090	SCZ	_	
133-164	24091-24092	–	_	
133-165	24093-24106	schizophrenia	_	
133-166	24106-24107	;	_	
133-167	24108-24110	BA	_	
133-168	24111-24112	–	_	
133-169	24113-24121	bradmann	_	
133-170	24121-24122	;	_	
133-171	24123-24126	MNI	_	
133-172	24127-24128	–	_	
133-173	24129-24137	Montreal	_	
133-174	24138-24150	Neurological	_	
133-175	24151-24160	Institute	_	
133-176	24160-24161	;	_	
133-177	24162-24163	B	_	
133-178	24164-24165	–	_	
133-179	24166-24175	bilateral	_	
133-180	24175-24176	;	_	
133-181	24177-24184	opr-IFG	_	
133-182	24185-24186	–	_	
133-183	24187-24196	operculum	_	
133-184	24197-24205	inferior	_	
133-185	24206-24213	frontal	_	
133-186	24214-24219	gyrus	_	
133-187	24219-24220	;	_	
133-188	24221-24225	MSFG	_	
133-189	24226-24227	–	_	
133-190	24228-24234	medial	_	
133-191	24235-24243	superior	_	
133-192	24244-24251	frontal	_	
133-193	24252-24257	gyrus	_	
133-194	24257-24258	;	_	
133-195	24259-24261	AC	_	
133-196	24262-24263	–	_	
133-197	24264-24272	anterior	_	
133-198	24273-24282	cingulate	_	
133-199	24282-24283	;	_	
133-200	24284-24287	MFG	_	
133-201	24288-24289	–	_	
133-202	24290-24296	middle	_	
133-203	24297-24304	frontal	_	
133-204	24305-24310	gyrus	_	
133-205	24310-24311	.	_	

#Text=ReHo difference analysis among MAP, SCZ and control recruits.
134-1	24312-24316	ReHo	_	
134-2	24317-24327	difference	_	
134-3	24328-24336	analysis	_	
134-4	24337-24342	among	_	
134-5	24343-24346	MAP	_	
134-6	24346-24347	,	_	
134-7	24348-24351	SCZ	_	
134-8	24352-24355	and	_	
134-9	24356-24363	control	_	
134-10	24364-24372	recruits	_	
134-11	24372-24373	.	_	

#Text=Brain region\tThe mean ReHo\tBA\tVoxels\tMNI coordinates (x, y, z)\tPeak F value\tGroup mean difference/significance\t \tMAP patients\tSCZ patients\tControl\tMAP-control/P\tSCZ-control/P\tMAP-SCZ/P\t \tL-orb-IFG\t0.96\t0.84\t0.77\t47\t8\t−39, 27, −18\t11.15\t0.19/ P<0.001\t0.07/ P=0.240\t0.12/ P=0.006\t \tR-HPC\t0.84\t0.88\t0.67\t\t7\t27, −18, −9\t11.81\t0.17/ P=0.002\t0.21/ P<0.001\t−0.04/ P=0.997\t \tL-LTN\t0.81\t1.02\t0.8\t\t14\t−24, 15, 6\t11.01\t0.01/ P=1.000\t0.22/ P<0.001\t−0.21/ P<0.001\t \tL-TRP/orp-IFG\t0.82\t1.03\t0.85\t13\t15\t−39, 18, 15\t15.9\t−0.03/ P=0.916\t0.18/ P<0.001\t−0.21/ P<0.001\t \tR-STG\t1.3\t1.02\t1.32\t22\t16\t66, −51, 21\t13.59\t−0.02/ P=1.000\t−0.30/ P<0.001\t0.28/ P<0.001\t \tL-MSFG\t1.27\t1.08\t1.44\t10\t22\t−3, 63, 18\t12.69\t−0.17/ P=0.034\t−0.36/ P<0.001\t0.19/ P=0.018\t \tR-PC\t1.55\t1.3\t1.63\t7\t9\t6, −75, 42\t13.22\t−0.08/ P=0.541\t−0.33/ P<0.001\t0.25/ P=0.001\t \tR-ANG\t1.44\t1.37\t1.69\t7\t7\t39, −63, 48\t10.66\t−0.25/ P=0.002\t−0.32/ P<0.001\t0.06/ P=0.945\t \tR-MFG/SFG\t1.14\t1.05\t1.39\t8\t20\t30, 30, 51\t11.94\t−0.25/ P=0.002\t−0.34/ P<0.001\t0.09/ P=0.595\t \tR-SFG\t1.17\t0.94\t1.27\t6\t26\t36, 12, 63\t15.62\t−0.10/ P=0.148\t−0.33/ P<0.001\t0.23/ P<0.000\t \t
#Text=ReHo – regional homogeneity; MAP – methamphetamine-associated psychosis; SCZ – schizophrenia; BA – bradmann; MNI – Montreal Neurological Institute; R – right; L – left; orb-IFG – orbital inferior frontal gyrus; HPC – hippocampus; LTN – lenticular nucleus; TRP – triangular part; opr-IFG – operculum inferior frontal gyrus; STG – superior temporal gyrus; MSFG – medial superior frontal gyrus; PC – precuneus; ANG – angular gyrus; MFG – middle frontal gyrus; SFG – superior frontal gyrus.
135-1	24374-24379	Brain	_	
135-2	24380-24386	region	_	
135-3	24387-24390	The	_	
135-4	24391-24395	mean	_	
135-5	24396-24400	ReHo	_	
135-6	24401-24403	BA	_	
135-7	24404-24410	Voxels	_	
135-8	24411-24414	MNI	_	
135-9	24415-24426	coordinates	_	
135-10	24427-24428	(	_	
135-11	24428-24429	x	_	
135-12	24429-24430	,	_	
135-13	24431-24432	y	_	
135-14	24432-24433	,	_	
135-15	24434-24435	z	_	
135-16	24435-24436	)	_	
135-17	24437-24441	Peak	_	
135-18	24442-24443	F	_	
135-19	24444-24449	value	_	
135-20	24450-24455	Group	_	
135-21	24456-24460	mean	_	
135-22	24461-24471	difference	_	
135-23	24471-24472	/	_	
135-24	24472-24484	significance	_	
135-25	24487-24490	MAP	_	
135-26	24491-24499	patients	_	
135-27	24500-24503	SCZ	_	
135-28	24504-24512	patients	_	
135-29	24513-24520	Control	_	
135-30	24521-24532	MAP-control	_	
135-31	24532-24533	/	_	
135-32	24533-24534	P	_	
135-33	24535-24546	SCZ-control	_	
135-34	24546-24547	/	_	
135-35	24547-24548	P	_	
135-36	24549-24556	MAP-SCZ	_	
135-37	24556-24557	/	_	
135-38	24557-24558	P	_	
135-39	24561-24570	L-orb-IFG	_	
135-40	24571-24575	0.96	_	
135-41	24576-24580	0.84	_	
135-42	24581-24585	0.77	_	
135-43	24586-24588	47	_	
135-44	24589-24590	8	_	
135-45	24591-24592	−	_	
135-46	24592-24594	39	_	
135-47	24594-24595	,	_	
135-48	24596-24598	27	_	
135-49	24598-24599	,	_	
135-50	24600-24601	−	_	
135-51	24601-24603	18	_	
135-52	24604-24609	11.15	_	
135-53	24610-24614	0.19	_	
135-54	24614-24615	/	_	
135-55	24616-24617	P	_	
135-56	24617-24618	<	_	
135-57	24618-24623	0.001	_	
135-58	24624-24628	0.07	_	
135-59	24628-24629	/	_	
135-60	24630-24631	P	_	
135-61	24631-24632	=	_	
135-62	24632-24637	0.240	_	
135-63	24638-24642	0.12	_	
135-64	24642-24643	/	_	
135-65	24644-24645	P	_	
135-66	24645-24646	=	_	
135-67	24646-24651	0.006	_	
135-68	24654-24659	R-HPC	_	
135-69	24660-24664	0.84	_	
135-70	24665-24669	0.88	_	
135-71	24670-24674	0.67	_	
135-72	24676-24677	7	_	
135-73	24678-24680	27	_	
135-74	24680-24681	,	_	
135-75	24682-24683	−	_	
135-76	24683-24685	18	_	
135-77	24685-24686	,	_	
135-78	24687-24688	−	_	
135-79	24688-24689	9	_	
135-80	24690-24695	11.81	_	
135-81	24696-24700	0.17	_	
135-82	24700-24701	/	_	
135-83	24702-24703	P	_	
135-84	24703-24704	=	_	
135-85	24704-24709	0.002	_	
135-86	24710-24714	0.21	_	
135-87	24714-24715	/	_	
135-88	24716-24717	P	_	
135-89	24717-24718	<	_	
135-90	24718-24723	0.001	_	
135-91	24724-24725	−	_	
135-92	24725-24729	0.04	_	
135-93	24729-24730	/	_	
135-94	24731-24732	P	_	
135-95	24732-24733	=	_	
135-96	24733-24738	0.997	_	
135-97	24741-24746	L-LTN	_	
135-98	24747-24751	0.81	_	
135-99	24752-24756	1.02	_	
135-100	24757-24760	0.8	_	
135-101	24762-24764	14	_	
135-102	24765-24766	−	_	
135-103	24766-24768	24	_	
135-104	24768-24769	,	_	
135-105	24770-24772	15	_	
135-106	24772-24773	,	_	
135-107	24774-24775	6	_	
135-108	24776-24781	11.01	_	
135-109	24782-24786	0.01	_	
135-110	24786-24787	/	_	
135-111	24788-24789	P	_	
135-112	24789-24790	=	_	
135-113	24790-24795	1.000	_	
135-114	24796-24800	0.22	_	
135-115	24800-24801	/	_	
135-116	24802-24803	P	_	
135-117	24803-24804	<	_	
135-118	24804-24809	0.001	_	
135-119	24810-24811	−	_	
135-120	24811-24815	0.21	_	
135-121	24815-24816	/	_	
135-122	24817-24818	P	_	
135-123	24818-24819	<	_	
135-124	24819-24824	0.001	_	
135-125	24827-24832	L-TRP	_	
135-126	24832-24833	/	_	
135-127	24833-24840	orp-IFG	_	
135-128	24841-24845	0.82	_	
135-129	24846-24850	1.03	_	
135-130	24851-24855	0.85	_	
135-131	24856-24858	13	_	
135-132	24859-24861	15	_	
135-133	24862-24863	−	_	
135-134	24863-24865	39	_	
135-135	24865-24866	,	_	
135-136	24867-24869	18	_	
135-137	24869-24870	,	_	
135-138	24871-24873	15	_	
135-139	24874-24878	15.9	_	
135-140	24879-24880	−	_	
135-141	24880-24884	0.03	_	
135-142	24884-24885	/	_	
135-143	24886-24887	P	_	
135-144	24887-24888	=	_	
135-145	24888-24893	0.916	_	
135-146	24894-24898	0.18	_	
135-147	24898-24899	/	_	
135-148	24900-24901	P	_	
135-149	24901-24902	<	_	
135-150	24902-24907	0.001	_	
135-151	24908-24909	−	_	
135-152	24909-24913	0.21	_	
135-153	24913-24914	/	_	
135-154	24915-24916	P	_	
135-155	24916-24917	<	_	
135-156	24917-24922	0.001	_	
135-157	24925-24930	R-STG	_	
135-158	24931-24934	1.3	_	
135-159	24935-24939	1.02	_	
135-160	24940-24944	1.32	_	
135-161	24945-24947	22	_	
135-162	24948-24950	16	_	
135-163	24951-24953	66	_	
135-164	24953-24954	,	_	
135-165	24955-24956	−	_	
135-166	24956-24958	51	_	
135-167	24958-24959	,	_	
135-168	24960-24962	21	_	
135-169	24963-24968	13.59	_	
135-170	24969-24970	−	_	
135-171	24970-24974	0.02	_	
135-172	24974-24975	/	_	
135-173	24976-24977	P	_	
135-174	24977-24978	=	_	
135-175	24978-24983	1.000	_	
135-176	24984-24985	−	_	
135-177	24985-24989	0.30	_	
135-178	24989-24990	/	_	
135-179	24991-24992	P	_	
135-180	24992-24993	<	_	
135-181	24993-24998	0.001	_	
135-182	24999-25003	0.28	_	
135-183	25003-25004	/	_	
135-184	25005-25006	P	_	
135-185	25006-25007	<	_	
135-186	25007-25012	0.001	_	
135-187	25015-25021	L-MSFG	_	
135-188	25022-25026	1.27	_	
135-189	25027-25031	1.08	_	
135-190	25032-25036	1.44	_	
135-191	25037-25039	10	_	
135-192	25040-25042	22	_	
135-193	25043-25044	−	_	
135-194	25044-25045	3	_	
135-195	25045-25046	,	_	
135-196	25047-25049	63	_	
135-197	25049-25050	,	_	
135-198	25051-25053	18	_	
135-199	25054-25059	12.69	_	
135-200	25060-25061	−	_	
135-201	25061-25065	0.17	_	
135-202	25065-25066	/	_	
135-203	25067-25068	P	_	
135-204	25068-25069	=	_	
135-205	25069-25074	0.034	_	
135-206	25075-25076	−	_	
135-207	25076-25080	0.36	_	
135-208	25080-25081	/	_	
135-209	25082-25083	P	_	
135-210	25083-25084	<	_	
135-211	25084-25089	0.001	_	
135-212	25090-25094	0.19	_	
135-213	25094-25095	/	_	
135-214	25096-25097	P	_	
135-215	25097-25098	=	_	
135-216	25098-25103	0.018	_	
135-217	25106-25110	R-PC	_	
135-218	25111-25115	1.55	_	
135-219	25116-25119	1.3	_	
135-220	25120-25124	1.63	_	
135-221	25125-25126	7	_	
135-222	25127-25128	9	_	
135-223	25129-25130	6	_	
135-224	25130-25131	,	_	
135-225	25132-25133	−	_	
135-226	25133-25135	75	_	
135-227	25135-25136	,	_	
135-228	25137-25139	42	_	
135-229	25140-25145	13.22	_	
135-230	25146-25147	−	_	
135-231	25147-25151	0.08	_	
135-232	25151-25152	/	_	
135-233	25153-25154	P	_	
135-234	25154-25155	=	_	
135-235	25155-25160	0.541	_	
135-236	25161-25162	−	_	
135-237	25162-25166	0.33	_	
135-238	25166-25167	/	_	
135-239	25168-25169	P	_	
135-240	25169-25170	<	_	
135-241	25170-25175	0.001	_	
135-242	25176-25180	0.25	_	
135-243	25180-25181	/	_	
135-244	25182-25183	P	_	
135-245	25183-25184	=	_	
135-246	25184-25189	0.001	_	
135-247	25192-25197	R-ANG	_	
135-248	25198-25202	1.44	_	
135-249	25203-25207	1.37	_	
135-250	25208-25212	1.69	_	
135-251	25213-25214	7	_	
135-252	25215-25216	7	_	
135-253	25217-25219	39	_	
135-254	25219-25220	,	_	
135-255	25221-25222	−	_	
135-256	25222-25224	63	_	
135-257	25224-25225	,	_	
135-258	25226-25228	48	_	
135-259	25229-25234	10.66	_	
135-260	25235-25236	−	_	
135-261	25236-25240	0.25	_	
135-262	25240-25241	/	_	
135-263	25242-25243	P	_	
135-264	25243-25244	=	_	
135-265	25244-25249	0.002	_	
135-266	25250-25251	−	_	
135-267	25251-25255	0.32	_	
135-268	25255-25256	/	_	
135-269	25257-25258	P	_	
135-270	25258-25259	<	_	
135-271	25259-25264	0.001	_	
135-272	25265-25269	0.06	_	
135-273	25269-25270	/	_	
135-274	25271-25272	P	_	
135-275	25272-25273	=	_	
135-276	25273-25278	0.945	_	
135-277	25281-25286	R-MFG	_	
135-278	25286-25287	/	_	
135-279	25287-25290	SFG	_	
135-280	25291-25295	1.14	_	
135-281	25296-25300	1.05	_	
135-282	25301-25305	1.39	_	
135-283	25306-25307	8	_	
135-284	25308-25310	20	_	
135-285	25311-25313	30	_	
135-286	25313-25314	,	_	
135-287	25315-25317	30	_	
135-288	25317-25318	,	_	
135-289	25319-25321	51	_	
135-290	25322-25327	11.94	_	
135-291	25328-25329	−	_	
135-292	25329-25333	0.25	_	
135-293	25333-25334	/	_	
135-294	25335-25336	P	_	
135-295	25336-25337	=	_	
135-296	25337-25342	0.002	_	
135-297	25343-25344	−	_	
135-298	25344-25348	0.34	_	
135-299	25348-25349	/	_	
135-300	25350-25351	P	_	
135-301	25351-25352	<	_	
135-302	25352-25357	0.001	_	
135-303	25358-25362	0.09	_	
135-304	25362-25363	/	_	
135-305	25364-25365	P	_	
135-306	25365-25366	=	_	
135-307	25366-25371	0.595	_	
135-308	25374-25379	R-SFG	_	
135-309	25380-25384	1.17	_	
135-310	25385-25389	0.94	_	
135-311	25390-25394	1.27	_	
135-312	25395-25396	6	_	
135-313	25397-25399	26	_	
135-314	25400-25402	36	_	
135-315	25402-25403	,	_	
135-316	25404-25406	12	_	
135-317	25406-25407	,	_	
135-318	25408-25410	63	_	
135-319	25411-25416	15.62	_	
135-320	25417-25418	−	_	
135-321	25418-25422	0.10	_	
135-322	25422-25423	/	_	
135-323	25424-25425	P	_	
135-324	25425-25426	=	_	
135-325	25426-25431	0.148	_	
135-326	25432-25433	−	_	
135-327	25433-25437	0.33	_	
135-328	25437-25438	/	_	
135-329	25439-25440	P	_	
135-330	25440-25441	<	_	
135-331	25441-25446	0.001	_	
135-332	25447-25451	0.23	_	
135-333	25451-25452	/	_	
135-334	25453-25454	P	_	
135-335	25454-25455	<	_	
135-336	25455-25460	0.000	_	
135-337	25464-25468	ReHo	_	
135-338	25469-25470	–	_	
135-339	25471-25479	regional	_	
135-340	25480-25491	homogeneity	_	
135-341	25491-25492	;	_	
135-342	25493-25496	MAP	_	
135-343	25497-25498	–	_	
135-344	25499-25525	methamphetamine-associated	_	
135-345	25526-25535	psychosis	_	
135-346	25535-25536	;	_	
135-347	25537-25540	SCZ	_	
135-348	25541-25542	–	_	
135-349	25543-25556	schizophrenia	_	
135-350	25556-25557	;	_	
135-351	25558-25560	BA	_	
135-352	25561-25562	–	_	
135-353	25563-25571	bradmann	_	
135-354	25571-25572	;	_	
135-355	25573-25576	MNI	_	
135-356	25577-25578	–	_	
135-357	25579-25587	Montreal	_	
135-358	25588-25600	Neurological	_	
135-359	25601-25610	Institute	_	
135-360	25610-25611	;	_	
135-361	25612-25613	R	_	
135-362	25614-25615	–	_	
135-363	25616-25621	right	_	
135-364	25621-25622	;	_	
135-365	25623-25624	L	_	
135-366	25625-25626	–	_	
135-367	25627-25631	left	_	
135-368	25631-25632	;	_	
135-369	25633-25640	orb-IFG	_	
135-370	25641-25642	–	_	
135-371	25643-25650	orbital	_	
135-372	25651-25659	inferior	_	
135-373	25660-25667	frontal	_	
135-374	25668-25673	gyrus	_	
135-375	25673-25674	;	_	
135-376	25675-25678	HPC	_	
135-377	25679-25680	–	_	
135-378	25681-25692	hippocampus	_	
135-379	25692-25693	;	_	
135-380	25694-25697	LTN	_	
135-381	25698-25699	–	_	
135-382	25700-25710	lenticular	_	
135-383	25711-25718	nucleus	_	
135-384	25718-25719	;	_	
135-385	25720-25723	TRP	_	
135-386	25724-25725	–	_	
135-387	25726-25736	triangular	_	
135-388	25737-25741	part	_	
135-389	25741-25742	;	_	
135-390	25743-25750	opr-IFG	_	
135-391	25751-25752	–	_	
135-392	25753-25762	operculum	_	
135-393	25763-25771	inferior	_	
135-394	25772-25779	frontal	_	
135-395	25780-25785	gyrus	_	
135-396	25785-25786	;	_	
135-397	25787-25790	STG	_	
135-398	25791-25792	–	_	
135-399	25793-25801	superior	_	
135-400	25802-25810	temporal	_	
135-401	25811-25816	gyrus	_	
135-402	25816-25817	;	_	
135-403	25818-25822	MSFG	_	
135-404	25823-25824	–	_	
135-405	25825-25831	medial	_	
135-406	25832-25840	superior	_	
135-407	25841-25848	frontal	_	
135-408	25849-25854	gyrus	_	
135-409	25854-25855	;	_	
135-410	25856-25858	PC	_	
135-411	25859-25860	–	_	
135-412	25861-25870	precuneus	_	
135-413	25870-25871	;	_	
135-414	25872-25875	ANG	_	
135-415	25876-25877	–	_	
135-416	25878-25885	angular	_	
135-417	25886-25891	gyrus	_	
135-418	25891-25892	;	_	
135-419	25893-25896	MFG	_	
135-420	25897-25898	–	_	
135-421	25899-25905	middle	_	
135-422	25906-25913	frontal	_	
135-423	25914-25919	gyrus	_	
135-424	25919-25920	;	_	
135-425	25921-25924	SFG	_	
135-426	25925-25926	–	_	
135-427	25927-25935	superior	_	
135-428	25936-25943	frontal	_	
135-429	25944-25949	gyrus	_	
135-430	25949-25950	.	_	

#Text=FC analysis among MAP, SCZ and control recruits.
136-1	25951-25953	FC	_	
136-2	25954-25962	analysis	_	
136-3	25963-25968	among	_	
136-4	25969-25972	MAP	_	
136-5	25972-25973	,	_	
136-6	25974-25977	SCZ	_	
136-7	25978-25981	and	_	
136-8	25982-25989	control	_	
136-9	25990-25998	recruits	_	
136-10	25998-25999	.	_	

#Text=Brain region\tThe mean GMD\tBA\tVoxels\tMNI coordinates (x, y, z)\tPeak F value\tGroup mean difference/significance\t \tMAP patients\tSCZ patients\tControl\tMAP-control/P\tSCZ-control/P\tMAP-SCZ/P\t \tR-HPC as the seed\t\t\t\t\t\t27, −18, −9\t\t\t\t\t \t L-INS\t−0.03\t0.18\t−0.03\t\t6\t−33, −18, 6\t11.29\t0.00/ P=1.000\t0.22/ P<0.001\t−0.22/ P<0.001\t \tL-MSFG as the seed\t\t\t\t\t\t−3, 63, 18\t\t\t\t\t \t R-MSFG\t0.51\t0.18\t0.55\t9\t14\t12, 57, 33\t13.03\t−0.01/ P=1.000\t−0.37/ P<0.001\t0.33/ P<0.001\t \t L-SFG/MFG\t0.13\t0.04\t0.32\t8\t12\t−15, 24,54\t9.78\t−0.19/ P=0.001\t−0.28/ P<0.001\t0.09/ P=0.269\t \t L-SFG\t0.35\t0.17\t0.56\t8\t14\t−21, 36, 54\t10.05\t−0.21/ P=0.015\t−0.39/ P<0.001\t0.18/ P=0.060\t \tR-ANG as the seed\t\t\t\t\t\t39, −63, 48\t\t\t\t\t \t R-ITG\t0.01\t0.07\t0.2\t20\t12\t60, −6, −33\t7.88\t−0.19/ P<0.001\t−0.13/ P=0.013\t−0.06/ P=0.617\t \tR-MFG/SFG as the seed\t\t\t\t\t\t30, 30, 51\t\t\t\t\t \t R-THL\t−0.02\t−0.21\t0.01\t\t6\t6, −15, 6\t10.88\t−0.03/ P=1.000\t−0.22/ P<0.001\t0.19/ P<0.001\t \t L-PC\t0.19\t0.09\t0.4\t31\t45\t−9, −63, 21\t14.29\t−0.21/ P=0.004\t−0.31/ P<0.001\t0.10/ P=0.278\t \t R-MFG\t0.1\t−0.03\t−0.25\t10\t29\t30, 45, 24\t13.7\t0.35/ P<0.001\t0.22/ P=0.003\t0.18/ P=0.280\t \t L-opr-IFG\t0.03\t−0.07\t−0.24\t\t8\t−45, 3, 24\t13.74\t0.27/ P<0.001\t0.17/ P=0.007\t0.10/ P=0.165\t \t L-MFG\t−0.07\t−0.09\t−0.35\t10\t12\t−33, 51, 27\t12.41\t0.28/ P<0.001\t0.26/ P<0.001\t0.002/ P=1.000\t \t L-ANG\t0.28\t0.23\t0.58\t39\t34\t−42, −66, 30\t12.87\t−0.30/ P<0.001\t−0.35/ P<0.001\t0.05/ P=1.000\t \t
#Text=FC – functional connectivity; MAP – methamphetamine-associated psychosis; SCZ – schizophrenia; BA – bradmann; MNI – Montreal Neurological Institute; R – right; L – left; HPC – hippocampus; INS – insula; MSFG – medial superior frontal gyrus; SFG – superior frontal gyrus; MFG – middle frontal gyrus; ITG – inferior temporal gyrus; THL – thalamus; PC – precuneus; opr-IFG – operculum inferior frontal gyrus; ANG – angular gyrus.
137-1	26000-26005	Brain	_	
137-2	26006-26012	region	_	
137-3	26013-26016	The	_	
137-4	26017-26021	mean	_	
137-5	26022-26025	GMD	_	
137-6	26026-26028	BA	_	
137-7	26029-26035	Voxels	_	
137-8	26036-26039	MNI	_	
137-9	26040-26051	coordinates	_	
137-10	26052-26053	(	_	
137-11	26053-26054	x	_	
137-12	26054-26055	,	_	
137-13	26056-26057	y	_	
137-14	26057-26058	,	_	
137-15	26059-26060	z	_	
137-16	26060-26061	)	_	
137-17	26062-26066	Peak	_	
137-18	26067-26068	F	_	
137-19	26069-26074	value	_	
137-20	26075-26080	Group	_	
137-21	26081-26085	mean	_	
137-22	26086-26096	difference	_	
137-23	26096-26097	/	_	
137-24	26097-26109	significance	_	
137-25	26112-26115	MAP	_	
137-26	26116-26124	patients	_	
137-27	26125-26128	SCZ	_	
137-28	26129-26137	patients	_	
137-29	26138-26145	Control	_	
137-30	26146-26157	MAP-control	_	
137-31	26157-26158	/	_	
137-32	26158-26159	P	_	
137-33	26160-26171	SCZ-control	_	
137-34	26171-26172	/	_	
137-35	26172-26173	P	_	
137-36	26174-26181	MAP-SCZ	_	
137-37	26181-26182	/	_	
137-38	26182-26183	P	_	
137-39	26186-26191	R-HPC	_	
137-40	26192-26194	as	_	
137-41	26195-26198	the	_	
137-42	26199-26203	seed	_	
137-43	26209-26211	27	_	
137-44	26211-26212	,	_	
137-45	26213-26214	−	_	
137-46	26214-26216	18	_	
137-47	26216-26217	,	_	
137-48	26218-26219	−	_	
137-49	26219-26220	9	_	
137-50	26228-26233	L-INS	_	
137-51	26234-26235	−	_	
137-52	26235-26239	0.03	_	
137-53	26240-26244	0.18	_	
137-54	26245-26246	−	_	
137-55	26246-26250	0.03	_	
137-56	26252-26253	6	_	
137-57	26254-26255	−	_	
137-58	26255-26257	33	_	
137-59	26257-26258	,	_	
137-60	26259-26260	−	_	
137-61	26260-26262	18	_	
137-62	26262-26263	,	_	
137-63	26264-26265	6	_	
137-64	26266-26271	11.29	_	
137-65	26272-26276	0.00	_	
137-66	26276-26277	/	_	
137-67	26278-26279	P	_	
137-68	26279-26280	=	_	
137-69	26280-26285	1.000	_	
137-70	26286-26290	0.22	_	
137-71	26290-26291	/	_	
137-72	26292-26293	P	_	
137-73	26293-26294	<	_	
137-74	26294-26299	0.001	_	
137-75	26300-26301	−	_	
137-76	26301-26305	0.22	_	
137-77	26305-26306	/	_	
137-78	26307-26308	P	_	
137-79	26308-26309	<	_	
137-80	26309-26314	0.001	_	
137-81	26317-26323	L-MSFG	_	
137-82	26324-26326	as	_	
137-83	26327-26330	the	_	
137-84	26331-26335	seed	_	
137-85	26341-26342	−	_	
137-86	26342-26343	3	_	
137-87	26343-26344	,	_	
137-88	26345-26347	63	_	
137-89	26347-26348	,	_	
137-90	26349-26351	18	_	
137-91	26359-26365	R-MSFG	_	
137-92	26366-26370	0.51	_	
137-93	26371-26375	0.18	_	
137-94	26376-26380	0.55	_	
137-95	26381-26382	9	_	
137-96	26383-26385	14	_	
137-97	26386-26388	12	_	
137-98	26388-26389	,	_	
137-99	26390-26392	57	_	
137-100	26392-26393	,	_	
137-101	26394-26396	33	_	
137-102	26397-26402	13.03	_	
137-103	26403-26404	−	_	
137-104	26404-26408	0.01	_	
137-105	26408-26409	/	_	
137-106	26410-26411	P	_	
137-107	26411-26412	=	_	
137-108	26412-26417	1.000	_	
137-109	26418-26419	−	_	
137-110	26419-26423	0.37	_	
137-111	26423-26424	/	_	
137-112	26425-26426	P	_	
137-113	26426-26427	<	_	
137-114	26427-26432	0.001	_	
137-115	26433-26437	0.33	_	
137-116	26437-26438	/	_	
137-117	26439-26440	P	_	
137-118	26440-26441	<	_	
137-119	26441-26446	0.001	_	
137-120	26450-26455	L-SFG	_	
137-121	26455-26456	/	_	
137-122	26456-26459	MFG	_	
137-123	26460-26464	0.13	_	
137-124	26465-26469	0.04	_	
137-125	26470-26474	0.32	_	
137-126	26475-26476	8	_	
137-127	26477-26479	12	_	
137-128	26480-26481	−	_	
137-129	26481-26483	15	_	
137-130	26483-26484	,	_	
137-131	26485-26490	24,54	_	
137-132	26491-26495	9.78	_	
137-133	26496-26497	−	_	
137-134	26497-26501	0.19	_	
137-135	26501-26502	/	_	
137-136	26503-26504	P	_	
137-137	26504-26505	=	_	
137-138	26505-26510	0.001	_	
137-139	26511-26512	−	_	
137-140	26512-26516	0.28	_	
137-141	26516-26517	/	_	
137-142	26518-26519	P	_	
137-143	26519-26520	<	_	
137-144	26520-26525	0.001	_	
137-145	26526-26530	0.09	_	
137-146	26530-26531	/	_	
137-147	26532-26533	P	_	
137-148	26533-26534	=	_	
137-149	26534-26539	0.269	_	
137-150	26543-26548	L-SFG	_	
137-151	26549-26553	0.35	_	
137-152	26554-26558	0.17	_	
137-153	26559-26563	0.56	_	
137-154	26564-26565	8	_	
137-155	26566-26568	14	_	
137-156	26569-26570	−	_	
137-157	26570-26572	21	_	
137-158	26572-26573	,	_	
137-159	26574-26576	36	_	
137-160	26576-26577	,	_	
137-161	26578-26580	54	_	
137-162	26581-26586	10.05	_	
137-163	26587-26588	−	_	
137-164	26588-26592	0.21	_	
137-165	26592-26593	/	_	
137-166	26594-26595	P	_	
137-167	26595-26596	=	_	
137-168	26596-26601	0.015	_	
137-169	26602-26603	−	_	
137-170	26603-26607	0.39	_	
137-171	26607-26608	/	_	
137-172	26609-26610	P	_	
137-173	26610-26611	<	_	
137-174	26611-26616	0.001	_	
137-175	26617-26621	0.18	_	
137-176	26621-26622	/	_	
137-177	26623-26624	P	_	
137-178	26624-26625	=	_	
137-179	26625-26630	0.060	_	
137-180	26633-26638	R-ANG	_	
137-181	26639-26641	as	_	
137-182	26642-26645	the	_	
137-183	26646-26650	seed	_	
137-184	26656-26658	39	_	
137-185	26658-26659	,	_	
137-186	26660-26661	−	_	
137-187	26661-26663	63	_	
137-188	26663-26664	,	_	
137-189	26665-26667	48	_	
137-190	26675-26680	R-ITG	_	
137-191	26681-26685	0.01	_	
137-192	26686-26690	0.07	_	
137-193	26691-26694	0.2	_	
137-194	26695-26697	20	_	
137-195	26698-26700	12	_	
137-196	26701-26703	60	_	
137-197	26703-26704	,	_	
137-198	26705-26706	−	_	
137-199	26706-26707	6	_	
137-200	26707-26708	,	_	
137-201	26709-26710	−	_	
137-202	26710-26712	33	_	
137-203	26713-26717	7.88	_	
137-204	26718-26719	−	_	
137-205	26719-26723	0.19	_	
137-206	26723-26724	/	_	
137-207	26725-26726	P	_	
137-208	26726-26727	<	_	
137-209	26727-26732	0.001	_	
137-210	26733-26734	−	_	
137-211	26734-26738	0.13	_	
137-212	26738-26739	/	_	
137-213	26740-26741	P	_	
137-214	26741-26742	=	_	
137-215	26742-26747	0.013	_	
137-216	26748-26749	−	_	
137-217	26749-26753	0.06	_	
137-218	26753-26754	/	_	
137-219	26755-26756	P	_	
137-220	26756-26757	=	_	
137-221	26757-26762	0.617	_	
137-222	26765-26770	R-MFG	_	
137-223	26770-26771	/	_	
137-224	26771-26774	SFG	_	
137-225	26775-26777	as	_	
137-226	26778-26781	the	_	
137-227	26782-26786	seed	_	
137-228	26792-26794	30	_	
137-229	26794-26795	,	_	
137-230	26796-26798	30	_	
137-231	26798-26799	,	_	
137-232	26800-26802	51	_	
137-233	26810-26815	R-THL	_	
137-234	26816-26817	−	_	
137-235	26817-26821	0.02	_	
137-236	26822-26823	−	_	
137-237	26823-26827	0.21	_	
137-238	26828-26832	0.01	_	
137-239	26834-26835	6	_	
137-240	26836-26837	6	_	
137-241	26837-26838	,	_	
137-242	26839-26840	−	_	
137-243	26840-26842	15	_	
137-244	26842-26843	,	_	
137-245	26844-26845	6	_	
137-246	26846-26851	10.88	_	
137-247	26852-26853	−	_	
137-248	26853-26857	0.03	_	
137-249	26857-26858	/	_	
137-250	26859-26860	P	_	
137-251	26860-26861	=	_	
137-252	26861-26866	1.000	_	
137-253	26867-26868	−	_	
137-254	26868-26872	0.22	_	
137-255	26872-26873	/	_	
137-256	26874-26875	P	_	
137-257	26875-26876	<	_	
137-258	26876-26881	0.001	_	
137-259	26882-26886	0.19	_	
137-260	26886-26887	/	_	
137-261	26888-26889	P	_	
137-262	26889-26890	<	_	
137-263	26890-26895	0.001	_	
137-264	26899-26903	L-PC	_	
137-265	26904-26908	0.19	_	
137-266	26909-26913	0.09	_	
137-267	26914-26917	0.4	_	
137-268	26918-26920	31	_	
137-269	26921-26923	45	_	
137-270	26924-26925	−	_	
137-271	26925-26926	9	_	
137-272	26926-26927	,	_	
137-273	26928-26929	−	_	
137-274	26929-26931	63	_	
137-275	26931-26932	,	_	
137-276	26933-26935	21	_	
137-277	26936-26941	14.29	_	
137-278	26942-26943	−	_	
137-279	26943-26947	0.21	_	
137-280	26947-26948	/	_	
137-281	26949-26950	P	_	
137-282	26950-26951	=	_	
137-283	26951-26956	0.004	_	
137-284	26957-26958	−	_	
137-285	26958-26962	0.31	_	
137-286	26962-26963	/	_	
137-287	26964-26965	P	_	
137-288	26965-26966	<	_	
137-289	26966-26971	0.001	_	
137-290	26972-26976	0.10	_	
137-291	26976-26977	/	_	
137-292	26978-26979	P	_	
137-293	26979-26980	=	_	
137-294	26980-26985	0.278	_	
137-295	26989-26994	R-MFG	_	
137-296	26995-26998	0.1	_	
137-297	26999-27000	−	_	
137-298	27000-27004	0.03	_	
137-299	27005-27006	−	_	
137-300	27006-27010	0.25	_	
137-301	27011-27013	10	_	
137-302	27014-27016	29	_	
137-303	27017-27019	30	_	
137-304	27019-27020	,	_	
137-305	27021-27023	45	_	
137-306	27023-27024	,	_	
137-307	27025-27027	24	_	
137-308	27028-27032	13.7	_	
137-309	27033-27037	0.35	_	
137-310	27037-27038	/	_	
137-311	27039-27040	P	_	
137-312	27040-27041	<	_	
137-313	27041-27046	0.001	_	
137-314	27047-27051	0.22	_	
137-315	27051-27052	/	_	
137-316	27053-27054	P	_	
137-317	27054-27055	=	_	
137-318	27055-27060	0.003	_	
137-319	27061-27065	0.18	_	
137-320	27065-27066	/	_	
137-321	27067-27068	P	_	
137-322	27068-27069	=	_	
137-323	27069-27074	0.280	_	
137-324	27078-27087	L-opr-IFG	_	
137-325	27088-27092	0.03	_	
137-326	27093-27094	−	_	
137-327	27094-27098	0.07	_	
137-328	27099-27100	−	_	
137-329	27100-27104	0.24	_	
137-330	27106-27107	8	_	
137-331	27108-27109	−	_	
137-332	27109-27111	45	_	
137-333	27111-27112	,	_	
137-334	27113-27114	3	_	
137-335	27114-27115	,	_	
137-336	27116-27118	24	_	
137-337	27119-27124	13.74	_	
137-338	27125-27129	0.27	_	
137-339	27129-27130	/	_	
137-340	27131-27132	P	_	
137-341	27132-27133	<	_	
137-342	27133-27138	0.001	_	
137-343	27139-27143	0.17	_	
137-344	27143-27144	/	_	
137-345	27145-27146	P	_	
137-346	27146-27147	=	_	
137-347	27147-27152	0.007	_	
137-348	27153-27157	0.10	_	
137-349	27157-27158	/	_	
137-350	27159-27160	P	_	
137-351	27160-27161	=	_	
137-352	27161-27166	0.165	_	
137-353	27170-27175	L-MFG	_	
137-354	27176-27177	−	_	
137-355	27177-27181	0.07	_	
137-356	27182-27183	−	_	
137-357	27183-27187	0.09	_	
137-358	27188-27189	−	_	
137-359	27189-27193	0.35	_	
137-360	27194-27196	10	_	
137-361	27197-27199	12	_	
137-362	27200-27201	−	_	
137-363	27201-27203	33	_	
137-364	27203-27204	,	_	
137-365	27205-27207	51	_	
137-366	27207-27208	,	_	
137-367	27209-27211	27	_	
137-368	27212-27217	12.41	_	
137-369	27218-27222	0.28	_	
137-370	27222-27223	/	_	
137-371	27224-27225	P	_	
137-372	27225-27226	<	_	
137-373	27226-27231	0.001	_	
137-374	27232-27236	0.26	_	
137-375	27236-27237	/	_	
137-376	27238-27239	P	_	
137-377	27239-27240	<	_	
137-378	27240-27245	0.001	_	
137-379	27246-27251	0.002	_	
137-380	27251-27252	/	_	
137-381	27253-27254	P	_	
137-382	27254-27255	=	_	
137-383	27255-27260	1.000	_	
137-384	27264-27269	L-ANG	_	
137-385	27270-27274	0.28	_	
137-386	27275-27279	0.23	_	
137-387	27280-27284	0.58	_	
137-388	27285-27287	39	_	
137-389	27288-27290	34	_	
137-390	27291-27292	−	_	
137-391	27292-27294	42	_	
137-392	27294-27295	,	_	
137-393	27296-27297	−	_	
137-394	27297-27299	66	_	
137-395	27299-27300	,	_	
137-396	27301-27303	30	_	
137-397	27304-27309	12.87	_	
137-398	27310-27311	−	_	
137-399	27311-27315	0.30	_	
137-400	27315-27316	/	_	
137-401	27317-27318	P	_	
137-402	27318-27319	<	_	
137-403	27319-27324	0.001	_	
137-404	27325-27326	−	_	
137-405	27326-27330	0.35	_	
137-406	27330-27331	/	_	
137-407	27332-27333	P	_	
137-408	27333-27334	<	_	
137-409	27334-27339	0.001	_	
137-410	27340-27344	0.05	_	
137-411	27344-27345	/	_	
137-412	27346-27347	P	_	
137-413	27347-27348	=	_	
137-414	27348-27353	1.000	_	
137-415	27357-27359	FC	_	
137-416	27360-27361	–	_	
137-417	27362-27372	functional	_	
137-418	27373-27385	connectivity	_	
137-419	27385-27386	;	_	
137-420	27387-27390	MAP	_	
137-421	27391-27392	–	_	
137-422	27393-27419	methamphetamine-associated	_	
137-423	27420-27429	psychosis	_	
137-424	27429-27430	;	_	
137-425	27431-27434	SCZ	_	
137-426	27435-27436	–	_	
137-427	27437-27450	schizophrenia	_	
137-428	27450-27451	;	_	
137-429	27452-27454	BA	_	
137-430	27455-27456	–	_	
137-431	27457-27465	bradmann	_	
137-432	27465-27466	;	_	
137-433	27467-27470	MNI	_	
137-434	27471-27472	–	_	
137-435	27473-27481	Montreal	_	
137-436	27482-27494	Neurological	_	
137-437	27495-27504	Institute	_	
137-438	27504-27505	;	_	
137-439	27506-27507	R	_	
137-440	27508-27509	–	_	
137-441	27510-27515	right	_	
137-442	27515-27516	;	_	
137-443	27517-27518	L	_	
137-444	27519-27520	–	_	
137-445	27521-27525	left	_	
137-446	27525-27526	;	_	
137-447	27527-27530	HPC	_	
137-448	27531-27532	–	_	
137-449	27533-27544	hippocampus	_	
137-450	27544-27545	;	_	
137-451	27546-27549	INS	_	
137-452	27550-27551	–	_	
137-453	27552-27558	insula	_	
137-454	27558-27559	;	_	
137-455	27560-27564	MSFG	_	
137-456	27565-27566	–	_	
137-457	27567-27573	medial	_	
137-458	27574-27582	superior	_	
137-459	27583-27590	frontal	_	
137-460	27591-27596	gyrus	_	
137-461	27596-27597	;	_	
137-462	27598-27601	SFG	_	
137-463	27602-27603	–	_	
137-464	27604-27612	superior	_	
137-465	27613-27620	frontal	_	
137-466	27621-27626	gyrus	_	
137-467	27626-27627	;	_	
137-468	27628-27631	MFG	_	
137-469	27632-27633	–	_	
137-470	27634-27640	middle	_	
137-471	27641-27648	frontal	_	
137-472	27649-27654	gyrus	_	
137-473	27654-27655	;	_	
137-474	27656-27659	ITG	_	
137-475	27660-27661	–	_	
137-476	27662-27670	inferior	_	
137-477	27671-27679	temporal	_	
137-478	27680-27685	gyrus	_	
137-479	27685-27686	;	_	
137-480	27687-27690	THL	_	
137-481	27691-27692	–	_	
137-482	27693-27701	thalamus	_	
137-483	27701-27702	;	_	
137-484	27703-27705	PC	_	
137-485	27706-27707	–	_	
137-486	27708-27717	precuneus	_	
137-487	27717-27718	;	_	
137-488	27719-27726	opr-IFG	_	
137-489	27727-27728	–	_	
137-490	27729-27738	operculum	_	
137-491	27739-27747	inferior	_	
137-492	27748-27755	frontal	_	
137-493	27756-27761	gyrus	_	
137-494	27761-27762	;	_	
137-495	27763-27766	ANG	_	
137-496	27767-27768	–	_	
137-497	27769-27776	angular	_	
137-498	27777-27782	gyrus	_	
137-499	27782-27783	.	_	
